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Summary
A hallmark of retroviral replication is the reverse transcription of the viral RNA genome into a
double stranded DNA copy that becomes stably integrated into the host chromosomal DNA by means
of the viral integrase (IN). This integration event forever links the fate of the invading virus to that of
its host cell. Retroviral integration is a non-random process and depending on the genus, integration
occurs near specific features of the host genome. HIV-1 and other lentiviruses preferentially integrate
into the body of actively transcribed genes. Much alike other viruses, HIV-1 relies on the presence
of essential cellular co-factors to complete its viral replication cycle. In 2002 our lab identified Lens
Epithelium-derived Growth Factor (LEDGF/p75) as a binding partner of HIV-1 IN [Cherepanov et al.,
2003] responsible for orchestrating HIV-1 integration into active transcription units through interaction
with the viral IN via its Integrase Binding Domain (IBD) [Ciuffi et al., 2005; Gijsbers et al., 2011a;
Schrijvers et al., 2012b] and interaction with the host chromatin via its PWWP domain [De Rijck
et al., 2010; Pradeepa et al., 2012; Eidahl et al., 2013; Gijsbers et al., 2011a; van Nuland et al., 2013].
Depletion of LEDGF/p75 shifts integration out of transcription units [Ciuffi et al., 2005; Marshall et al.,
2007; Shun et al., 2007; Schrijvers et al., 2012b]. Additionally, replacement of the chromatin binding
domains of LEDGF/p75 with alternative domains retargets integration near genomic loci bound by
these domains [Ferris et al., 2010; Gijsbers et al., 2009].
In my Ph.D. project I continued along this research line and studied the mechanism of lentiviral in-
tegration and the role of LEDGF/p75 therein. The LEDGF/p75-IN interplay was studied to better
understand the relationship between integration site selection, subnuclear positioning and proviral gene
expression forming the common thread throughout the chapters. In this doctoral dissertation two
research manuscripts are bundled.
In the first part of my work (see Chapter 3), I exploited chimeric versions of LEDGF/p75 as a tool to
retarget lentiviral integration to potentially ’safer’ regions within the human genome. As such, Serious
Adverse Events (SAEs) associated with the use of retroviral vectors in gene therapeutic applications
may be overcome. I designed LEDGF/p75-based tethers that resulted in a more random integration
pattern which is generally believed to reduce the risk or probability of transcriptional dysregulation of
neighbouring genes, an event dubbed ’insertional mutagenesis’ [Chatziandreou et al., 2011; Derse et al.,
2007; Kaufmann et al., 2013; Suerth et al., 2012].
Secondly (see Chapter 4), I studied the importance of integration site distribution in the context of
HIV persistence. The development of antivirals and combination AntiRetroviral Therapy (cART) in
the last decades revolutionized the treatment of HIV/AIDS, however, the major impediment towards a
cure for HIV infection lies in the existence of long-lasting reservoirs containing transcriptionally silent
but replication competent HIV provirus that is unaffected by cART [Trono et al., 2010]. From these
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quiescent or latent reservoirs HIV rebounds within a few weeks after cessation of cART. Since integration
is believed to affect the transcriptional activity of the integrated provirus, I assessed whether targeting
and integration site selection affect the reactivation potential of the quiescent integrated provirus.
Therefore I evaluated whether LEDGINs, bona fide small molecule inhibitors (2-(quinolin-3-yl)acetic
acid derivates) binding to the IN dimer interface and thereby blocking the LEDGF/p75 interaction
and interfering with the catalytic activity of IN [Christ et al., 2010, 2012], could affect the functional
reservoir formation. I studied both (i) the establishment of HIV-1 latency and (ii) the reactivation from
latency following treatment with different Latency Reversing Agents (LRAs).
Both studies on the role of the LEDGF/p75-IN interplay in integration site selection and HIV persistence
either contribute to the development of safer viral vectors for gene therapeutic applications or to
alternative approaches to cure HIV by aiming for a modulation or prevention of the generation of a
residual HIV-1 reservoir able to rebound from latency once drug administration is withdrawn.
iv
Samenvatting
Een typerend kenmerk van retrovirale replicatie is de omgekeerde transcriptie van een enkelstrengig
viraal RNA genoom tot een dubbelstrengige DNA kopij, die vervolgens stabiel wordt geïnsereerd in
het gastheerchromatine via het viraal integrase (IN). Dit integratie-evenement verbindt het lot van het
provirus onomkeerbaar met dat van de cel. Ondertussen weten we dat deze insertie niet op een ran-
dom manier gebeurt maar dat integratie, afhankelijk van het genus, welbepaalde voorkeursplaatsen in
het genoom verkiest. Het Humaan ImmunodeficiëntieVirus (HIV-1) en andere lentivirussen integreren
preferentieel in actieve genen. Net zoals alle virussen, is ook HIV-1 afhankelijk van de aanwezigheid
van essentiële eiwitten in de cel om zijn replicatiecyclus te kunnen voltooien. In 2002 identificeerde
onze onderzoeksgroep het Lens Epithelium-derived Growth Factor (LEDGF/p75) eiwit als een bind-
ingspartner van HIV-1 IN [Cherepanov et al., 2003]. LEDGF/p75 is verantwoordelijk voor het sturen
van HIV-1 integratie naar actieve transcriptie-eenheden door een interactie met het viraal IN via zijn
Integrase Binding Domain (IBD) enerzijds [Ciuffi et al., 2005; Gijsbers et al., 2011a; Schrijvers et al.,
2012b] en een interactie met het gastheerchromatine via zijn PWWP-domein anderzijds [De Rijck et al.,
2010; Pradeepa et al., 2012; Eidahl et al., 2013; Gijsbers et al., 2011a; van Nuland et al., 2013]. De-
pletie van LEDGF/p75 in de cel stuurt integratie weg van transcriptie-eenheden [Ciuffi et al., 2005;
Marshall et al., 2007; Shun et al., 2007; Schrijvers et al., 2012b]. Wanneer het chromatine-bindende
domein van LEDGF/p75 wordt vervangen door alternatieve domeinen is er een preferentiële toename
van integraties in de buurt van de loci herkend door deze domeinen [Ferris et al., 2010; Gijsbers et al.,
2009].
Mijn PhD-project bouwt verder op deze onderzoekslijn. Ik bestudeerde het mechanisme van lentivirale
integratie en de rol van LEDGF/p75 hierin. De wisselwerking tussen LEDGF/p75 en IN werd onder-
zocht om de relatie tussen integratieplaatskeuze, subnucleaire positionering en provirale genexpressie
beter te begrijpen. Dit vormt dan ook de rode draad doorheen dit manuscript dat bestaat uit een
bundeling van twee verschillende onderzoeksprojecten.
In een eerste deel van mijn werk (zie Hoofdstuk 3), gebruik ik chimere versies van LEDGF/p75 als een
tool om integratie te sturen naar potentieel ’veiligere’ regio’s in het humaan genoom. Hierdoor kunnen
ernstige nevenwerkingen geassocieerd met het gebruik van retrovirale vectoren in gentherapeutische
toepassingen mogelijks vermeden worden. Ik ontwierp LEDGF/p75 gebaseerde ankers die resulteerden
in een meer random integratiepatroon, waarvan algemeen aanvaard wordt dat dit het risico op tran-
scriptionele dysregulatie van naburige genen of ’insertionele mutagenese’ beperkt [Chatziandreou et al.,
2011; Derse et al., 2007; Kaufmann et al., 2013; Suerth et al., 2012].
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Hierna (zie Hoofdstuk 4), bestudeerde ik het belang van integratieplaatsdistributie in de context van
HIV-persistentie. In de laatste decennia zorgde de ontwikkeling van antivirale middelen en combinatie
AntiRetrovirale Therapie of cART voor een ware revolutie in de behandeling van HIV/AIDS. Het
grootste struikelblok ter genezing van HIV blijft echter de aanwezigheid van een stabiel reservoir met
transcriptioneel inactief maar replicatiecompetent HIV-provirus dat niet vatbaar is voor cART [Trono
et al., 2010]. Deze sluimerende of latente HIV-reservoiren zijn verantwoordelijk voor een heropleving
van HIV-viremie reeds enkele weken na de stopzetting van cART. Er wordt algemeen aangenomen dat
de integratieplaats en lokale chromatineomgeving een rol spelen in de regulatie van de transcriptionele
activiteit van het geïntegreerd provirus. Daarom evalueerde ik of de integratieplaatsselectie mogelijks
het reactivatiepotentieel van latent provirus kon beïnvloeden. Meer bepaald ging ik na of LEDGINs,
bona fide kleine inhibitoren (2-(quinolin-3-yl)azijnzuur-derivaten) die de interactie tussen IN-dimeren
en LEDGF/p75 blokkeren en interfereren met de catalytische activiteit van IN [Christ et al., 2010,
2012], het functioneel reservoir kunnen beïnvloeden. Tijdens mijn doctoraat onderzocht ik zowel (i)
het tot stand komen van HIV-1-latentie als de (ii) reactivatie van latentie na toediening van ’Latency
Reversing Agents’ (LRAs).
Deze studies omtrent de rol van de LEDGF/p75-IN wisselwerking in integratieplaatskeuze en HIV-
persistentie dragen bij tot de ontwikkeling van veiligere virale vectoren voor gentherapeutische toepassin-
gen ofwel tot een alternatieve strategie voor een HIV-genezing. Hierbij streven we naar een modulatie of
preventie van de vorming van het residueel HIV-1-reservoir dat verantwoordelijk is voor de heropleving
van HIV-replicatie na het stopzetten van de antivirale behandeling.
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Glossary of Terms
A3 or APOBEC3 apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 family
aa amino acid residues
AAVS1 adeno-associated virus integration site 1
AIDS acquired immune deficiency syndrome
ART antiretroviral therapy
ASLV avian sarcoma leukosis virus
AZT zidovudine
BET bromodomain and extra-terminal domain
BMT bone marrow transplantation
bNAb broadly neutralizing antibodies
BRD4 bromodomain-containing protein 4
BSA bovine serum albumin
CA capsid
CAR chimeric antigen receptor
cART combination antiretroviral therapy
CBS chromatin binding sequence
CCD catalytic core domain
CCR5 C-C chemokine type 5 receptor
CD4 cluster of differentiation 4
CDK9 cyclin-dependent kinase 9
cDNA copy deoxyribonucleic acid
CNS central nervous system
CPSF6 cleavage and polyadenylation specificity factor 6
CR1-4 charged regions 1-4
CRISPR clustered regularly interspaced short palindromic repeats
CTD C-terminal domain
CTL cytotoxic T-lymphocyte
DAPI 4’, 6-diamidino-2-phenylindole
DC dentritic cells
DHS dnase I-hypersensitive sites
DMEM dulbecco’s modified eagle’s medium
DMSO dimethyl sulfoxide
DTG dolutegravir
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GLOSSARY OF TERMS
DTT dithiotreitol
EC50 half maximal effective concentration
EDTA ethylenediaminetetraacetic acid
EFV efavirenz
eGFP enhanced green fluorescent protein
ELISA enzyme-linked immunosorbent assay
EVG elvitegravir
FACS fluorescence-activated cell sorting
FDA U.S. food and drug administration
fLuc firefly luciferase
GALT gut-associated lymphatic tissue
GFP green fluorescent protein
GO gene ontology
H2A histone 2A
H2B histone 2B
H3K4 lysine 4 of histone H3
H3K36 lysine 36 of histone 3
H3K79 lysine 79 of histone 3
H4K16 lysine 16 of histone 4
HDAC histone deacetylase
HDACi histone deacetylase inhibitor
HEK293T human embryonic kidney 293T cells
HEXIM1 hexamethylene bis-acetamide inducible 1
HIV human immunodeficiency virus
HMT histone methyltransferase
HP1 heterochromatin protein 1
HPV human papillomavirus
HRP horseradish peroxidase
HRP-2 HDGF related protein 2
HSCT haematopoietic stem cell transplantation
IBD integrase binding domain
IC50 50 % inhibitory concentration
IL interleukin
IN integrase
iPS induced-pluripotent stem cells
IWS1 interacts with Spt6
JPO2 cell division cycle-associated 7-like protein (CDCA7L)
KD knockdown
KO knockout
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KSHV kaposi’s sarcoma-associated herpes virus
LANA latency-associated nuclear antigen
LARP7 lupus antigen related protein 7
LB lysogeny broth
LEDGF lens epithelium derived growth factor
LRA latency reversing agents
LTR long terminal repeat
LV lentiviral vector
MA matrix
MFI mean fluorescence intensity
MLL myeloid/lymphoid leukemia or mixed-lineage leukemia
MLV murine leukemia virus
MMTV mouse mammary tumour virus
MRC matched random control
mRNA messenger RNA
NC nucleocapsid
NCINI non-catalytic site integrase inhibitor
Nef negative regulatory factor
NFκB nuclear factor κB
NLS nuclear localization signal
NNRTI non-nucleoside reverse transcriptase inhibitor
NRTI nucleoside/nucleotide reverse transcriptase inhibitor
NTD N-terminal domain
NUP nucleopore
ORF open reading frame
PAGE polyacrylamide gel electrophoresis
PBS phosphate buffered saline
PCR polymerase chain reaction
PDB protein data bank
PEI polyethylenimine
PFV prototype foamy virus
PI protease inhibitor
PIC pre-integration complex
PogZ pogo transposable element with zinc finger domain
PrEP pre-exposure prophylaxis
PSIP1 PC4- and SFRS1-interacting protein 1
P-TEFb positive transcription elongation factor b
PV papillomavirus
PWWP Pro-Trp-Trp-Pro domain
ix
GLOSSARY OF TERMS
qPCR quantitative PCR
RNAi RNA interference
RPMI roswell park memorial institute medium
RT reverse transcriptase
RT qPCR real time quantitative PCR
RV retroviral vector
SDS sodium dodecyl sulfate
SFFV spleen focus-forming virus
SI selectivity index
SIN self-inactivating
SIV simian immunodeficiency virus
SRD supercoiled recognition domain
START strategic timing of antiretroviral treatment
SU surface unit
TALEN transcription activator-like effector nucleases
TAR transactivation response element
Tat transactivator of transcription
TM transmembrane unit
TSS transcription start site
UCR ultra conserved regions
vDNA viral deoxyribonucleic acid
Vif virus infectivity factor
VOA viral outgrowth assay
Vpr viral protein R
Vpu viral protein unique
vRNA viral ribonucleic acid
VSV-G vesicular stomatitus virus glycoprotein
WAS wikott-aldrich syndrome
WT wild-type
WPRE woodchuck hepatitis virus post-transcriptional regulatory element
X-SCID X-linked severe combined immunodeficiency
X-CGD X-linked chronic granulomatous disease
x
Table of Contents
Acknowledgements i
Summary iii
Samenvatting v
Glossary of Terms vii
Table of Contents xi
List of Figures xv
List of Tables xvii
1 General Introduction 1
1.1 HIV, the causative agent of AIDS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.1.1 HIV epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.1.2 Retroviral taxonomy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.1.3 HIV pathophysiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.1.4 HIV particle structure and genomic organization . . . . . . . . . . . . . . . . . . 4
1.1.5 HIV replication cycle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.1.6 Retroviral integration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
1.1.6.1 Retroviral integrase and intasome structure . . . . . . . . . . . . . . . 8
1.1.6.2 Determinants of retroviral integration site selection . . . . . . . . . . . 11
1.1.6.3 LEDGF/p75, an HIV IN cellular cofactor . . . . . . . . . . . . . . . . 13
1.1.6.4 Small molecules targeting the LEDGF/p75-IN interface . . . . . . . . . 15
LEDGINs display a multi-modal mechanism of action. . . . . . . . . . . . 17
1.2 Towards an HIV cure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
1.2.1 HIV reservoirs and anatomical sanctuaries . . . . . . . . . . . . . . . . . . . . . 19
1.2.2 Heterogenous regulatory mechanisms of HIV Latency . . . . . . . . . . . . . . . 21
1.2.2.1 Viral gene-regulatory circuitry . . . . . . . . . . . . . . . . . . . . . . . 22
1.2.2.2 Environmental determinants . . . . . . . . . . . . . . . . . . . . . . . . 23
1.2.3 Current HIV treatment regimens . . . . . . . . . . . . . . . . . . . . . . . . . . 25
1.2.4 Shock-and-kill approach . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
1.2.5 Alternative approaches to cure HIV . . . . . . . . . . . . . . . . . . . . . . . . . 28
xi
TABLE OF CONTENTS
1.2.6 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
1.3 Lentiviral vectors for safer gene therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
1.3.1 Re-harnessing viruses to generate viral vectors for efficient gene transfer . . . . . 32
1.3.2 Severe adverse events and the risk of insertional mutagenesis . . . . . . . . . . . 33
1.3.3 Towards a safer retroviral integration profile . . . . . . . . . . . . . . . . . . . . 34
1.3.3.1 Safe harbour regions . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
1.3.3.2 Pre-clinical assays to assess safety . . . . . . . . . . . . . . . . . . . . . 36
1.3.4 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2 Objectives 37
3 Towards a Safer, More Randomized Lentiviral Integration Profile Exploring Artifi-
cial LEDGF Chimeras 41
3.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
3.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
3.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
3.3.1 Generation of LEDGF-hybrids and stable cell lines . . . . . . . . . . . . . . . . 45
3.3.2 LEDGF-hybrids locate to the nucleus and display a distinct subnuclear distribution 46
3.3.3 LEDGF-peptide fusions rescue lentiviral vector transduction . . . . . . . . . . . 48
3.3.4 LEDGF-peptide fusions efficiently redistribute lentiviral integration . . . . . . . 50
3.3.5 Artificial LEDGF/p75-peptide hybrids result in a safer integration profile . . . . 54
3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
3.5 Experimental procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
3.5.1 Generation of stable cell lines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
3.5.2 Cell culture. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
3.5.3 Retroviral vector production (SIV-based) and transduction. . . . . . . . . . . . . 60
3.5.4 Immunocytochemistry and Laser scanning microscopy. . . . . . . . . . . . . . . 61
3.5.5 Western Blot. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
3.5.6 Luciferase assay. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
3.5.7 Flow cytometric analysis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
3.5.8 Integration site amplification and sequencing. . . . . . . . . . . . . . . . . . . . 62
3.6 Author contributions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
3.7 Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
3.8 Disclosure statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
3.9 Supporting information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
3.9.1 Supplementary figures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
4 LEDGIN-Mediated Inhibition of Integrase-LEDGF/p75 Interaction Reduces Reac-
tivation of Residual Latent HIV 69
4.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
xii
TABLE OF CONTENTS
4.2 Research in context (Layman’s terms) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
4.3 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
4.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
4.4.1 LEDGF/p75 depletion results in a quiescent reservoir. . . . . . . . . . . . . . . 72
4.4.2 LEDGF/p75 depletion decreases the reactivation potential of the quiescent reser-
voir. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
4.4.3 LEDGIN treatment shifts HIV integration out of transcription units. . . . . . . 75
4.4.4 Abrogation of LEDGF/p75-IN interaction shifts 3D localization of the integrated
provirus towards the inner nuclear compartment. . . . . . . . . . . . . . . . . . 79
4.4.5 The residual reservoir upon LEDGIN treatment is more quiescent. . . . . . . . . 80
4.4.6 LEDGIN treatment results in a quiescent reservoir resistant to HIV reactivation. 84
4.4.7 LEDGIN treatment retargets HIV integration into safer locations . . . . . . . . 84
4.4.8 LEDGIN treatment inhibits integration, relatively increases the quiescent viral
reservoir and reduces reactivation in primary CD4+ T cells. . . . . . . . . . . . 89
4.4.9 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
4.5 Experimental procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
4.5.1 Cell culture, virus production and transduction. . . . . . . . . . . . . . . . . . . 93
4.5.2 Reporter viruses. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
4.5.3 Flow cytometry analysis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
4.5.4 Drug treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
4.5.5 Genomic DNA isolation and quantification of Integrated copy number. . . . . . 95
4.5.6 Integration site amplification. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
4.5.7 Single Cell Imaging of Proviral HIV (SCIP) assay. . . . . . . . . . . . . . . . . . 96
4.5.8 CD4+ T-cell enrichment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
4.5.9 Reactivation of latent provirus in primary CD4+ T-cells. . . . . . . . . . . . . . 97
4.5.10 Statistical analysis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
4.5.11 VISA-trimming non-genomic portions of sequence reads. . . . . . . . . . . . . . 97
4.5.12 Virus production in the presence of LEDGINs . . . . . . . . . . . . . . . . . . . 98
4.6 Author contributions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
4.7 Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
4.8 Disclosure statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
4.9 Supporting information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
4.9.1 Supplementary results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
4.9.1.1 LEDGIN treatment shifts HIV integration out of transcription units. . 99
4.9.1.2 LEDGIN treatment induces a silent reservoir resistant to HIV reactivation.100
4.9.1.3 LEDGIN treatment does not affect the local integration site preferences. 100
4.9.2 Supplementary figures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
5 Concluding Discussion 115
xiii
TABLE OF CONTENTS
Bibliography 125
Curriculum Vitae 155
Appendix 163
xiv
List of Figures
1 General Introduction 1
1.1 Disease progression from viral infection to the development of AIDS . . . . . . . . . . . 4
1.2 HIV-1 particle structure and genomic organization . . . . . . . . . . . . . . . . . . . . . 5
1.3 HIV replication cycle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
1.4 Schematic overview of the lentiviral integration process . . . . . . . . . . . . . . . . . . 8
1.5 Functional domains of the lentiviral integrase . . . . . . . . . . . . . . . . . . . . . . . 9
1.6 Retroviral intasome structures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.7 Overview of retroviral integration targeting parameters . . . . . . . . . . . . . . . . . . 12
1.8 Schematic representation of the LEDGF/p52, LEDGF/p75 and HRP-2 domain structure. 14
1.9 LEDGINs bind to the IN dimer interface . . . . . . . . . . . . . . . . . . . . . . . . . . 16
1.10 INSTIs & LEDGIN congeners . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
1.11 Multi-modal mechanism of action of LEDGINs . . . . . . . . . . . . . . . . . . . . . . . 18
1.12 Latent reservoirs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
1.13 Simplified model of HIV-1 proviral transcription. . . . . . . . . . . . . . . . . . . . . . . 22
1.14 Shock and kill approach . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
1.15 Gene Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
1.16 Plasmid constructs required for efficient viral vector production . . . . . . . . . . . . . 32
3 Towards a Safer, More Randomized Lentiviral Integration Profile Exploring Artifi-
cial LEDGF Chimeras 41
3.1 Schematic representation of the LEDGF/p75 domain structure and artificial LEDGF-
hybrids. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
3.2 Subcellular localization of LEDGF-hybrids in interphase cells. . . . . . . . . . . . . . . 47
3.3 Rescue of lentiviral vector transduction by artificial LEDGF-hybrids. . . . . . . . . . . 49
3.4 LEDGF-hybrids retarget lentiviral integration towards a more randomized pattern (a). 53
3.4 LEDGF-hybrids retarget lentiviral integration towards a more randomized pattern (b). 54
S3.1 Western analysis of LEDGF-fusions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
S3.2 LEDGF-hybrids retarget lentiviral integration towards a more randomized pattern (G.). 64
S3.3 LEDGF-hybrids retarget lentiviral integration towards a more randomized pattern (E.). 65
xv
LIST OF FIGURES
4 LEDGIN-Mediated Inhibition of Integrase-LEDGF/p75 Interaction Reduces Reac-
tivation of Residual Latent HIV 69
4.1 LEDGF/p75 depletion increases the silent reservoir. . . . . . . . . . . . . . . . . . . . . 73
4.2 LEDGF/p75 depletion reduces HIV reactivation from latency. . . . . . . . . . . . . . . 75
4.3 LEDGIN inhibition of the LEDGF/p75-IN interaction retargets lentiviral integration. . 79
4.4 LEDGIN treatment shifts HIV-1 proviral localization towards the inner nuclear compart-
ment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
4.5 LEDGIN mediated retargeting of integration increases the quiescent reservoir. . . . . . 83
4.6 LEDGIN treatment reduces reactivation from latency. . . . . . . . . . . . . . . . . . . . 86
4.7 LEDGIN treatment inhibits integration, induces quiescence of the residual viral reservoir
and reduces reactivation in primary CD4+ T cells. . . . . . . . . . . . . . . . . . . . . . 90
S4.1 LEDGF/p75 depletion relatively increases the silent reservoir (a). . . . . . . . . . . . . 102
S4.1 LEDGF/p75 depletion relatively increases the silent reservoir (b). . . . . . . . . . . . . 103
S4.2 LEDGIN-mediated inhibition of single round lentiviral transduction. . . . . . . . . . . . 104
S4.3 LEDGIN inhibition of the LEDGF/p75-IN interaction retargets lentiviral integration (G.).105
S4.3 LEDGIN inhibition of the LEDGF/p75-IN interaction retargets lentiviral integration (E.).106
S4.3 LEDGIN inhibition of the LEDGF/p75-IN interaction retargets lentiviral integration
(E.). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
S4.4 LEDGIN treatment reduces reactivation from latency. . . . . . . . . . . . . . . . . . . . 108
S4.5 The integration site sequence logo remains unaffected by LEDGIN-mediated inhibition
of the LEDGF/p75-IN interaction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
S4.6 LTR substrings. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
S4.7 Addition of LEDGINs during production results in transcriptionally silent provirus after
integration. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
5 Concluding Discussion 115
5.1 Schematic diagram of the effect of LEDGINs on the residual HIV-1 reservoir . . . . . . 121
5.2 Cases of transient or sustained HIV remission off ART . . . . . . . . . . . . . . . . . . 123
Appendix 161
A.1 Sequencing of proviral integration sites . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
xvi
List of Tables
3 Towards a Safer, More Randomized Lentiviral Integration Profile Exploring Artifi-
cial LEDGF Chimeras 41
3.1 Peptide characteristics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
3.2 Integration frequency near genomic features. . . . . . . . . . . . . . . . . . . . . . . . . 52
3.3 Integration frequency near safe harbor criteria. . . . . . . . . . . . . . . . . . . . . . . . 56
S3.1 Primer oligos used in this study. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
S3.2 Integration frequency near safe harbor criteria. . . . . . . . . . . . . . . . . . . . . . . . 67
S3.3 Gene ontology analysis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
4 LEDGIN-Mediated Inhibition of Integrase-LEDGF/p75 Interaction Reduces Reac-
tivation of Residual Latent HIV 69
4.1 Integration frequency near mapped genomic features in the human genome. . . . . . . . 78
4.2 Integration frequency near safe harbor criteria. . . . . . . . . . . . . . . . . . . . . . . . 88
S4.1 LEDGIN inhibition of the LEDGF/p75-IN interaction retargets lentiviral integration. . 113
S4.2 Percentage of imperfect LTR-chromosome junctions. . . . . . . . . . . . . . . . . . . . . 113
S4.3 Integration orientation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
xvii
LIST OF TABLES
xviii
1
General Introduction
1
CHAPTER 1. GENERAL INTRODUCTION
For more than 10 years our research group has been focusing on cellular cofactors that support
Human Immunodeficiency Virus (HIV) replication. HIV is the prototype of the Lentiviridae which
are characterized by their ability to stably integrate a viral DNA copy into the host cell genome and
efficiently infect both dividing and non-dividing cells. These characteristics qualify lentiviral vectors
as attractive gene transfer vehicles for a range of gene therapeutic applications. In 2003, the Lens
Epithelium-Derived Growth Factor/p75 (LEDGF/p75) was identified as the major cellular cofactor
orchestrating lentiviral integration and integration site selection. This manuscript encompasses two
lines of research with a main focus on LEDGF/p75. In a first part I modified LEDGF/p75 to redirect
lentiviral integration, improving the lentiviral vector genotoxicity profile for gene therapeutic purposes
(see Chapter 3). In a second part, I studied the effect of the LEDGF/p75-IN interplay, lentiviral
integration site distribution and nuclear topology on HIV latency and reactivation (see Chapter 4).
Both studies are preceded by a general introduction on HIV molecular biology.
1.1 HIV, the causative agent of AIDS
1.1.1 HIV epidemiology
Human Immunodeficiency Virus (HIV) is a human pathogen and the causative agent of the Acquired
Immune Deficiency Syndrome or AIDS. A series of reports on clustered cases of Pneumocystis carinii
pneumonia [Centers for Disease Control (CDC), 1981] and Kaposi’s sarcoma [Hymes et al., 1981] among
homosexual men in the early 80’s triggered global awareness for a till then unknown disease. Few more
years after these reports the research groups of Prof. Luc Montagnier [Barre-Sinoussi et al., 1983]
(Institute Pasteur, Paris) and Prof. Robert Gallo [Gallo et al., 1983] (National Cancer Institute,
Washington D.C.) isolated a new virus strain, coined Lymphadenopathy-Associated Virus or Human
T-Lymphotropic Virus III respectively, acting as the responsible etiological agent of AIDS. Both viruses
were shown to be identical and later renamed Human Immunodeficiency Virus (HIV) in 1986. The HIV
virus originated from separate zoonotic transmissions with SIV (Simian Immunodeficiency Virus) strains
from African primate species. HIV type-1 was transmitted from chimpanzee [Gao et al., 1999], whereas
HIV type-2 originated from sooty mangabey monkeys [Sharp et al., 2001]. The HIV type-1 accounts for
the current global HIV pandemic and almost invariably results in immunodeficiency while HIV-2 is less
transmissible and infection progresses more slowly towards AIDS. Since the start of the AIDS pandemic
in the early 1980s and until recently, annual AIDS deaths have been steadily increasing. Today over 36
million people across the world are living with HIV (UNAIDS, 2015) of which the majority are living
in Sub-Saharan Africa. 2.1 million new infections were estimated in 2015 with over 1 million annual
deaths from AIDS-related causes. HIV-1 infection in humans is considered to be pandemic by the World
Health Organization (WHO, Global summary of the AIDS epidemic, 2010)). Introduction of effective
combination AntiRetroviral Therapy (cART) in the late 1990’s is able to suppress plasma viral loads
below the level of detection and dramatically reduced mortality and morbidity associated with HIV-
1 infection. Yet currently, merely half of the diagnosed cases worldwide have access to antiretroviral
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therapy (17 million). However, despite the success of cART, persistence of latent, replication-competent
HIV provirus remains the major impediment towards a cure of HIV/AIDS.
1.1.2 Retroviral taxonomy
HIV is an enveloped RNA virus enclosing a diploid, single-stranded, positive RNA genome and belongs
to the family of the retroviridae (Retroviruses). A hallmark of these viruses is their ability to reverse
transcribe their RNA genome into a double stranded DNA copy which gets stably incorporated into
the host cell genome by the viral integrase enzyme (IN). This integration event irreversibly links the
fate of the invading virus to that of its host cell. Depending on their genetic complexity retroviruses
are generally categorized as being simple or complex. The subfamily of the Orthoretrovirinae to which
HIV belongs can be divided into six distinct genera based on the phylogenetic alliance of the highly
conserved pol gene: the Alpha-, Beta-, Gamma-, Delta-, Epslilonretroviridae and Lentiviridae. The
subfamily of Spumaretrovirinae only consists of the Spumaviridae. Classification based on pol similarity
is congruent with a number of other structural and biological traits; significant differences are found
in genetic complexity, host range and host interaction. HIV belongs to the Lentiviridae, with lentus
meaning slow referring to the long incubation period between initial infection by an HIV founder virus
and the onset of clinical symptoms of AIDS (see Section 1.1.3). These lentiviruses harbor the unique
capability to infect non-dividing cells in addition to dividing cells. Different HIV-1 strains can be further
classified into genetically diverse subgroups M, N, O and P, of which M is the most prevalent.
1.1.3 HIV pathophysiology
In general, HIV transmission occurs via semen or vaginal fluid upon sexual contact, via infected blood
(-products) or in a vertical manner from mother to child. Disease progression towards AIDS can be
roughly divided in three phenotypically distinct phases: I) acute seroconversion, II) asymptomatic
infection (or clinically latent phase) and III) AIDS. Acute infection (phase I, Figure 1.1 panel a on page
4) is initiated at the mucosal membrane where a first infected focal founder population of CD4+ T-cells
allows for rapid viral expansion and a boost in plasma viral loads causing a strong inflammatory response
(Figure 1.1 panel b). This acute phase can be associated with flu-like symptoms and lymphadenopathy.
Of note, early during infection a reservoir of latently infected cells is established mainly residing in long-
lived memory CD4+ T-cells. The subsequent immune system clearance (innate and adaptive immune
responses) contributes to the establishment of a steady state level (asymptomatic phase II, Figure 1.1
panel a). Here, infected individuals show relatively few or no symptoms even though ongoing viral
replication occurs. This phase is typically characterized by a slow (lentus) decline in CD4+ T-cells (the
predominant target cells of HIV) and disease progression. The decrease in CD4+ T-cells is a consequence
of both immune hyperactivation driving T-cell apoptosis and viral cytophatic effects [Goonetilleke et al.,
2009]. Over time mutations in key epitopes emerge often leading to immune escape as a consequence
of the error prone HIV RT function. The final phase III is characterized by AIDS (Figure 1.1 panel a)
usually taking place around 10 years post infection and is diagnosed when CD4+ T-cell counts shrink
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to less than 200 cells/µl. Deregulation of the CD4+/CD8+ T-cell balance leads to an improper immune
response, unable to adequately counteract opportunistic infections such as e.g. Kaposi’s sarcoma or
Tuberculosis (TB) which remains the leading cause of death among people living with HIV.
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Figure 1.1: Disease progression from viral infection to the development of AIDS. Panel a) depicts
the CD4+ T-cell counts and plasma viral load changes over time post HIV founder infection for untreated
patients. During the course of infection viral escape mutants arise allowing HIV to bypass the immune surveil-
lance. The reservoir of latently infected cells is established already early during infection and persists during
the life time of the patient (mainly in resting memory CD4+ T-cells). Panel b) depicts the acute immune re-
sponse to HIV infection as represented by the changes in immune activation and production of non-neutralizing
antibodies and HIV specific T-cells. CD, cluster of differentiation; LPS, lipopolysaccharide. (Modified from
[Maartens et al., 2014])
1.1.4 HIV particle structure and genomic organization
An enveloped HIV virion has a spherical morphology with a diameter of roughly 100 to 120 nm (depicted
in Figure 1.2 a on page 5). The phospholipid envelope bilayer contains the viral surface glycoprotein
gp120 (SU) and transmembrane protein gp41 (TM) forming the viral spikes or cap (composed of three
gp120 units and three gp41 units). The inner surface of the envelope is lined by the matrix (MA or p17)
protein which encloses a cone-shaped core, constituted of hexamers and pentamers of CA protein or p24
[Pornillos et al., 2011]. The viral core encompasses two positive single strands of a 9.7 kb RNA genome
along with viral (IN, RT, PR, Nef, Vpr and Vif) and cellular proteins. This viral diploid RNA genome
is covered by nucleocapsid (NC or p7) proteins. The HIV-1 genome (Figure 1.2 b, [Foley et al., 2015])
is flanked on both sides by long terminal repeats (LTRs) initially consisting of a 5’ unique element (U5)
and a repeat element (R) at the 5’ end and a 3’ unique element (U3) and R at the 3’ end. Following
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reverse transcription both LTRs contain U3-R-U5, the full-length LTR. Like all other Retroviridae,
HIV-1 contains three major Open Reading Frames (ORFs); gag, pol and env. These ORFs encode
for polyproteins that are subsequently cleaved into mature proteins. Gag encodes for the structural
proteins MA, CA and NC while pol encodes for the viral enzymes PR, RT and IN. Env encodes for
the gp120 and gp41 glycoproteins. In addition, complex retroviruses like lentiviruses encode for several
accessory proteins. In the case of HIV-1 six accessory proteins are present: Vif, Vpr, Tat, Rev, Vpu and
Nef (reviewed in [Simon et al., 2015]). Vif or virion infectivity factor is able to counteract the cellular
restriction factor APOBEC3 (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3),
a single-stranded cytidine deaminase able to induce GG to AG or GA to AA hypermutations. Viral
protein R (Vpr) affects cell cycle arrest and apoptosis. Tat or transactivating protein is the major
determinant of the positive feedback circuitry driving viral transcription. Regulator of viral protein
expression (Rev) binds to the Rev responsive element (RRE), stabilizing unspliced and singly spliced
viral RNA and enhancing nuclear export to the cytoplasm. Vpu or unique viral protein stimulates CD4
receptor degradation. Both Vpu and Nef (negative regulatory factor) prevent tetherin (BST2) from
holding on to the budding virus at the plasma membrane.
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Figure 1.2: HIV-1 particle structure and genomic organization. a) Diagram of an HIV virion depicting
both structural and enzymatic constituents. b) Genetic organization of HIV, a complex retrovirus. The HIV-1
proviral genome is flanked by long terminal repeats (LTRs) at both sides. Like all other Retroviridae, HIV-1
contains three major open reading frames; gag, pol and env. Gag encodes for structural proteins MA, CA and
NC. Pol encodes for the viral enzymes PR, RT and IN. Env encodes for the gp120 and gp41 glycoproteins.
Complex retroviruses like lentiviruses additionally encode for accessory proteins. In the case of HIV-1 these
accessory proteins are the virion infectivity factor (Vif), the viral protein R (Vpr), the transactivating protein
(Tat), Regulator of viral protein expression (Rev), unique viral protein (Vpu) and negative regulatory factor
(Nef). PR, protease; NC, nucleocapsid; SU, surface envelope glycoprotein; TM, transmembrane protein; MA,
matrix; CA, capsid; RT, reverse transcriptase; IN, integrase; LTR, long terminal repeat.
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1.1.5 HIV replication cycle
In order to replicate in their hosts, viruses need to navigate around the complexities of the cell, co-opting
mechanisms of cellular physiology while defeating restriction factors able to halt their proliferation. The
success of HIV-1 stands in contrast to its apparent simplicity. Even though its small 9.7 kb genome
only encodes 15 mature proteins (depicted in Figure 1.2 on page 5) the virus is able to elegantly
employ the infected cell and subvert the innate and adaptive immune responses of the host, resulting
in a persistent infection in humans. Viral replication proceeds through a number of characteristic
steps, depicted in Figure 1.3 on page 7. Briefly, HIV predominantly infects CD4+ T-cells like T-
lymphocytes, macrophages and dendritic cells through initial attachment (1) of the gp120 spike proteins
to the cellular CD4 receptor. The latter allows interaction with the C-X-C chemokine receptor type
4 (CXCR-4, R4 tropic HIV) or C-C chemokine receptor type 5 (CCR5, R5 tropic HIV) co-receptors
which induces a conformational change that triggers membrane fusion (2) of the viral particle with
the host cell membrane. Of note, for research purposes HIV particles are often pseudotyped with a
Vesicular Stomatitis Virus Glycoprotein (VSV-G) envelope which broadens the cell tropism but leads
to a different entry mode. Upon fusion the viral core is released into the cell cytoplasm. En route
towards the nucleus the virus tightly interacts with the cellular cytoskeleton and moves across the
filament network [McDonald et al., 2002]. During this translocation the capsid core uncoats (3) and a
double stranded DNA copy of the viral RNA genome is created by the reverse transcriptase (RT, 4). A
PreIntegration nucleoprotein Complex (PIC) is formed by association of both viral and cellular proteins
and is actively transported into the nucleus via the Nuclear Pore Complex (NPC) (5). Subsequently,
the vDNA intermediate will become integrated in the host chromosomal DNA by means of the viral
integrase enzyme, forever linking the fate of the invading provirus to that of its host cell (6). The
integrated provirus will adopt a silent/quiescent state or actively produce new virions. HIV therefore
hijacks the normal transcription and translation machinery of the host cell. Early multiply spliced RNA
transcripts encode for accessory proteins Tat and Rev. A Tat regulated positive feedback loop stimulates
RNA Pol II mediated HIV transcription by binding to the TransActivation Response element (TAR)
in the viral LTR promoter and attracts the Positive Transcription Elongation Factor-b (P-TEFb). Rev
mediates nuclear export of both unspliced and singly spliced RNA leading to the production of Gag,
Pol, Env. These polyproteins align then at the cellular membrane and assemble into budding viral
particles (10, 11). Upon release the viral particles will undergo proteolytic maturation induced by the
viral PRotease enzyme (PR), producing novel infectious virions (12, 13).
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Figure 1.3: HIV replication cycle. Schematic representation of both ’early’ and ’late’ steps in the HIV
replication cycle together with the antiretroviral drug classes acting on the respective processes. Upon Env-
mediated attachment of the virion to the host cell CD4 receptor and CXCR4 or CCR5 co-receptor, a fusion of
the viral envelope with the cell membrane occurs. Fusion triggers a release of the conical capsid core into the
cytoplasm. On its way to the nucleus the capsid disassembles and RT creates a double-stranded DNA copy of
the viral genome. Various viral and endogenous proteins will assemble into a PreIntegration Complex (PIC)
which is actively imported into the nucleus. The viral integrase catalyzes the insertion of the vDNA into the
host chromatin. Proviral transcription, export and translation of viral mRNA leads to the production of novel
virions. These particles are released from the cell and mature via polyprotein processing by the viral protease.
FIs, fusion inhibitors; NRTIs, nucleoside/nucleotide reverse transcriptase inhibitors; NNRTIs, non-nucleoside
reverse transcriptase inhibitors; INSTIs, integrase strand transfer inhibitors; PIs, protease inhibitors.
1.1.6 Retroviral integration
Upon nuclear entry the PIC encounters the host cell chromatin. The viral integrase inserts the reverse
transcribed viral genome, a point of no return (illustrated schematically in Figure 1.4 on page 8 and
reviewed in [Li et al., 2011]). Hereby the fate of the invading virus is forever linked to that of its host
cell, persisting for the lifetime of the infected cell or its progeny. Briefly, a dimer of IN enzymes bound
to each viral LTR end is required to remove a dinucleotide (GT in the case of HIV) from both 3’ LTR
ends (upon synthesis of the ds vDNA), a process referred to as 3’ processing (3P, Figure 1.4 a and
b). Removal of the terminal GT nucleotides exposes a nucleophilic 3’-hydroxyl group on the conserved
CA dinucleotide. The retroviral intasome will next capture the host target DNA in a specific manner,
showing a weak palindromic sequence preference owing to the intasome central dyad axis (Figure 1.4
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c and subsubsection 1.1.6.2). The processed vDNA with the recessed LTR ends, now in complex with
a multimer of IN proteins (intasome, at least a tetramer [Hare et al., 2010]), will be inserted in the
host cell genome via a transesterification reaction (Figure 1.4 d). This Strand Transfer reaction (ST)
results in a gapped intermediate where both vDNA strands are joined by their 3’ ends to the opposing
strands. The insertion sites are separated by 4-6 bp (reviewed in [Engelman and Cherepanov, 2014]).
These corresponding gaps are repaired by the host cell DNA repair machinery (Figure 1.4 e) leading to
provirus establishment.
3’ - processing
b)a)
Strand transfer
c)
e)
d)
5′
5′
5′
5′ 5′ 5′
Target capture
Disassembly
 and repair
Figure 1.4: Schematic overview of the lentiviral integration process. (a) 3’ processing takes place
on the way to the nucleus following reverse transcription. (b) The water-mediated endonucleolytic cleavage of
the viral DNA (green arrow), 3’ from the conserved CA dinucleotides, generates a reactive 3’-hydroxyl group
at both viral ends (indicated with red circles); The IN - vDNA assembly, known as the intasome, captures
the target DNA (blue) (c) and carries out the strand transfer reaction (yellow stars (d), 3’-end joining). The
two vDNA 3’-hydroxyl ends (red circles) attack a DNA phosphodiester bond on each strand of the host DNA
acceptor with a five-base-pair stagger across the DNA major groove. (e) The removal of unpaired 5’-ends of
the viral DNA (arrows in e) and gap filling are done by cellular repair enzymes. All other 3’-hydroxyl ends
and 5’-phosphate ends are shown as red and green dots, respectively. (Modified from [Pommier et al., 2005])
1.1.6.1 Retroviral integrase and intasome structure
The lentiviral IN is a 32 kDa enzyme encoded by the Pol ORF. All retroviral IN proteins share three
structurally conserved domains which are interconnected by flexible linker regions: (1) the amino-
Terminal Domain (NTD) (2) the Catalytic Core Domain (CCD) and (3) the Carboxy-Terminal Domain
(CTD) (Figure 1.5 on page 9, reviewed in [Jaskolski et al., 2009; Cherepanov et al., 2011]). Together
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these domains are involved in DNA capture and IN multimerization and required for its biological
activity. The NTD contains a His2-Cys2 (HH-CC) Zn2+ coordinating motif involved in stabilization of
the triple helix bundled structure (Figure 1.5 left panel, [Zheng et al., 1996; Cai et al., 1997; Eijke-
lenboom et al., 2000]). The CCD is highly conserved among different Retroviridae and contains the
catalytic DDE triad, which is responsible for the coordination of two Mg2+ or Mn2+ ions necessary for
its activity (Figure 1.5 middle panel). The CCD domain is composed of five β-sheets surrounded by
several α-helices. The CTD forms a 5-stranded β-barrel structure (Figure 1.5 right panel).
NTD1–46 CCD59–202 CTD223–270
Zn2+
H     C
H     C D
64 D116 E152 288HIV
Figure 1.5: Functional domains of the lentiviral integrase. Depiction of the different HIV-1 integrase
domains; Left panel depicts the tertiary structure of the N-Terminal Domain, middle panel the Catalytic
Core Domain and right panel the C-Terminal Domain (NTD, CCD and CTD, respectively) (Modified from
[Demeulemeester et al., 2015])
Unfortunately, full length HIV IN has been refractory to structural studies. However, structural homol-
ogy among retroviral IN orthologues has allowed their use as a proxy for HIV IN [Hare et al., 2010]. The
crystal structure of the prototype foamy virus IN (PFV, Spumaviridae, Figure 1.6 a & b on page 10)
therefore represented a landmark in the field of retrovirology and unveiled some of the workings of the
integration machinery. Here, the intasome complex consists of a dimer of IN dimers [Hare et al., 2010;
Maertens et al., 2010; Hare et al., 2012; Maskell et al., 2015]. The two inner subunits are responsible for
bridging both dimers and are making extensive contacts with the vDNA [Hare et al., 2010]. Only the
inner dimer is responsible for the integration reaction while the outer IN dimers interact solely through
the CCD. The target DNA (tDNA) is accommodated in the cleft between the active sites, displaying
a severely bent conformation. Positioning of the active sites allows targeting of the phosphodiester
bonds in the major groove [Maertens et al., 2010]. This structural insight explains the preference of IN
for host DNA sites that allow a minimal bendability such as nucleosomal DNA [Pryciak and Varmus,
1992; Pruss et al., 1994b,a; Maskell et al., 2015]. More recently, three-domain crystal structures of the
Rous Sarcoma Virus (RSV, Alpharetroviridae, [Yin et al., 2016]) and Mouse Mammary Tumour Virus
(MMTV, Betaretroviridae, Figure 1.6 c [Ballandras-Colas et al., 2016]) together with vDNA indicated
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a novel octameric intasome assembly and highlights a remarkable diversity among retroviruses. Here,
the core is formed by a pair of proximal IN dimers interacting with the vDNA ends and engagement
of two flanking non-catalytic IN dimers via their CTD domain bridging the interaction in trans. Their
respective composition differs in linker length between the CCD and the CTD. For PFV this linker is
comprised of 50 aa residues, which affords positioning of the the inner CTD for both viral and target
DNA binding. In MMTV and RSV this linker is only a mere 8 aa. Therefore, additional flanking
IN dimers are required positioning their CTD in the intasome core. HIV-1 IN however, contains an
intermediate linker length of 20 aa, fueling the ongoing debate about the exact IN stoichiometry in the
HIV intasome complex responsible for concerted integration.
b) PFV 
CTD 1
CT D3
Dimer B (IN3/IN4)
Dimer A (IN1/IN2) 
NTD 1
NED 1
CCD 3
NT D3
NE D3
CCD 4
CCD 2
CCD 1
c) MMTV 
CTD 6 CTD 8
Dimer A (IN1/IN2)
Dimer C (IN5/IN6)
Dimer D (IN7/IN8)
Dimer B (IN3/IN4)
CTD 4
CTD 2
CTD 1
NTD 2
CTD 5 NTD 1
NTD 4
CTD 7
CCD 2
NTD 1
CCD 4
CCD 5
CCD 6
NTD 6
NTD 5
NTD 7 CCD 8
CCD 7
NTD 8
CCD CCD
NEDNED
CCD CCD
vDNAvDNA
tDNA
a) PFV 
Figure 1.6: Retroviral intasome structures. a) Perpendicular representation of the PFV intasome in
complex with the viral and target DNA. Inner subunits form the active cleft (green and blue). b and c) PFV and
MMTV intasome architecture respectively. Core dimers A and B are colored red/orange and green/lightgreen
while for MMTV the flanking IN dimers C and D are colored blue/skye blue and purple/light pink. NTD,
N-Terminal Domain; CCD, Catalytic Core Domain; CTD, C-Terminal Domain; NED, N-terminal Extension
Domain. (Modified from [Maertens et al., 2010] and [Ballandras-Colas et al., 2016])
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1.1.6.2 Determinants of retroviral integration site selection
At first, it was accepted that retroviruses integrated close to random throughout the genome of the
invaded cells. However, during the last decade, it became clear that retroviral integration is a non-
random, multi-step process in which biases are introduced at different levels leading to an integration
profile distinct for all retroviral genera, each favoring specific chromatin environments (reviewed in
[Demeulemeester et al., 2015]). Lentiviruses, such as the Human Immunodeficiency Virus Type-1
(HIV-1) for instance preferentially integrate into the body of actively transcribed regions [Schroder
et al., 2002]. Conversely, gammaretroviruses such as the Murine Leukaemia Virus (MLV) target active
promoter-proximal as well as distal enhancer elements [Wu et al., 2003; Mitchell et al., 2004; LaFave
et al., 2014]. Avian Sarcoma-Leukosis Virus (ASLV, Alpharetroviruses) maintains a preference for
open chromatin regions, but shows no bias for transcriptional regulatory elements or transcription
units [Moiani et al., 2014]. A first asymmetry is introduced by the nuclear entry route (Figure 1.7
panel a on page 12). Lentiviruses evolved the unique ability to traverse nuclear pore complexes (NPC)
allowing them to infect non-dividing cells while other viruses, such as MLV, evolved mechanisms to
segregate along with the chromosomes during mitosis [Elis et al., 2012]. The lentiviral capsid core is
believed to dock onto the cytoplasmic side of the NPC through interactions with Nup358-RanBP2.
Engagement of other nucleoporins such as Nup153 and Nup98-Nup96, additional import factors such
as Transportin-SR2 (TRN-SR2, TNPO3) or cellular cofactors such as Cleavage and Polyadenylation
Specificity Factor 6 (CPSF6) orchestrate the complex process of size limited import of the PIC to
the nucleoplasm. This implies that the first nuclear subcompartment a lentiviral PIC encounters is the
NPC-associated cone-like Heterochromatin Exclusion Zones (HEZs) near their nuclear baskets [Pascual-
Garcia and Capelson, 2014; Sood and Brickner, 2014] adjacent to the heterochromatin amassment of
Lamin-Associated Domains (LADs, [Guelen et al., 2008]). Different fluorescent microscopy studies
reported that the HIV PIC as well as the provirus are located in euchromatin regions in proximity of
the nuclear rim [Albanese et al., 2008; Di Primio et al., 2013] as opposed to MLV, which distributes
more randomly throughout the nucleus [Quercioli et al., 2016].
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Figure 1.7: Overview of retroviral integration targeting parameters. Retroviral integration is a non-
random, multi-step process in which biases are introduced at different levels. a) Taking a specific route into the
nucleus (nuclear import or chromosome segregation upon mitosis) generates a first asymmetry. b) Hijacking of
cellular cofactors further defines tethering towards specific chromatin regions. c) Capture of the nucleosomal
target DNA by the intasome, catalyzing the integration process, results in an additional contribution to the
overall integration site selection. NPC, Nuclear Pore Complex; LEDGF/p75, Lens Epithelium-Derived Growth
Factor p75; BRD4, Bromodomain Containing protein 4. (Modified from [Demeulemeester et al., 2015])
Next the PIC co-opts cellular cofactors tethering it to particular chromatin contexts (Figure 1.7
panel b). In the case of lentiviruses, Lens Epithelium Derived Growth Factor/p75 (LEDGF/p75) is re-
sponsible for directing integration towards the body of active transcription units [Schroder et al., 2002;
Maertens et al., 2003] by direct interaction with the viral IN and specific histone tails (H3K36me3).
Conversely, gamma-retroviral PICs adopt Bromodomain and ExtraTerminal domain (BET) proteins
targeting integration towards active promoter-proximal as well as distal enhancer elements after chro-
mosome segregation [De Rijck et al., 2013; Gupta et al., 2013; Sharma et al., 2013].
A third parameter determining integration site choice is the molecular recognition between the retro-
viral intasome and the local target nucleosome (Figure 1.7 panel c). Recent studies employed the PFV
intasome structure to predict and modify IN-tDNA contacts in the context of HIV-1 infection [Serrao
et al., 2014; Demeulemeester et al., 2014b]. Two IN-aa form close contacts with the tDNA base (HIV-1
INS119 and INR231) and directly influence the local palindromic sequence preference owing to the central
dyad axis. Different amino acids at these two positions yield distinct local sequence biases for viral
integration and modulate central tDNA bending. Surprisingly, HIV-1 INS119G and INR231G mutations
at these positions also shifted global integration preference away from gene-dense regions which could
possibly be explained by different tDNA bending requirements which consequently reduces the shape
and/or electrostatic compatibility with certain nucleosomes.
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1.1.6.3 LEDGF/p75, an HIV IN cellular cofactor
Lens Epithelium Derived Growth Factor p75 or LEDGF/p75 is a ubiquitously expressed chromatin
reader of 530 aa encoded by the PC4- and SFRS1-interacting protein 1 gene (PSIP1 ) together with
its smaller splice variant LEDGF/p52 (333 aa), which is located on chromosome 9p22.2 (Figure 1.8
on page 14, [Ge et al., 1998]). LEDGF/p75 has been identified as the main cellular cofactor directing
lentiviral integration towards the body of actively transcribed genes and was initially discovered as a
binding partner of the lentiviral IN in 2003 [Cherepanov et al., 2003]. Meanwhile LEDGF/p75 has been
thoroughly validated as an essential HIV cofactor (for a review see [Debyser et al., 2015]).
LEDGF/p75 is a bimodal protein and a member of the Hepatoma-Derived Growth Factor (HDGF)
family, characterized by its N-terminal PWWP domain corresponding to the Pro-Trp-Trp-Pro motif
(aa 1-91 Figure 1.8, [Izumoto et al., 1997; Stec et al., 2000]). This domain recognizes nucleosomal DNA
and specific methyl lysines on histone tails (H3K36me3), present in transcriptionally active chromatin
regions [Eidahl et al., 2013; van Nuland et al., 2013]. In addition to the chromatin reading domain,
LEDGF/p75 contains several additional DNA binding motifs; a nuclear localization signal (NLS, aa
148-156 [Maertens et al., 2004]), two A/T hook-like elements (aa 178-199) [Maertens et al., 2004; Llano
et al., 2006] and 4 charged regions (CR1-4) overlapping with a negatively super-coiled DNA recogni-
tion domain (aa 206-336, CR-2-4) [Tsutsui et al., 2011]. Aside from these N-terminal chromatin/DNA
interacting domains, LEDGF/p75 also harbors a unique C-terminal protein binding domain (PBD, aa
347-454), which is absent in LEDGF/p52. In contrast, LEDGF/p52 contains a small C-terminal tail of
8 aa residues. The PBD is constituted of a compact right-handed bundle of 5 α-helices which has been
coined Integrase Binding Domain or IBD [Cherepanov et al., 2004]. The main interaction interface
with the lentiviral IN is formed between the IBD of LEDGF/p75 and the catalytic core domain of
IN dimers. Binding of LEDGF/p75 to the viral integrase dimer interface modulates IN multimeriza-
tion and catalytic activity [Cherepanov et al., 2003], protecting IN from proteolytic degradation [Llano
et al., 2004]. Next to LEDGF/p75 the paralogue Hepatoma Derived Growth Factor-Related Protein
2 (HRP-2, HDGFRP2 ) is the only additional endogenous protein carrying both such PWWP and
IBD domains (Figure 1.8, [Cherepanov et al., 2004]). HIV IN hijacks these host cell proteins in order
to tether the viral Pre-Integration Complex (PIC) towards the host cell chromatin [Schrijvers et al.,
2012b; Wang et al., 2012]. Depletion of LEDGF/p75 reduces HIV infection and shifts integration out
of transcription units, a phenotype which is more pronounced in LEDGF/p75 KO cells [Ciuffi et al.,
2005; Shun et al., 2007; Marshall et al., 2007; Schrijvers et al., 2012b], although still not completely
random. This bias in part can be ascribed to HRP-2. Only in the abscence of LEDGFp/75, HRP-2
orchestrates integration site selection [Schrijvers et al., 2012b; Wang et al., 2012]. Simultaneous knock
down of both proteins further reduces, but not completely abolishes, integration in transcription units
[Schrijvers et al., 2012b,a]. Biophysical studies revealed a scan-and-lock mechanism for chromatin teth-
ering of LEDGF/p75 [Hendrix et al., 2011]. The remaining preferences are determined by the intrinsic
IN properties and for a major part by nuclear topology or nuclear entry route.
Not much is known about the exact physiological roles of LEDGF/p75. In general, LEDGF/p75 func-
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tions as molecular tether for a variety of proteins to the cell chromatin (Figure 1.8) such as the Mixed-
Lineage Leukemia/Menin (MLL/MENIN) complex [Yokoyama and Cleary, 2008], CDC7-activator of S
phase kinase complex [Hughes et al., 2010], JPO2 [Maertens et al., 2006; Bartholomeeusen et al., 2007]
and Pogo transposable element with zinc finger domain (PogZ, [Bartholomeeusen et al., 2009]). Some
reports suggested a possible role for LEDGF/p75 as a transcriptional co-activator in promoting cell
survival under stress conditions [Shinohara et al., 2002] and functioning in homologous recombination
upon induction of a DNA double-stranded break [Daugaard et al., 2012].
PWWP
AT-hooks
333
IBD
NLS SRD
530
LEDGF/p52
LEDGF/p75
671HRP2
1 91 148–156 206–333
178–199
1 91 148–156 206–339
178–199
347 454
1 91 222–231 304–462273–294 470 576
D366
Figure 1.8: Schematic representation of the LEDGF/p52, LEDGF/p75 and HRP-2 domain struc-
ture. The PSIP1 gene encodes for two distinct splice variants LEDGF/p52 and LEDGF/p75. LEDGF/p75
contains a unique C-terminal protein-binding domain, coined Integrase Binding Domain (IBD, blue) responsi-
ble for HIV-IN interaction. Several endogenous proteins like JPO2, PogZ and MLL bind to the same interface.
At its N-terminal end LEDGF carries multiple chromatin interacting domains; the PWWP domain (green),
the AT hook-like domain (AT, red), four charged regions (CR1-4) and a negatively super-coiled DNA recogni-
tion motif. D366 is a pivotal amino acid involved in HIV-IN interaction (green arrowhead). Mutation to Asn
(D366N) abolishes HIV-IN interaction. HRP-2 is the only human paralogue carrying both a PWWP and an
IBD domain. Boxes highlight, from left to right, structures of a PWWP domain bound to a methylated histone
peptide (in red), and the IBD. PWWP, Trp- Pro-Pro-Trp; NLS, Nuclear Localization Signal; AT-hook, AT-
hook minor groove DNA binding motif; SRD, Super-Coiled DNA recognition region; IBD, Integrase-Binding
Domain. (Modified from [Demeulemeester et al., 2015])
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1.1.6.4 Small molecules targeting the LEDGF/p75-IN interface
Integration into the host cell genome is a pivotal step in the HIV replication cycle and is catalyzed by
the viral IN enzyme. Blocking the viral IN therefore forms a valuable therapeutic target for antiviral
therapy. Targeting of its catalytic function led to the development of several potent INtegrase Strand
Transfer Inhibitors (INSTIs), such as raltegravir (RAL, MK-0518), elvitegravir (EVG, JTK-303/GS-
9137) and dolutegravir (DTG, S/1349572) which represent a significant milestone in the field of HIV-1
drug discovery and are currently in clinical use (see Figure 1.10 a on page 17). However, a steady HIV
mutation rate together with poor adherence may result in cART escape mutations and the emergence of
drug resistant HIV strains causing subsequent treatment failure. Emergence of (cross)-resistance against
INSTIs in patients receiving treatment therefore warranted research into novel, allosteric non-catalytic
IN inhibitors with distinct mechanisms of action.
LEDGF/p75 knockdown/knockout studies showed that the LEDGF/p75-IN interaction is crucial for
HIV replication [Ciuffi et al., 2005; Shun et al., 2007; Marshall et al., 2007; Schrijvers et al., 2012b]. Over-
expression of the IBD domain or LEDGF/p75 based peptides outcompeted endogenous LEDGF/p75
and blocked HIV replication [De Rijck et al., 2006; Hayouka et al., 2007]. In 2005 Cherepanov et al.
reported the crystal structure of the HIV-IN CCD dimer in complex with the LEDGF/p75 IBD (PDB
accession number 2B4J, [Cherepanov et al., 2005]). Amino acids Ile365, Asp366, Phe406 and Val408 of
LEDGF/p75 where shown to be crucial in mediating the interaction with IN. The LEDGF/p75-IN
interaction site comprised a well-defined binding pocket and led to the structure based development of
two 2-(tert-butoxy)-2-substituted acetic acid derivatives, at the University of Leuven (LEDGIN 1 & 2,
depicted in Figure 1.10 b). These compounds comprised a novel class of potent allosteric IN inhibitors
and were coined LEDGINs [Christ et al., 2010]. Co-crystals of the identified hit compounds soaked into
the HIV-1 IN CCD confirmed the initial pharmacophore binding to the LEDGF/p75 binding pocket
on the CCD dimer interface (see Figure 1.9 on page 16), information which was crucial for the design
and further development of the more potent congeners CX05045 [Christ et al., 2010] and CX014442
[Christ et al., 2012] with improved biological activities, inhibiting HIV replication in the nanomolar
range (Figure 1.10 b). CX014442 inhibits viral replication at an EC50 of 69 ± 3 nM and a selectivity
index of 1391 (CC50/EC50) comparable to those of FDA approved drugs. In addition, these congeners
displayed a dose-response curve with a steep Hill slope.
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Figure 1.9: LEDGINs bind to the IN dimer interface. a) Structures depicting the LEDGF/p75
IBD (pale green) in complex with a dimer of IN CCDs (light and dark grey) (PDB acession number 2B4J). b)
LEDGF/p75 integrase binding domain (IBD) binding to the well-defined pocket formed by two IN CCD dimers.
c) Superposition of LEDGIN3 on the LEDGF/p75 IN interface [Christ et al., 2010] (PDB acession number 2B4J
and 3LPI respectively). d) LEDGINs are able to displace LEDGF/p75. Their concensus pharmacophores are
based on residues Ile365, Asp366 and Leu368. Renderings are generated using the PyMOL software [Schrödinger,
LLC, 2015].
Apart from structure based design, other groups have independently identified small molecules
inhibiting the LEDGF/p75-IN interaction based on a high throughput screening assay, e.g. Boehringer
Ingelheim, Canada (BI, Figure 1.10 b [Fader et al., 2014]). The LEDGIN compounds core is relatively
solvent exposed and may be varied while the key pharmacophoric feature is an acetic acid group
substituted in the 2-position with hydrophobic bulk, preferably ter-but(oxy/yl), paced in ortho from a
substituted phenyl ring. The importance of the acetic acid residue lies in mimicking of the LEDGF/p75
residue D366. At present, LEDGINs are still early in the clinical developmental stage (BI 224436) but
have gained significant interest of nearly all major pharmaceutical companies involved in the treatment
of HIV/AIDS (a patent overview is provided in [Demeulemeester et al., 2014a]).
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Figure 1.10: INSTIs & LEDGIN congeners. Figure depicting different a) integrase strand transfer
inhibitors (INSTIs) and b) LEDGINs developed by the KU Leuven and others (Boehringer Ingelheim (BI) as
reviewed in [Demeulemeester et al., 2014a]. (Modified from [Demeulemeester et al., 2014a])
LEDGINs display a multi-modal mechanism of action.
By perturbing IN assembly LEDGINs compete with the LEDGF/p75 cofactor and block chromatin
tethering of the PIC. Unlike strand transfer inhibitors potent LEDGIN congeners inhibit both strand
transfer and 3’-processing catalytic activities, and enhance the formation of IN dimers, disrupting
the precise and timely IN oligomeriation which prevents a productive complex assembly (’early effects’,
Figure 1.11 on page 18, [Christ et al., 2010, 2012; Kessl et al., 2012]). Moreover, binding of LEDGINs to
the IN dimer interface is independent of LTR assembly (in contrast to INSTIs). The enhanced potency
of LEDGINs in LEDGF/p75 knockout cells highlights the importance of LEDGF/p75 displacement
during the early steps [Wang et al., 2012]. Additionally, when LEDGINs are present during the late
stages of viral replication the newly produced virions are significantly less infectious showing defects
during reverse transcription, nuclear import and integration stages of the next round infection (’late
effect’, Figure 1.11, [Le Rouzic et al., 2013; Jurado et al., 2013; Desimmie et al., 2013; Gupta et al.,
2014]). Both effects synergistically contribute to the overall inhibition of HIV-1 replication and cannot
be uncoupled in the infected cell. Transmission electron microscopy studies revealed that roughly 60
% of the produced particles displayed morphological aberrations (ribonucleoprotein mis-localization
outside the capsid core or cone malformation). When pre-incubated with HIV IN prior to addition
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of the LTR fragment, CX014442 and BI-B/1001 also inhibited 3’ processing and strand transfer in
vitro in the submicromolar range [Christ et al., 2012; Kessl et al., 2012]. Overall, LEDGINs display
activity against different HIV clades (HIBIIIB, HIVBAL, HIVU2, HIVNL4.3) and clinical isolates [Christ
et al., 2010, 2012; Fenwick et al., 2014] but are less active against HIV-2 and SIV due to a amino acid
substitution at position IN128 involved in the interaction with LEDGF/p75365. LEDGIN resistant HIV
strains however did not display any cross-resistance to INSTIs. An additive or even modest synergistic
inhibitory phenotype is observed when co-administered together with most NRTIs/NNRTIs or INSTIs
[Christ et al., 2012; Fenwick et al., 2014].
5’LTR 3’LTR
Maturation
Reverse
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Nuclear
Import
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Integration
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Figure 1.11: Multi-modal mechanism of action of LEDGINs. During EARLY replication steps,
LEDGINs act as allosteric inhibitors of HIV IN through a stabilizing effect on IN multimerization, ultimately
leading to the inhibition of the 3’ processing and DNA strand transfer. Simultaneously the binding of LEDGINs
to integrase inhibits the interaction with the chromatin tethering factor LEDGF/p75 leading to a block in HIV
integration. When LEDGINs are present during the formation of viral particles, increased formation of IN
multimers leads to a maturation defect evidenced by misshaped viral particles with the ribonucleoprotein
located outside of the viral core (’late effect’). This maturation defect leads to aborted reverse transcription
and defective nuclear import upon de novo infection of the host cell.
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1.2 Towards an HIV cure
The development of antivirals in the last decades revolutionized the treatment of HIV/AIDS, enabling
clinicians to suppress HIV replication to undetectable levels, restore the immune system of an infected
individual and profoundly increase a patients survival which turned HIV infection from a life-threatening
disease into a chronic disorder. Yet, current antiretroviral therapy fails to cure HIV infection nor does it
fully prevent pathology or restore the normal life span of HIV-infected patients. The major impediment
towards an HIV cure lies in the existence of a stable reservoir of latently infected cells having a long
half-life and carrying replication competent provirus. In addition, anatomical sanctuaries where the
drug penetration is poor could allow low levels of ongoing viral replication [Lorenzo-Redondo et al.,
2016]. Upon infection of the host cell, HIV can either actively replicate to rapidly produce progeny
virions (which typically results in cell death) or enter a long-lived quiescent state. The dormant pool of
virus is established in few infected cells early on during acute infection and enables HIV to persist for
decades evading host immune surveillance and potent cART. It is the presence of this latent provirus
that triggers a rapid rebound of viremia within weeks after therapy cessation requiring patients to
adhere to a lifelong suppressive therapy which on its turn may be associated with drug related side
effects (reviewed in [Torres and Lewis, 2014]). Moreover, the rapid replication and mutation rate of HIV,
its extensive genetic diversity and suboptimal compliance of patients to ART drive HIV in becoming
increasingly drug resistant resulting in treatment failure. Therefore, new curative strategies to treat
HIV/AIDS are urgently needed and exhaustion of the latent reservoir has become a highly prioritized
goal in HIV-1 research. Over the past years, tremendous progress has been made in defining and
characterizing this latent reservoir which is summarized in the next subsections.
1.2.1 HIV reservoirs and anatomical sanctuaries
HIV tropism is mainly defined by the interaction of the viral envelope glycoproteins (gp120 and gp41,
see section 1.1.5) with the CD4 cellular surface receptor and CXCR4 or CCR5 co-receptors. Hence,
HIV specifically targets CD4+ T-cells and cells of the monocyte/macrophage lineage. Other chemokine
receptors such as CCR3 and CCR8 can also function as HIV co-receptors and therefore HIV, although to
a lesser extent, is also able to infect dendritic cells (DCs), natural killer (NK) cells and some specialized
cell types of the central nervous system (CNS) (see Figure 1.12 on page 1.12, [Churchill et al., 2009]).
In activated T-cells HIV infection generally proceeds with the generation of progeny virions while in
resting T-cells the virus is more likely to enter quiescence as part of the host cell genome. Resting,
memory CD4+ T-cells form the most prominent cells contributing to the long-lived latent reservoir,
with a frequency of 1/106 resting CD4+ T-cells harboring latent provirus in patients receiving cART
(estimated using the viral outgrowth assay, VOA [Eriksson et al., 2013]). Recent experimental evidence
however showed that a fraction of the non-reactivated proviruses is still replication competent and that
the exact size of the latent reservoir might be larger than initially anticipated. Quantitative PCR
measurements suggested a ± 60-fold underestimation of the reservoir size by VOA measurements [Ho
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et al., 2013]). Infection of resting CD4+ T-cells is far less efficient than activated CD4+ T-cells [Swiggard
et al., 2005], therefore HIV latency may primarily be established upon transition of activated cells
towards a resting memory state [Siliciano et al., 2003]. However, ex vivo latency can also be established
directly in activated T-cells [Chavez et al., 2015]. Next to the well-established and characterized resting
CD4+ T-cell reservoir, several groups have confirmed the presence of latent provirus in the heterogeneity
of tissues targeted by HIV including the Gut-Associated Lymphoid Tissues (GALT, [Yukl et al., 2013b;
Chun et al., 2008; Yukl et al., 2010]), gentical tract, lymph nodes, CNS and spleen. At present the key
question remains which exact cellular source is responsible for reseeding of viral infection upon therapy
cessation. More controversial is the question whether ongoing replication or homeostatic proliferation
[Chomont et al., 2009; Bosque et al., 2011; Maldarelli et al., 2014] is involved in maintenance of the
HIV-1 reservoir. Trace levels of viremia have been previously reported in ART treated patients [Frenkel
et al., 2003] supported by genetic divergence [Palmer et al., 2008; Shiu et al., 2009; Fletcher et al.,
2014; Lorenzo-Redondo et al., 2016] with impaired drug penetration in lymphatic tissues allowing
ongoing replication to contribute to the latent reservoir. Others found an increase in 2-LTR circles
following cART intensification using INSTIs [Buzón et al., 2010; Hatano et al., 2013]. These data
would point towards a role for ongoing replication in the maintenance of HIV persistence. However, the
lack of a reduction of the reservoir size upon cART intensification and a lack of viral evolution in other
studies challenged these conclusions [Gandhi et al., 2012; Kearney et al., 2014; Chéret et al., 2015b]. It
will become clear in the next paragraphs that both the heterogeneity in cell types and corresponding
diversity in molecular mechanisms responsible for the establishment and maintenance of latent provirus
together with the lack of biomarkers able to distinguish latently infected cells from uninfected cells
complicate the search for an HIV cure.
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Figure 1.12: Latent reservoirs. Figure depicting the heterogeneity of anatomic focuses harboring latent
HIV infections. In addition to resting memory CD4+ T-cell subsets found in the peripheral blood, a significant
portion of latently infected cells can be found in the lymphoid tissue, GALT and CNS. Furthermore, tissues
such as lungs and skin may also contain latent HIV proviruses and unknown reservoirs remain to be defined.
The unique characteristics of each cell type harboring latent provirus illustrates the multifactorial nature of
transcriptional latency. (Figure derived from [Barton et al., 2016])
1.2.2 Heterogenous regulatory mechanisms of HIV Latency
HIV latency has long been believed to be an epiphenomenon rather than an evolutionary maintained
threat until recently some proposed that latency is "hardwired" into the HIV’s gene-regulatory circuitry
[Razooky et al., 2015; Rouzine et al., 2015]. Modeling studies predicted enhanced transmission of
virus having an innate propensity to establish a latent infection which could provide a transmission
advantage by enabling the virus to persist in the mucosal environment [Rouzine et al., 2015]. In the
following section the major endogenous host-cell mechanisms, host-cell environmental and autonomous
viral circuitry controls involved in the regulation of this phenotypic bifurcation are highlighted. At
present the exact interplay between these parameters remains largely unclear and may be biologically
distinct within different cell populations of the latent reservoir, yielding a number of possible distinct
basal transcriptional states for HIV soon after infection. In general, two different types of latency can be
designated based on the integration state of the viral DNA; I) pre-integration and II) post-integration
latency. Unintegrated HIV-1 DNA (pre-integration latency) will either degrade or integrate in the
host cell genome and is likely to present a stable reservoir only in slowly or non-dividing cells such as
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macrophages. Post-integration latency on the other hand refers to the presence of integrated retroviral
DNA which is transcriptionally inactive. Here, the mechanisms controlling HIV latency can be broadly
classified in cis-acting such as the site of integration or local chromatin environment and trans-acting
mechanisms such as transcription factor regulation, cellular relaxation state etc.
viral genome
NF-kB Sp1 TBP
P-TEFb
Tat-
TAR
...
5’ LTR5’ flanking chromatin
Nuclear architecture
Chromatin conformation
3’ flanking chromatin
+ +
Poll II
transcriptional interference (occlusion, collision)
influencing or deregulation
Latent
Active
P
(a
ct
)
P
(inact)
Nuc-0 Nuc-1
Me
CpG
Me Me Me
CpG
(cytoplasmic) 
TF Sequestration
coactivators/chromatin modifiers
CpGCpG
Rev
MS RNA
Nuclear export
Translation Host miRNA
RISC
TCR
signaling
Figure 1.13: Simplified model of HIV-1 proviral transcription. Schematic representation of HIV-1
proviral transcription. The chromatin context, both in cis and in trans, together with the presence of various
LTR-binding transcription factors, determine the intrinsic proviral activity through various other co-activators
and chromatin modifiers. The viral Trans-activator of transcription (Tat) binds to the Trans-Activation Re-
sponse (TAR) RNA stem-loop at the 5’ end of viral transcripts and recruits P-TEFb stimulating transcription
elongation. Amplification of basal viral expression by this Tat positive feedback creates a robust latency switch.
Influencing the different parameters of the switch, results in different probabilities for the ON and OFF states.
Me, Methylation; TCR, T-Cell Receptor; MS RNA, Multiply Spliced RNA; miRNA, microRNA; RISC, RNA-
Induced Silencing Complex; TF, Transcription Factor; TBP, TATA-Binding Protein; NFκB, Nuclear factor-κB;
P-TEFb, Positive Transcription Elongation Factor b. (Modified from [Demeulemeester et al., 2015])
1.2.2.1 Viral gene-regulatory circuitry
After integration of the HIV-1 virus in the host cell genome, the virus completely relies on the host
RNA polymerase II (Pol II) for RNA transcription and the subsequent generation of viral proteins.
This transcriptional process can be generally subdivided in different stages; pre-initiation, initiation,
promoter clearance, elongation, and termination [Fuda et al., 2009]. The HIV genome encodes for
a transcriptional master circuitry which is driven by the HIV Tat protein. Upon infection, HIV-1
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will initially produce only short completely spliced mRNAs encoding the viral regulatory proteins Tat
and Rev. Tat or transactivator of transcription protein is an absolute requirement for transcription
elongation [Jones, 1997] and will establish a positive feedback loop able to amplify stochastic fluctuations
in basal transcription from the viral promoter [Weinberger et al., 2005, 2008; Burnett et al., 2009] by
enhancing RNA pol II efficiency and processivity [Peterlin and Price, 2006]. Elongation will result in the
synthesis and nuclear export of longer unspliced species of RNA mediated by Rev. These longer RNA
products are required for the generation of infectious viral particles. When Tat accumulates above
a critical threshold level, HIV transcription elongation is stimulated by binding of the Tat protein
to an RNA stem cell loop structure called the Trans-Activation Response (TAR) element present at
the 5’ end of all viral transcripts and recruitment of the Positive Transcription Elongation Factor b
(P-TEFb). P-TEFb forms a heterodimer composed of the cyclin-dependent kinase 9 (CDK9) and its
regulatory partner cyclin T1 (CycT1) and is able to phosphorylate, either directly or indirectly, the
C-terminal domain (CTD) of the largest subunit (RPB1) of Pol II. In addition P-TEFb phosphorylates
several negative elongation factors. In the cell, the P-TEFb level is tightly regulated as it is required
for elongation of many endogenous genes. P-TEFb can be sequestered in a kinase-inactive complex
containing the 7SK small nuclear RNA (snRNA) [Nguyen et al., 2001; Yang et al., 2001]. The integrity
of the 7SK snRNP complex is maintained by other associated factors such as HEXamethylene bis-
acetamide inducible 1 (HEXIM1), Lupus Antigen Related Protein 7 (LARP7) and MePCE which
control sequestration of unused P-TEFb in the inactive state. In resting CD4+ T-cells CycT1 levels
are rather low and P-TEFb is sequestered promoting a latent phenotype [Hoque et al., 2011; Chiang
and Rice, 2012; Budhiraja et al., 2013]. Under specific conditions including TCR activation or the
exposure of cells to hypertrophic or stress signals P-TEFb is released. The free P-TEFb is generally
engaged by Brd4, which recognizes specific acetylated histones, and tethered to chromatin regions
in order to stimulate transcription elongation. The HIV Tat protein however will directly compete
with Brd4 for recruitment of P-TEFb in order to ameliorate HIV transcription elongation (reviewed
in [Liu et al., 2014]). Of note, Brd4-P-TEFb appears to be relevant for basal HIV-1 transcription
but is inhibitory to Tat-transactivation [Yang et al., 2005]. Recent evidence suggests that stochastic
fluctuations in the Tat circuit are sufficient in driving the provirus in one of the respective transcriptional
phenotypes [Weinberger et al., 2005, 2008; Burnett et al., 2009]. It appears as if viral evolution evolved
to a modular viral circuitry which is able to maintain a remarkable autonomy from environmental
stimuli and simultaneously being influenced by probabilistic ON-OFF decision making. The hardwiring
of this latency switch has been proposed to represent a bet hedging strategy, preserving fitness in
unpredictable, fluctuating environments by probabilistically switch phenotypes optimized to maximize
lentiviral transmission.
1.2.2.2 Environmental determinants
Just like expression of endogenous genes, the transcriptional profile of integrated proviral DNA is
affected by a combination of environmental parameters. Because eukaryotic chromatin is highly orga-
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nized and contains very versatile environments displaying different degrees of compaction it has long
been suspected that the integration site and associated local chromatin context could affect the HIV
transcriptional phenotype. HIV integration is a non-random process which is preferentially targeted
into transcriptionally active regions in proximity to the nuclear rim [Di Primio et al., 2013; Marini
et al., 2015]. This integration preference is orchestrated by interaction of the HIV-IN protein with
LEDGF/p75 [Ciuffi et al., 2005] and to a lesser extent HRP-2 [Schrijvers et al., 2012b]. Several studies
reported on the dependency of the HIV expression levels on the surrounding chromatin context and 3D
spatial localization, a variabile inducing up to a 1000 fold difference in expression levels and affecting
the transcriptional noise [Jordan et al., 2001; Singh et al., 2010; Dar et al., 2012; Akhtar et al., 2013].
Integration of HIV-1 in heterochromatin regions could repress viral transcription [Jordan et al., 2003;
Lewinski et al., 2005] while integration in euchromatin could increase transcriptional activity.
Post-translational modifications of nucleosomal histone tails (such as methylation and acetylation)
by chromatin-modifying enzymes play a key role in compaction and amassment of the chromatin and
thereby affect the recruitment of available positive and negative transcription factors to the viral LTR
promoter. Open chromatin is typically correlated with histone acetylation (regulated by Histone Acetyle
Transferases (HAT) and Histone DeACetylases (HDAC)) while condensed chromatin is promoted by
histone methylation (by Histone Methyl Transferases (HMT)). Surprisingly, a study involving five-
well defined models of HIV latency did not find a significant correlation of specific genomic and/or
epigenetic features with a latent phenotype across these models [Sherrill-Mix et al., 2013]. Another
variable affecting transcriptional activity is the orientation of the integrated provirus with respect to
the host gene. In general, a parallel orientation downstream of an actively transcribed gene increases
transcriptional interference by read-through transcription from the RNA polymerase in the host gene
[Han et al., 2008; Lenasi et al., 2008] via promoter occlusion while a anti-parallel orientation could lead
to convergent transcription and collision of the transcription machinery. However, debate exists as to
which extent this proviral orientation affects HIV transcription.
In the transcriptionally inactive state, two key nucleosomes are located at the HIV-LTR. Nuc-(0)
spanning the region from position -415 to position -255 and Nuc- (+1) from position +1 to +155 with
respect to the transcription start site of HIV genome. Both histones are susceptible to post-translational
modifications [Keedy et al., 2009; Friedman et al., 2011]. For several histone deacetylases and histone
methyl transferases (EZH2, G9a and SUV39H1) it has been shown that they contribute to latency.
The extent by which DNA methylation of cytosine residues within the viral promoter epigenetically
regulates HIV transcriptional state remains poorly understood. Methylation of two CpG sites bordering
the transcription start site have been linked with transcriptional silencing [Kauder et al., 2009; Blazkova
et al., 2009]. Contradictory results, however, have been obtained about the level of LTR promoter
methylation in vivo [Blazkova et al., 2012; Palacios et al., 2012]. In between the two nucleosomes
the LTR promoter contains several recognition elements for different host transcription factors such as
NF-κB, NFAT, SP-1, AP-1, LEF-1, COUP-TF, USF, Ets1, and CREB [Verdin et al., 1993; Van Lint
et al., 1996; Rohr et al., 2003]. Many of these transcription factors are sequestered to the cytoplasm
in resting CD4+ T-cells and will only allow HIV transcription upon T-cell activation. E.g. the NF-κB
24
1.2. TOWARDS AN HIV CURE
heterodimer p65/p50 (active form) is sequestered to the cytoplasm by IκB while the homodimer p50/50
occupies the HIV-1 promoter.
Debate still remains regarding the exact mode of establishment of latent provirus in resting CD4+
T-cells in vivo. Several studies showed a cell-driven silencing of HIV transcription related to a change in
the cellular relaxation state of activated CD4+ T-cells towards a resting memory state [Finzi et al., 1999;
Siliciano and Siliciano, 2004]. While other studies showed that transitioning of primary T-lymphocytes
from activated to resting did not silence HIV expression and suggested that the intrinsic viral program
was the major determinant controlling the establishment of latency. Based on our current understanding
it seems rather likely that the exact combinatorial mechanism will differ between patients, cells and
different HIV-strains. The threshold levels of Tat necessary for achieving a productive infection might
change over time as cells encounter different stimuli or evolve/ differentiate and age over time.
1.2.3 Current HIV treatment regimens
At present combinatorial AntiRetroviral Therapy (cART) functions as the standard treatment regimen
for patients infected with HIV and enables complete suppression of HIV plasma viral loads, dramatically
reducing mortality and morbidity. cART treatment radically changed the face of HIV infection from a
lethal disease into a manageable chronic condition. A definite cure of HIV infection however, is impeded
by the formation, early after primary infection, of viral reservoirs of latently integrated provirus in
long-lived blood cells. As a result, HIV is able to rebound viremia within weeks after therapy cessation
and patients are committed to a life-long treatment. The financial burden for society together with
the treatment burden for patients are significant. In particular, the treatment burden directly affects
treatment adherence and imposes a risk on the development of HIV drug resistance.
Currently more than 30 small molecules are approved by the U.S. Food and Drug Administration
(FDA) for treatment of HIV infection. These drugs interfere with different steps of the HIV replica-
tion cycle (depicted in Figure 1.3 on page 7) and can be classified in 6 different classes: entry and
Fusion Inhibitors (FIs, e.g. Maraviroc or Enfuvirtide) inhibit early steps, RT can be inhibited by Nu-
cleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs, e.g. AZT) or Non-Nucleoside Reverse
Transcriptase Inhibitors (NNRTIs, e.g. Efavirenz), Protease Inhibitors (PIs, e.g. Darunavir) block
proteolytic maturation (late steps). Integrase Strand Transfer Inhibitors (INSTIs, e.g. Raltegravir)
block the integration step. cART comprises at least three compounds from two or more classes aiming
for synergistic effects and trying to minimize drug resistance development due to a lack in proofreading
activity of the reverse transcriptase. Often two nucleoside/nucleotide reverse transcriptase inhibitors
(NRTIs, e.g. tenofovir disoproxil fumarate (TDF) or abacavir (ABC)) are combined with a third drug
from a different class. A combination with integrase strand transfer inhibitors (INSTIs) is becoming
increasingly popular due to their high antiviral potency and excellent tolerability profiles (e.g. Dolute-
gravir (DTG)) while PI-based treatments display a high genetic barrier to resistance (e.g. Federally
approved HIV/AIDS medical practice guidelines; URL: http://aidsinfo.nih.gov/guidelines). In all, the
patient’s exact regimen is selected based on antiviral activity, potential adverse effects, pill burden, dos-
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ing frequency, drug-drug compatibility, resistance barrier, social status, and cost and requires a highly
individualized approach with a close monitoring of immune recovery, drug-related side effects and re-
sistance occurrence. Luckily, varying drug pharmacochemical profiles allow alternatives after failure
of first-line treatment. New drug combinations aim to relieve the pill burden by providing fixed dose
combinations of different drugs as a ’one pill a day’ formula (e.g. Atripla, complera, Triumeq, Truvada
...). Increased safety profiles and long-term tolerability together with simplified treatment regimens
are of high priority as these improve therapy compliance and decrease the risk of HIV drug resistance.
A recent large scale clinical trial on the Strategic timing of AntiRetroviral Treatment (START) [The
INSIGHT START Study Group, 2015] concluded to immediately start cART upon diagnosis, indepen-
dent of the CD4+ T-cell counts. Earlier treatment reduced the transmission rate, reduced the size of
the latent reservoir and improved immune recovery and health [Hocqueloux et al., 2013; Le et al., 2013;
Tabernilla and Poveda, 2015].
1.2.4 Shock-and-kill approach
Recently, several new therapeutic approaches have been proposed aiming to remit (functional cure) or
eliminate (sterilizing/ eradicating cure) the viral reservoir, including novel pharmacological agents, HIV
gene therapy, Bone Marrow Transplantation (BMT), immune-modulation and combination approaches.
The approach that has become the most prioritized goal within HIV-1 research is the so-called "shock
and kill" or "purge and kill" strategy (see Figure 1.14 on page 27). This approach aims to develop
therapies capable of exhausting the latent viral reservoir, primarily residing within long-lived resting
CD4+ T-cells, by the use of pharmacological agents reverting the HIV transcriptional state by inducing
transcription (so-called "shock"). Subsequent production of viral proteins in the latently infected cells
should theoretically expose these cells to immune-mediated clearance and/or viral cytopathic effects
(so-called "kill"). Uninfected cells at the same time are protected by ongoing cART administration. In
general, pharmacologic strategies for reactivation of HIV-1 expression have sought to minimize general
T-cell activation avoiding a possible systemic shock.
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Figure 1.14: Shock and kill approach. The major impediment towards a cure for HIV/AIDS is the exis-
tence of a reservoir of latently infected cells able to rebound viremia upon therapy cessation. Stable integration
into the host cell genome forever links the fate of the provirus to that of its host. A new therapeutic approach
("shock and kill") aims to reactivate viral expression of dormant HIV in patients. Current treatment regimens
such as cART would protect uninfected cells from becoming infected and viral cytophatic effects together with
immune system clearing would serve to destroy the infected cells. cART, combination AntiRetroviral Therapy;
LRA, Latency Reversing Agent; HDACi, Histone DeACetylase inhibitors; PKC, Protein Kinace C
Histone DeACetylase inhibitors or HDACi have been an attractive choice for pilot eradication tri-
als because they offer an acceptable balance between proviral transcriptional activation and cellular
activation. HDACi effects on chromatin remodeling and HIV promoter accessibility have been ex-
tensively reviewed [Barton et al., 2014]. The best-studied putative HDACis to date are Vorinostat
(SuberoylAnilide Hydroxamic Acid, SAHA), Panobinostat and Romidepsin. Recently, it was shown
that HDACis could also promote HIV reactivation by enhancing P-TEFb release [Bartholomeeusen
et al., 2013]. Several clinical trials have shown an upregulation of cellular HIV-1 RNA levels often
without increases in plasma viremia [Archin et al., 2012, 2014a; Rasmussen et al., 2014; Søgaard et al.,
2015]. Hence, the modest outcomes of these clinical trials have led to a re-evaluation of these agents
as lead compounds. It remains unclear whether increases in cellular HIV transcription are the result
of cellular read-through transcripts and correlate with functional unspliced HIV RNA or translation of
viral proteins and subsequent detection by the immune system.
Next to HDACi, a wide range of Latency-Reversing Agents (LRAs) has been investigated in vitro
and ex vivo [Shang et al., 2015; Darcis et al., 2015] acting on different pharmacological targets but few
compounds however advanced into clinical trials and none have shown any durable effect on the size
of the latent HIV-1 reservoir [Elliott et al., 2014; Rasmussen et al., 2014; Søgaard et al., 2015]. This
in part could be attributed to the variety of cell types being part of the persistent HIV reservoir and
the heterogeneity of molecular mechanisms involved in regulation of the HIV transcriptional state. A
tremendous effort went into the development of in vitro models of HIV latency (compared and reviewed
in [Archin et al., 2014b; Spina et al., 2013]) but none of these precisely reflect the multifactorial nature
of cells harbouring latent provirus from patients.
Protein Kinase C (PKC) agonists (such as phorbol esters, prostratin, bryostatin-1 and ingenol
derivatives) appear to be some of the most potent reactivating agents across different models, exerting
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their action by promoting the NF-κB pathway. Degrading IκB triggers a translocation of the active
NF-κB heterodimer to the nucleus promoting transcription [Trushin et al., 2005]. In addition PKC
agonists stimulate production and release of P-TEFb [Sung and Rice, 2006; Fujinaga et al., 2012;
Pandeló José et al., 2014]. This bipolar profile makes PKC agonists interesting molecules to purge the
latent reservoirs. Moreover, PKC agonists also downregulate the expression of the HIV-1 receptor CD4
and co-receptors CXCR4 and CCR5. Other examples of LRAs focus on HMTi, interference with the
BRD4-P-TEFb competition (JQ1) or DNA methylation inhibitors (DNAMTi, 5-AzadC).
Although it is clear that individual LRAs can trigger the production and release of virions from
a subset of infected cells in vitro, more potent LRAs are required. Therefore, current efforts opt for
using combinatorial approaches as the therapeutic potential was illustrated by strong synergy profiles
observed when co-administration of two kinds of LRA classes working on distinct regulatory mechanisms
[Bouchat et al., 2012; Laird et al., 2015; Darcis et al., 2015].
In the face of the challenges presented by viral latency, measurable and incremental progress has
been made. Early eradication studies provided vital information on the nature of the latent reservoir.
Important questions remain unanswered with regard to the ideal combination of agents necessary to
perturb the heterogeneous reservoir and result in cell death or enable immune recognition. Debate
remains as to what are the most reliable means of quantifying latency reversal and reservoir depletion.
To completely disrupt HIV latency it will be of key importance to also better understand HIV mRNA
export, splicing, translation, antigen expression/processing and presentation allowing latently infected
cells to be revealed to or targeted by the immune system. Of note, latent viruses often contain cytotoxic
T-lymphocyte (CTL) escape mutations which might, despite successful reversion of latency, impair
immune clearance and require CTL stimulation [Shan et al., 2012; Deng et al., 2015].
1.2.5 Alternative approaches to cure HIV
The strategies to achieve an HIV-cure can be broadly classified into three categories: a complete
eradication (eliminating all viral reservoirs), a functional cure (immune control without reservoir erad-
ication) and a combinatorial or hybrid cure (reduced or altered reservoir with augmented immune
control). These approaches taken towards an HIV cure involve (i) host cell modification to restrict
HIV-1 infection, (ii) T-cell engineering to specifically recognize HIV infected cells, (iii) broadly neu-
tralizing antibodies, (iv) therapeutic vaccination, (v) latency enforcement and (vi) the afore mentioned
shock-and-kill approach.
To date the only documented case of an HIV eradication is Timothy Ray Brown, referred to as the so-
called ’Berlin patient’ [Hütter et al., 2009; Yukl et al., 2013a] who was HIV-1 positive and diagnosed with
acute myeloid leukemia. Timothy Ray Brown experienced a near complete immune system replacement
after myeloablative conditioning, through allogenic Hematopoietic Stem Cell Transplantation (HSCT)
from a donor carrying a homozygous CCR5 δ32 mutation. The mutated CCR5 co-receptor leaves
CD4+ T-cells resistant to most HIV-1 strains. This approach, unfortunately, is not broadly applicable
due to its high morbidity and mortality rate. In addition, only a low percentage of compatible donors
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carry this mutation. Therefore, the approach is only suitable for those with life-threatening hematologic
malignancies. Of Note, at present at least another six patients received a graft from a donor screened
for CCR5 δ32/δ32 homozygosity. However, none of these patients survived for longer than 1 year.
As reported by Kordelas et al. this was explained due to the rebound of a CXCR4-tropic HIV-1
variant [Kordelas et al., 2014]. Among four of the six patients the grafts were associated with a higher
rate of early death. Continued administration of cART until stable donor chimerism and appropriate
HLA matching CCR5 δ32/δ32 are worth careful consideration [Verheyen et al., 2014]. Hence, most
approaches are focusing on achieving a functional or combinatorial cure.
With the advent of gene editing technologies such as Zinc-finger nucleases, Transcription activator
like effector nucleases (TALENs) and Clustered Regularly-Interspaced Short Palindromic Repeats-Cas
(CRISPR-Cas), autologous CD4+ T-cells or HSCs have been engineered to constrain HIV infection.
By generating a knock out for e.g. the CCR5 gene the ability of HIV-1 to enter via its co-receptor
can be blocked [Holt et al., 2010; Tebas et al., 2014; Li et al., 2013]. This approach recently advanced
to clinical trials. It is however still unclear to what proportion cells need to be modified to constrain
HIV replication and whether CXCR4-tropic virus emerges over time. Others are trying to directly
target the provirus disrupting it using a CRISPR-Cas based platform [Liao et al., 2015]. Off-note,
measures are to be taken to decrease the intrinsic propensity of gene editing technologies for causing
off-target effects (reviewed in [Stella and Montoya, 2015]). Alternatively, designer immune responses
are gaining interest, having proven their efficacy in combating B-cell lymphomas [Porter et al., 2011].
An example is the generation of Chimeric Antigen Receptor (CAR) expressing CD8+ T-lymphocytes
targeting different invariant HIV epitopes. The major concern however is related to possible off-target
cross-reactivity [Linette et al., 2013]. T-cell mediated immunity is an event observed in a rarity group of
HIV positive patients called ’elite controllers’ capable of suppressing viral replication in the absence of
cART. Understanding of the mechanisms behind their effective CD8+ T-cell responses and occurrence
of favorable HLA alleles would contribute to the development of designer immune responses and proper
therapeutic vaccination. Another encouraging report on immune control is the occurrence of post-
treatment control in a subset of individuals in the VISCONTI cohort [Sáez-Cirión et al., 2013]. The
immunologic correlates however are yet to be defined. A valid alternative approach is based on the
recently discovered broadly neutralizing antibodies (bNAbs). bNAbs hold great promise for future HIV-
1 treatment but it will remain challenging to elicit proper HIV-specific bNAb-like antibody responses
through therapeutic vaccination due to the required extensive affinity maturation [Mascola and Haynes,
2013]. On the contrary, passive infusion of a cocktail of non-autologous bNAbs could form a valid
alternative. Here the risk of triggering anti-bNAb antibodies complicates their applicability. It will be
vital for vaccine researchers to better understand and overcome the challenges with glycan shielding
of conserved epitopes (a review on HIV-1 neutralizing Abs can be found in [Mascola and Haynes,
2013]). The latest of the approaches taken towards an HIV cure has been the most actively pursued
(shock-and-kill), however at present short term treatment using a single LRA dose is currently unable
to reduce the size of the latent HIV-1 reservoir. Clinical trials have shown significant increases in viral
transcription levels but it remains unclear whether the in vivo viral reservoirs can be depleted either by
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viral cythopatic effects or by immune system clearance. These clinical outcomes have led to the initiation
of new trials based on a combination of different LRAs together with therapeutic HIV-1 vaccination
or immune therapy boosting of the existing or novel immune responses to recognize and clear infected
cells. In contrast to the "shock and kill" approach several groups have advocated for the enforcement
of a permanently suppressed transcriptional state. With endogenous retroviruses constituting roughly
8 percent of the human genome being permanently suppressed and nonpathogenic [Jern and Coffin,
2008], mimicking of such a permanently silenced endogenized state may provide an attractive strategy
for achieving an HIV remission manageable by the immune system. A rather controversial idea which
until now has not been extensively pursued. Exciting progress has been made regarding the suppression
of the Tat-based positive feedback loop which drives HIV transcription recruiting P-TEFb [Jin et al.,
2016].
1.2.6 Conclusion
Whereas significant progress has been made in the treatment of HIV/AIDS during the past decades
and cART is saving the lives of millions of people across the world, a complete HIV cure is still lacking.
It is clear that much remains to be learned about the multi-factorial and probabilistic nature of the
latent reservoir. Although the pursuit of the "shock and kill" approach provides us with significant
novel insights in the biological mechanisms by which HIV operates, clinical outcomes have been rather
modest. Moving beyond a complete focus on this strategy, exploring alternative approaches seems rather
mandatory. Careful consideration must be given to the ethics of translational research with volunteers
infected with HIV living a rather healthy life. In addition, reducing the pill and financial burden,
possible drug-related side effects and improving world wide accessibility of cART treatment should be
of absolute priority, necessary to increase compliance and reduce the risk of HIV drug resistance.
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1.3 Lentiviral vectors for safer gene therapy
In general gene therapy encompasses all those therapies that interfere with a patients genetic material
at the genomic, transcriptional or the translational level, a concept that has long appealed to biomedical
researchers and clinicians as it promised to treat nearly all diseases at their origins. This therapeutic
approach can be roughly classified in three categories; gene addition, gene knockdown/ knockout and
gene correction/ alteration or editing of which gene addition is the most commonly pursued. Here,
treatment is achieved by counteracting or replacing a malfunctioning gene within cells being adversely
affected by the condition (Figure 1.15 on page 31), an approach which is mostly appealing to monogenic,
autosomal recessive disorders. During the past decade gene therapy based on stable insertion of retro-
viral or lentiviral vectors has evolved towards a reproducible cutting-edge technology and an effective
treatment option for several hematological malignancies, mainly Primary Immunodeficiency Disorders
(PIDs, [Rothe et al., 2014a; Touzot et al., 2015]). Retroviral vectors are excellent tools to stably insert
a therapeutic gene into the host cell genome, thereby modifying its genetic characteristics indefinitely
and avoiding diminution of the therapeutic effect by dilution. The efficiency by which cells can be ge-
netically corrected and the large therapeutic benefit has shifted gene therapy towards a clinical reality.
In a recent retrospective study a gene therapy treatment even outperformed an allogenic haploidentical
Hematopoietic Stem Cell Transplantation (HSCT) accounting for a faster immune reconstitution and
improved thymus response [Touzot et al., 2015]. Recently a first retroviral vector (StrimvelisTM) was
approved by the European Commission for the treatment of ADA-SCID [Cicalese et al., 2016], a leap
forward in the gene therapy field.
Figure 1.15: Gene Therapy. David Vetter "The Bubble Boy" (1971 - 1984) had a rare monogenic immune
disease, X-linked Severe Combined Immune Deficiency (X-SCID), that required him to live in a sterile envi-
ronment to protect him from infections. If born today, Vetter would likely have been a perfect candidate for
an alternative gene therapy treatment able to provide him with a functional immune system.
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1.3.1 Re-harnessing viruses to generate viral vectors for efficient gene
transfer
Over the past million years, viruses have evolved ingenious ways to efficiently transfer their genetic
material into a variety of cell types as they infect a host cell and subsequently hijack the host cell
machinery for progeny virion production that in turn are able to infect other cells (see section 1.1.5 on
page 6). Viral vectors, on the other hand, transduce a host cell and once stably integrated in the host
cell chromatin, will not replicate but employ the cellular machinery to produce the therapeutic gene
product. Over the past 30 years, viral vectors have been engineered to be efficient gene transfer tools
which are intrinsically replication deficient based on the segregation of genetic information over different
plasmids for cis- and trans-acting elements (see Figure 1.16 b - d on page 32). Genes for trans-elements
encode structural proteins. This segregation over different plasmids enables the transfer plasmid (Figure
1.16 c) to hold a gene of interest (GOI) and reduces the possibility of forming replication-competent
virus via homologous recombination events. Transfection of all constructs in producer cells will result
in the generation of vector particles that will transfer the gene of interest into the target cell.
pol
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nef 
LTR LTR
U3  R U5U3  R U5
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PBS DIS
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Figure 1.16: Plasmid constructs required for efficient viral vector production. a) Genetic orga-
nization of WT HIV virus b) Packaging constructs provide mainly structural viral proteins in trans required
for vector production c) Transfer construct contains the packaging signal and encodes the gene of interest
expression cassette driven by a constitutively active promoter, flanked by inactivated LTR ends. d) Envelope
construct allows for pseudotyping of viral vectors by providing an heterologous envelope gene. ψ, packaging
signal; PBS, Primer Binding Site; DIS, genome Dimerization Initiation Signal; LTR, Long Terminal Repeat;
hCMV, human CytoMegalo-Virus promoter; VSV-G, Vesicular Stomatitis Virus Glycoprotein G.
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1.3.2 Severe adverse events and the risk of insertional mutagenesis
Already in the early 1970’s, gene therapy was predicted to be the next-generation treatment option
for a plethora of genetic disorders. In the early nineties, Adenosine DeAminase Severe Combined
ImmunoDeficiency (ADA-SCID) was treated successfully using MLV-based vectors [Bordignon et al.,
1995; Blaese et al., 1995; Onodera et al., 1998], fueling the development of additional gene therapeutic
approaches for other monogenetic immunedisorders such as X-SCID. In the late nineties, several other
patients were treated successfully, providing a functional immune system to these so-called ’bubble’-
boys (see Figure 1.15 on page 31) that were sentenced to a life in a sterile bubble. In 2003, however,
a major setback tempered the broad application and general acceptance of gene therapy as a valuable
treatment alternative [Hacein-Bey-Abina et al., 2003a]. Initial reports of Severe Adverse Events (SAE)
in X-linked Severe Combined Immunodeficiency (SCID-X1,[Hacein-Bey-Abina et al., 2003a, 2008]) and
Chronic Granulomatous Disease (CGD, [Ott et al., 2006; Stein et al., 2010]) gene therapy trials rose
concern and scepticism over the further deployment of such strategies as an alternative to haematopoetic
stem cell (HSC) transplantations, but provided vital information to improve the safety of future gene
therapy trials. It became apparent that retroviral vectors exhibited common integration sites and that
the observation of aberrant T-cell proliferation was associated with the integration of a viral vector in
proximity of proto-oncogenes (e.g. SPAG6, CCND2, LMO2 [Ott et al., 2006; Stein et al., 2010]). The
presence of strong enhancer sequences in the viral LTR promoter of the early generation Moloney murine
Leukemia Virus (MLV)-derived gammaretroviral viral vectors triggered transcriptional dysregulation
of neighbouring genes [Hacein-Bey-Abina et al., 2003b; Ott et al., 2006; Howe et al., 2008; Stein et al.,
2010]. Later, massive parallel integration site sequencing allowed detailed integrome studies, that
highlighted the intrinsic integration preferences of different retroviral vector platforms but were not
fully capable of explaining the vector-related SAEs [Aiuti et al., 2007]. The generation of a plethora of
clinical and preclinical safety data resulted in important advancements in the biosafety of gene transfer
technologies. Development of Self-INactivating Long Terminal Repeats (SIN LTRs, see Figure 1.16 c)
lacking strong enhancer sequences and a shifted interest to lentivirus-derived viral vectors substantially
reduced the insertional genotoxicity observed in X-linked AdrenoLeukoDystrophy (ALD, [Cartier et al.,
2009]) and β-thalassemia patients ([Cavazzana-Calvo et al., 2010]).
However, at present no definitive consensus exists on the real combinatorial causes of the adverse events
observed in the distinct clinical contexts. A retrospective study pin-pointed the complex interplay of
different parameters such as vector platform used, vector design and promoter, vector insertion profile
[Cartier et al., 2009; Cavazzana-Calvo et al., 2010], mean viral copy number, viral splice sites [Trono,
2012], disease background [Shou et al., 2006; Ginn et al., 2010; Bosticardo et al., 2009], transgene nature
and transgene product levels [Woods et al., 2006; Grez et al., 2011] having a possible influence on the
likelihood of insertional genotoxicity manifestation in a trial [Rothe et al., 2014b]. So far, current assays
to test the mutagenic potential of integrating viral vectors lack substantial power and capability to fully
predict the exact levels of toxicity that might be observed in any given clinical gene therapy context
and no standardized scoring for the genotoxic potential of a new viral vector exists [Rothe et al., 2014b].
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The next subsections focus on the effect of the vector integration profile and the search for genomic
safe harbor regions.
1.3.3 Towards a safer retroviral integration profile
Retroviral integration was long time considered to be a random process, with the viral IN acting
as the major determinant. Large scale integration site sequencing studies revealed a genus specific
integration preferences with lentiviruses and gammaretroviruses integrating in the proximity of genes
[Schroder et al., 2002; Mitchell et al., 2004]. Lentiviruses displayed an integration pattern that did
not show a preference for strong enhancer and promoter regions. Next to improvements in vector
design, initial efforts to further lower the toxicity profile aimed at targeting integration away from
active transcription units. With the viral IN being the prime determinant of the integration site itself,
initial efforts to retarget lentiviral integration were based on fusions between IN and DNA binding
domains (e.g. the E. coli LexA repressor [Holmes-Son, 2002], bacteriophage λ-repressor [Bushman,
1994; Bushman and Miller, 1997] or engineered zinc finger proteins (Zif268) [Tan et al., 2006]) of
which most retained catalytic activity in vitro but often significantly impaired vector production upon
incorporation in vector particles and additionally decreased transduction efficiency. When it became
clear that retroviruses co-opted different cellular proteins to tether their PICs towards the cellular
chromatin several groups aimed at modifying this interaction. In the case of lentiviruses, LEDGF/p75
is the major cellular cofactor orchestrating integration [Ciuffi et al., 2005]. Replacement of its PWWP
chromatin binding domain with alternative DNA binding modules resulted in an increased integration
near features recognized by those domains [Ferris et al., 2010; Silvers et al., 2010; Gijsbers et al., 2009].
LEDGF-fusions were shown to rescue a X-CGD disease phenotype in cell culture [Vets et al., 2013].
Only recently Bromodomain and ExtraTerminal domain containing family of proteins (BET proteins;
BRD2, BRD3, and BRD4 [Gupta et al., 2013; Sharma et al., 2013; De Rijck et al., 2013]) were reported
to guide gammaretroviral integration by direct interaction with the viral IN. A single INW390A point
mutation [El Ashkar et al., 2014] abrogated the interaction and resulted in a reduced integration in
the neighbourhood of promoters and regulatory elements. Next to retargeting of integration for the
existing MLV or LV platforms newer vector systems are being explored because of their closer-to-
random integration pattern such as alpharetroviral vectors [Suerth et al., 2012; Moiani et al., 2014] or
transposon based platforms [Moldt et al., 2011; Turchiano et al., 2014] which could possibly reduce
the probability of SAEs. Off note, approaches where stable genetic modification of the host genome
is required will always carry an intrinsic risk of genomic perturbation to be related to the scale of the
correction.
1.3.3.1 Safe harbour regions
Since the clinical observation of the retroviral integration site being a responsible for diminished ther-
apeutic effects or dysregulation of endogenous genes leading to malignant host cell transformation
[Hacein-Bey-Abina et al., 2003b; Ellis, 2005; Cavazzana-Calvo et al., 2010], several strategies have
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aimed for redirecting integration towards distinct regions. In parallel, different criteria were put for-
ward in order to define an "ultimate" integration environment able to accommodate integration of new
genetic material in a manner that enables functionality prediction and does not harm the host cell or
organism. Such regions are referred to as "Genomic Safe Harbor" regions (GSHs) and should minimally
perturbate or dysregulate the transcriptional profile of neighbouring genes. The basic criteria aim to
exclude regions in close proximity to transcription start sites (<50 kb), oncogenes (<300 kb) or miRNA
coding regions (<300 kb), transcription units and ultraconserved elements (defining potentially unsafe
integration events, [Papapetrou et al., 2011; Sadelain et al., 2011a; Papapetrou and Schambach, 2016]).
Three different loci have been mostly targeted for transgene insertion in the past: (i) a common in-
tegration site of the human non-pathogenic AAV, located between exon 1 and intron 1 of the protein
phosphatase 1 regulatory subunit 12C (PPP1R12C ) on chromosome 19, known as the AAV site 1
(AAVS1); (ii) the chemokine (C-Cmotif) receptor 5 (CCR5 ) gene, a chemokine receptor gene known
as an HIV-1 co-receptor for which a homozygous deletion is found in seemingly healthy individuals;
and (iii) the human orthologue of the mouse Rosa26 locus, a locus extensively validated in the murine
setting for insertion of ubiquitously expressed transgenes [Liu et al., 1996; Kotin et al., 1992; Irion et al.,
2007; Perez et al., 2008]. Even though these loci do not perfectly match the above mentioned criteria
these sites gained interest due to the functional data available on expression robustness or transcrip-
tional dysregulation [Lombardo et al., 2011] and may therefore be of interest for research applications
but require a higher burden of proof of safety for clinical applications. Recent evidence indicated that
the AAVS1 locus does not faithfully support expression of all transgenes in all cell types and might be
silenced by DNA methylation [Ordovás et al., 2015]. Moreover, information is lacking about the effect
of PPP1R12C haploinsufficiency in different cell types. CCR5 KO increased susceptibility to disease
caused by the West Nile Virus [Glass et al., 2006] and Japanese Encephalitis Virus [Larena et al.,
2012]. Whereas previously GSHs were mostly empirically discovered or defined on the basis criteria
and known genome annotations, it became clear that the definition of a GSH had to be amended to
take into account the rapid discovery of new genomic elements (e.g. non-coding RNA or ncRNA),
epigenetic modifications (e.g DNA/histone tail modifications, nucleosomal remodeling), spatial organi-
zation (e.g. Topologically Associated Domains (TADs))[Papapetrou and Schambach, 2016] and long
range interactions. At present, no chromosomal location in the human genome has been demonstrated
to qualify as a bona fide GSH and the validation of a GSH will highly depend on reciprocal interactions
between a transgene and the cell’s genomic context. GSHs should maintain "neutrality" in the context
of both the linear genome as well as for longe-range interactions. Whereas bioinformatic predictions
can be a useful first step, future GSHs will need to be functionally validated in relevant settings since
expression and genotoxicity might be cell or differentiation stage dependent. The discovery of potential
GSHs, in parallel, will require increased efficiencies in site-specific gene targeting supporting near WT
transduction efficiencies (e.g. CRISPR-cas9, zinc-finger nucleases, meganucleases, TALE nucleases).
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1.3.3.2 Pre-clinical assays to assess safety
Before new gene therapy vectors enter clinical phases suitable preclinical vector toxicity data need to
be provided and approved by the EMA (Europe), FDA (US) or TGA (Australia). The current in vitro
and in vivo assays however lack the potency to completely predict a possible manifestation of SAEs. In
the hematopoietic system, a murine bone marrow transplantation model is used where lineage negative
HSCs or tumor prone HSCs (Cdkn2a-/- FVB/N.129 mice) are transduced ex vivo and transplanted in
wt or disease specific mice [Stein et al., 2013] allowing for a longer follow up period of the tempo-
spatial integrome [Montini and Cesana, 2012]. Neoplasia and integration near proto-oncogenes or high
risk insertions are monitored and the clonal size quantified. In addition a histopathological analysis is
performed and a biospatial profile obtained of the genetically modified cells. In conjunction several in
vitro assays allow for the analysis of vector induced differences in the cellular transcriptome or ability
to transform mouse lineage negative cells in vitro (In Vitro Immortalization Assay, IVIM assay). Here
lineage negative cells are isolated (C57BL6/J mice) transduced at using high vector titers, replated at
low cell density in the abscence of cytokines. Colony formation accounts for insertional mutagenesis
and vector genotoxicity. Uncertainty about the predictive capability of these assays and the limit of
detecting parameters contribution to a safer genotoxicity profile together with a cell specific readout
indicate the need for improved, more general and/or cell-type/ disease specific assays to evaluate vector
safety.
1.3.4 Conclusion
Gene therapy has emerged as an attractive alternative strategy to successfully treat a series of mono-
genic recessive disorders and enables to circumvent immune conflicts in the setting of allogenic cell
transplantation when HLA-identical siblings are lacking. In a recent study a gene therapy treatment
even outperformed the haploidentical HSCT [Touzot et al., 2015] accounting for a faster immune re-
constitution. While gene therapy often significantly prolongs the lifespan of patients and increases
the quality of life, several clinical challenges are yet to be overcome. Important advancements have
been made regarding the safety of gene transfer technologies but no consensus has been reached on the
exact and intrinsically different combinatorial causes of the adverse events observed in distinct clinical
contexts. Sophisticated design of gene transfer vehicles, a better understanding of the interplay with
the local chromatin environment together with more sensitive and predictive tests able to predict the
therapeutic outcome will allow for gene therapy to become a widely accepted treatment option.
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After decades of antiretroviral therapy, complete eradication of the HIV virus (HIV cure) remains
an elusive goal due to the existence of stable reservoir of latently infected cells. Therefore leading
scientists shifted strategies to exhaust the latent reservoir in their aim for a functional cure allowing at
least interruption of chronic cART administration. Stable integration is a hallmark of retroviruses and
a non-random process displaying genus specific integration site preferences. In the case of lentiviruses
LEDGF/p75 functions as the major cellular co-factor orchestrating integration towards transcription-
ally active regions. So far the evolutionary advantage of these different integration profiles remains
incompletely understood. As the surrounding chromatin environment of the integrated provirus is gen-
erally believed to affect the transcriptional activity of the virus I studied the role of proviral integration
site positioning in HIV persistence. Likewise, the retroviral integration allows for permanent modifi-
cation of its host cell and makes retroviral vectors interesting tools for gene therapeutic applications.
However, the intrinsic integration site preference of retroviral vectors has been the major bottleneck
as it was shown to be the cause of vector induced adverse events in early clinical trials. For these
reasons I embarked on two parallel research lines with a main focus on the intricate interplay between
LEDGF/p75-IN, contributing to the development of safer viral vectors for gene therapy and alternative
HIV cure strategies that modulate or prevent the generation of a reservoir able to rebound from latency
once drug administration is withdrawn.
I) Development of Safer LV Vectors Using Artificial LEDGF-Based Tethers
Lentiviral integration occurs in the body of active transcription units [Schroder et al., 2002; Mitchell
et al., 2004]. Previously, we and others showed that integration can be retargeted towards regions gen-
erally disfavored for integration by using artificial LEDGF-based tethers [Ferris et al., 2010; Gijsbers
et al., 2009, 2011b; Silvers et al., 2010]. In a first part of my work (Chapter 3 on page 41), I set out
to design new chimeric versions of LEDGF/p75 to retarget integration to distinct nuclear compart-
ments/locations and potentially ’safer’ regions within the human genome. As such, serious adverse
events associated with the use of retroviral vectors in gene therapeutic applications may be overcome
[Hacein-Bey-Abina et al., 2003b, 2008; Howe et al., 2008; Stein et al., 2010]. In light of a safer genotox-
icity profile, I tested whether truncation of LEDGF/p75 by deletion the N-terminal chromatin-reading
PWWP domain (responsible for binding H3K36me3 marks associated with active transcription units)
could result in a more randomized integration profile. A random integration is generally believed to
reduce the risk or probability of transcriptional dysregulation of neighbouring genes. In parallel, I
replaced the PWWP-domain with several alternative viral protein domains and motifs, described in
literature as pan-chromatin recognition peptides since they bind cellular chromatin without sequence
specificity aiding episomal viruses to persist during mitosis; The spumavirus, Prototype Foamy Virus
(PFV), contains a 13-amino acid motif in the group-specific antigen (Gag) binding the H2A/H2B core
nucleosome [Tobaly-Tapiero et al., 2008; Nowrouzi et al., 2006; Trobridge et al., 2006]. Likewise, the
Kaposi Sarcoma-associated Herpes Virus (KSHV) genome is tethered to the nucleosomal core via a
chromatin binding sequence (CBS) at the N-terminal end of the latency-associated nuclear antigen
protein (LANA) [Barbera et al., 2006]. Finally, in the β-Papillomaviruses (PV) a conserved motif in
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the E2 hinge promotes binding to chromatin and mitotic chromosomes of the invaded cell [Sekhar et al.,
2010; Sekhar and McBride, 2012; Võsa et al., 2012]. Retargeting was confirmed by proviral integration
site sequencing.
II) Study of The Impact of Integration Site Distribution on HIV Latency
The fact that lentiviral integration can be retargeted to genomic regions that are usually disfavoured
for integration indicates that these areas are disfavoured in WT cells due to active LEDGF/p75 teth-
ering rather than an inherent integration barrier such as steric hindrance resulting from condensed
chromatin. In a second research line (Chapter 4 on page 69), I studied the importance of integration
site selection/distribution in the context of HIV persistence, evaluating (I) the establishment of latency
and (II) the reactivation from latency following treatment with Latency Reversing Agents (LRAs).
Since integration is believed to affect the transcriptional activity of the integrated provirus, I assessed
whether targeting and integration site selection affect the reactivation potential of the quiescent in-
tegrated provirus and explored the relationship with chromatin structure and nuclear topography by
modulating the LEDGF/p75-IN interplay. Moreover, I investigated the hypothesis that LEDGIN treat-
ment, small molecules abrogating the LEDGF/p75 interaction, could result in re-targeted integration
and studied their effect on the formation of a functional HIV reservoir. A better characterization of
their mechanisms of action might aid their further clinical development and contribute to the devel-
opment of alternative strategies modulating or preventing the generation of latent reservoirs able to
rebound viremia and thereby help to overcome the HIV pandemic.
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Towards a Safer, More Randomized Lentiviral
Integration Profile Exploring Artificial LEDGF
Chimeras
This chapter has been previously published as an article manuscript in PLoS One (2016):
Vranckx, L.S., Demeulemeester, J., Gijsbers, R., Debyser, Z. (2016). Towards a Safer, More Ran-
domized Lentiviral Vector Integration Profile Exploring Artificial LEDGF Chimeras. PLoS One,
11(10), art.nr. 10.1371/journal.pone.0164167.
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CHAPTER 3. TOWARDS A SAFER, MORE RANDOMIZED LENTIVIRAL INTEGRATION
PROFILE EXPLORING ARTIFICIAL LEDGF CHIMERAS
3.1 Abstract
The capacity to integrate transgenes into the host cell genome makes retroviral vectors an interesting
tool for gene therapy. Although stable insertion resulted in successful correction of several monogenic
disorders, it also accounts for insertional mutagenesis, a major setback in otherwise successful clinical
gene therapy trials due to leukemia development in a subset of treated patients. Despite improvements
in vector design, their use is still not risk-free. Lentiviral vector (LV) integration is directed into
active transcription units by LEDGF/p75, a host-cell protein co-opted by the viral integrase. We
engineered LEDGF/p75-based hybrid tethers in an effort to elicit a more random integration pattern
to increase biosafety, and potentially reduce of proto-oncogene activation. We therefore truncated
LEDGF/p75 by deleting the N-terminal chromatin-reading PWWP-domain, and replaced this domain
with alternative pan-chromatin binding peptides. Expression of these LEDGF-hybrids in LEDGF-
depleted cells efficiently rescued LV transduction and resulted in LV integrations that distributed more
randomly throughout the host-cell genome. In addition, when considering safe harbor criteria, LV
integration sites for these LEDGF-hybrids distributed more safely compared to LEDGF/p75-mediated
integration in wild-type cells. This approach should be broadly applicable to introduce therapeutic or
suicide genes for cell therapy, such as patient-specific iPS cells.
3.2 Introduction
The capacity to integrate transgenes into the host cell genome makes Retroviral Vectors (RV) an inter-
esting tool for gene therapeutic applications as stable insertion of transgenes into the genome ensures
long-term expression. Use of RV-mediated gene transfer resulted in successful cure of several monogenic,
primary immunodeficiency disorders [Cavazzana-Calvo et al., 2000; Gaspar et al., 2004; Hacein-Bey-
Abina et al., 2003b]. Yet, stable insertion occasionally altered endogenous gene regulation resulting
in insertional mutagenesis. Due to this major setback 25% of treated patients developed leukemia
in otherwise successful clinical gene therapy trials for X-SCID and X-CGD [Hacein-Bey-Abina et al.,
2003b, 2008; Howe et al., 2008; Stein et al., 2010]. Both trials employed Murine Leukemia Virus (MLV)-
based gammaretroviral vectors (γRV) that integrate in close proximity to gene regulatory regions [Wu
et al., 2003; De Ravin et al., 2014; LaFave et al., 2014] and resulted in transcriptional deregulation
due to up-regulated LMO2 expression [Mitchell et al., 2004; Derse et al., 2007; Deichmann et al., 2007;
Cattoglio et al., 2007]. Similar reports on insertional mutagenesis were published after integration of
RV near CCDN2, BMI1 and EVI1 [Boztug et al., 2010; Braun et al., 2014]. Despite improvements
in vector design (e.g. self-inactivating (SIN) vectors) their use is still not risk-free [Hacein-Bey-Abina
et al., 2003b, 2008; Stein et al., 2010; Boztug et al., 2010; Braun et al., 2014; Maetzig et al., 2011],
which shifted attention from γRV towards HIV-derived lentiviral vectors (LV). Even though LV display
a more favorable integration pattern, induction of aberrant splicing [Cesana et al., 2012, 2014] and in-
sertional mutagenesis remain a major concern, as clonal expansion was observed in a gene therapy trial
for β-thalassemia [Cavazzana-Calvo et al., 2010]. In addition, two recent independent studies revealed
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clonal expansion in HIV-1 infected patients on antiretroviral therapy due to HIV-1 virus triggered inser-
tional mutagenesis [Maldarelli et al., 2014; Wagner et al., 2014]. Retroviral integration is a non-random
process which is, depending on the viral genus, associated with specific chromatin marks and genomic
features [Stevens and Griffith, 1996; Holman and Coffin, 2005; Wu et al., 2005]. γRV predominantly
integrate in the vicinity of gene regulatory regions, whereas LV preferably target the body of active
transcription units [Schroder et al., 2002; Mitchell et al., 2004]. Integration is catalyzed by the viral
INtegrase (IN), whereas integration site choice bias is attributed to the cellular chromatin readers that
are co-opted by the viral IN. Whereas the Bromodomain and Extra-Terminal domain (BET) family of
proteins (BRD2, 3 and 4) guide MLV integration [Sharma et al., 2013; De Rijck et al., 2013; Gupta
et al., 2013], LV integration is directed by Lens Epithelium-Derived Growth Factor p75 (LEDGF/p75)
[Cherepanov et al., 2003; Marshall et al., 2007]. Both function as molecular tethers in the cell, com-
bining a chromatin-binding and a protein-interacting region (reviewed in [Debyser et al., 2015] ). For
LEDGF/p75 (Figure 3.1a on page 44), the chromatin-binding part contains an N-terminal Pro-Trp-Trp-
Pro (PWWP) epigenetic reader domain (aa 1-93), recognizing H3K36me3 chromatin marks [De Rijck
et al., 2010; Pradeepa et al., 2012; Eidahl et al., 2013; Gijsbers et al., 2011a; van Nuland et al., 2013],
and a set of DNA-binding motifs (Figure 3.1a, [Turlure et al., 2006; Tsutsui et al., 2011]). Together,
these elements allow LEDGF/p75 to explore the chromatin in a dynamic scan-and-lock fashion [Hen-
drix et al., 2011]. Even though its cellular role is not fully understood, it is clear that LEDGF/p75 acts
as a molecular hub for a variety of endogenous proteins next to the lentiviral integrase (Figure 3.1a)
[Maertens et al., 2006; Bartholomeeusen et al., 2007, 2009; Hughes et al., 2010; Yokoyama and Cleary,
2008]. All these proteins, including the lentiviral integrase, bind the C-terminal Integrase-Binding
Domain (IBD, aa 347-429; Figure 3.1a) of LEDGF/p75. We and others showed that replacement of
the N-terminal LEDGF/p75 DNA-binding region (aa 1-325) with alternative DNA-binding domains
retargets LV integration towards genomic loci bound by these domains [Ferris et al., 2010; Gijsbers
et al., 2009, 2011b; Silvers et al., 2010]. Fusion of the heterochromatin binding Chromobox protein
homolog 1 (CBX1) to the IN-binding C-terminal end of LEDGF/p75 shifted LV integration into the
cognate H3K9mex-marked chromatin environment, pericentric heterochromatin and intergenic regions
[Gijsbers et al., 2009]. Despite integration in regions enriched in epigenetic marks associated with
gene silencing, transgene expression remained efficient and resulted in successful phenotypic correction
in a cell model for X-CGD [Vets et al., 2013]. Here we aimed at developing a LEDGF-based tether
that results in a more random integration pattern to reduce the overall risk of insertional mutagenesis
[Chatziandreou et al., 2011; Derse et al., 2007; Kaufmann et al., 2013; Suerth et al., 2012]. First,
we truncated LEDGF/p75 by deleting the N-terminal chromatin-reading PWWP domain that binds
H3K36me3 marks directing LEDGF/p75 into the body of active transcription units (Figure 3.1a & b).
In addition, we replaced the PWWP-domain with three alternative viral protein domains and motifs,
described in literature as pan-chromatin recognition peptides since they bind cellular chromatin without
sequence specificity (Figure 3.1b and Table 3.1 on page 44 and 45 respectively). Several viruses reside as
an episomal DNA genome in host cells, and evolved strategies to persist during mitosis through defined
chromatin binding motifs. The spumavirus, Prototype Foamy Virus (PFV), contains a 13-amino acid
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motif in the group-specific antigen (Gag) binding the H2A/H2B core nucleosome [Tobaly-Tapiero et al.,
2008; Nowrouzi et al., 2006; Trobridge et al., 2006]. Likewise, the Kaposi Sarcoma-associated Herpes
Virus (KSHV) genome is tethered to the nucleosomal core via a Chromatin Binding Sequence (CBS)
at the N-terminal end of the Latency-Associated Nuclear Antigen protein (LANA) [Barbera et al.,
2006]. Finally, in the β-PapillomaViruses (PV) a conserved motif in the E2 hinge promotes binding
to chromatin and mitotic chromosomes of the invaded cell [Sekhar et al., 2010; Sekhar and McBride,
2012; Võsa et al., 2012]. Following the generation of stable cells lines, we monitored LV integration
preferences and evaluated integration sites based on safe harbor region criteria [Papapetrou et al., 2011]
and determined a genotoxicity profile.
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Figure 3.1: Schematic representation of the LEDGF/p75 domain structure and artificial LEDGF-
hybrids. (a) LEDGF/p75 contains a C-terminal protein-binding domain, coined Integrase Binding Domain
(IBD) responsible for HIV-IN interaction. Several endogenous proteins like Jpo2, PogZ and MLL bind to the
same interface. At its N-terminal end carries multiple chromatin interacting domains, the PWWP domain,
the AT hook-like domain (AT) and three Charged Regions (CR1, 2, 3). D366 is a pivotal amino acid involved
in HIV-IN interaction (green arrowhead). Mutation to Asn (D366N) abolishes HIV-IN interaction. The lower
panel (b) depicts the different LEDGF-hybrids, PFV Gag534-546-δN93-LEDGF, HPV5 E2242-257-δN93-LEDGF,
HPV8 E2240-255-δN93-LEDGF and LANA1-31-δN93-LEDGF respectively. Numbers indicate the different amino
acid residues. AT, AT-Hook; CR, Charged Region; SRD, Supercoiled Recognition Domein; IBD, Integrase
Binding Domain; PWWP, Pro-Trp-Trp-Pro Domain; PFV, Prototype Foamy Virus; LANA, Latency Associated
Nuclear Antigen; HPV, Human Papilloma Virus; LEDGF, Lens Epithelium-Derived Growth Factor; NLS,
Nuclear Localization Signal.
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Peptide Name Sequence Target Reference
PFV Gag 534-546 QGGYNLRPRTYQP H2A-H2B core histones
HPV5 E2242-257 QTETRGRRYGRRPSSK 12-bp DNA motifs-E2 binding sites (E2BS)
ACCN6GGT
HPV8 E2240-255 QTETKGRRYGRRPSSR 12-bp DNA motifs-E2 binding sites (E2BS)
ACCN6GGT
Tobaly-Tapiero 2008, Nowrouzi 2006,              
Trobridge 2006
Sekhar and McBride, 2012; Sekhar et al., 2010;            
Vosa 2012
Sekhar and McBride, 2012; Sekhar et al., 2010;            
Vosa 2012
Barbera Science 2006
Human papilloma virus                                              
E2 protein
Human papilloma virus                                              
E2 protein
Prototype foamy virus                                           
chromatin binding segment Gag
Kaposi sarcoma herpes virus                               
latency associated nuclear antigenKSHV LANA1-31
MAPPGMRLRSGRSTGAPLTRGSCRKR
NRSPE H2A-H2B nucleosome core
Table 3.1: Peptide characteristics. Table showing the acronyms, aa-sequences and binding characteristics
of the peptides used to generate the artificial LEDGF-tethers. PFV, Prototype Foamy Virus; HPV, Human
Papilloma Virus; KSHV, Kaposi’s Sarcoma Herpes Virus; LANA, Latency Associated Nuclear Antigen.
3.3 Results
3.3.1 Generation of LEDGF-hybrids and stable cell lines
In an effort to distribute lentiviral vector integration more randomly over the genome, we modified
LEDGF/p75, the cellular tether of the HIV Pre-Integration Complex (PIC), by deleting the chromatin-
reading PWWP-domain (δN93-LEDGF, Figure 3.1a, b on page 44) [De Rijck et al., 2010; Pradeepa
et al., 2012; Eidahl et al., 2013] relying on the remaining non-specific DNA-interacting regions in
LEDGF93-325, such as the AT-hook domains and the CRs (Figure 3.1a; [Hendrix et al., 2011]). In addi-
tion, we generated LEDGF-hybrids where the PWWP-domain was exchanged with a set of alternative
pan-chromatin recognition peptides of viral origin (Figure 3.1b and Table 3.1 on page 45). Prototype
Foamy Virus chromatin binding segment of Gag534-546 (PFV Gag534-546) [Tobaly-Tapiero et al., 2008;
Nowrouzi et al., 2006; Trobridge et al., 2006], Human Papilloma Virus serotype 5 E2242-257, Human
Papilloma Virus serotype 8 E2240-255 (HPV5 E2242-257 and HPV8 E2240-255, respectively)[Sekhar et al.,
2010; Sekhar and McBride, 2012; Võsa et al., 2012] and Kaposi’s Sarcoma Herpes Virus Latency Asso-
ciated Nuclear Antigen1-31 (KSHV LANA1-31) [Barbera et al., 2006] were used to replace the PWWP
domain, generating δN93-LEDGF, PFV Gag534-546-δN93-LEDGF, HPV5 E2242-257-δN93-LEDGF, HPV8
E2240-255-δN93-LEDGF and KSHV LANA1-31-δN93-LEDGF fusions, respectively. All above-mentioned
LEDGF-hybrids were used to complement LEDGF/p75-depleted cells (HeLaP4 (LEDGFKD) [Osório
et al., 2014] and Nalm (LEDGFKO) cells [Schrijvers et al., 2012a]) employing SIV-based lentiviral vec-
tors. As a positive control, cells were complemented with WT LEDGF/p75 (referred to as LEDGF/p75
back complementation (LEDGFBC)). In order to control for non-specific effects resulting from the ex-
pression of the fusion proteins we also generated stable cell lines expressing the respective chimeras
carrying a D366N mutation in the LEDGF/p75 part, which abrogates the interaction with lentiviral
integrase (IN) [Cherepanov et al., 2005]. Protein integrity was corroborated by Western Blot (WB)
analysis, with all LEDGF-hybrids migrating at the predicted molecular weights (Supplementary Figure
S3.1 on page 63). Of note, protein levels of PFV Gag534-546-δN93-LEDGF were lower in all experiments.
Viability and growth rates of all cell lines were comparable to the parental HeLaP4 cells (data not
shown).
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3.3.2 LEDGF-hybrids locate to the nucleus and display a distinct subnu-
clear distribution
In a first step, we evaluated the subcellular localization of the truncated δN93-LEDGF and the re-
spective δN93-LEDGF-hybrids by immunocytochemistry (Figure 3.2 on page 47). Complementation of
LEDGF-depleted HeLaP4 cells (LEDGFKD) with LEDGFBC resulted in a typical pattern of dense, fine
speckles in the nucleoplasm excluded from the nucleoli during interphase (Figure 3.2c), phenocopying
the endogenous LEDGF/p75 pattern (Figure 3.2a), which is in line with earlier reports [Gijsbers et al.,
2009]. On the contrary, LEDGF/p75 lacking the chromatin-reading PWWP-domain exhibited a more
diffuse nuclear distribution and located to the nucleoli as well (δN93-LEDGF, Figure 3.2d). In addition,
all δN93-LEDGF peptide-fusions located to the nucleus (Figure 3.2e-h), displaying a unique sub-nuclear
distribution: the PFV Gag534-546- and the KSHV LANA1-31-fusion to δN93-LEDGF showed a punctate
appearance in the nucleus and were excluded from nucleoli (Figure 3.2e, h), contrary to both HPV5
E2242-257- and HPV8 E2240-255-δN93-LEDGF fusions that were enriched in the nucleoli (Figure 3.2f, g).
Similar subcellular distributions were observed for the respective cognate LEDGFD366N-hybrids (data
not shown).
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MergeDAPIα-LEDGF480-530
WT
LEDGFKD
LEDGFBC
ΔN93-LEDGF
HPV5 E2242-257 
-ΔN93-LEDGF
HPV8 E2240-255 
-ΔN93-LEDGF
PFV Gag534-546
-ΔN93-LEDGF
KSHV LANA1-31 
-ΔN93-LEDGF
a
b
c
d
f
g
e
h
Interphase
Figure 3.2: Subcellular localization of LEDGF-hybrids in interphase cells. LEDGF/p75 depleted
cell lines were complemented with the respective LEDGF-fusions. Laser scanning confocal images of HelaP4
cells, stained using an Ab recognizing LEDGF480-530, are shown in green. Nuclei were stained using DAPI
(shown in blue). A merge of green and blue fluorescence is shown. Data depicted are representative for the
respective cell lines. PFV, Prototype Foamy Virus; LANA, Latency Associated Nuclear Antigen; HPV, Human
Papilloma Virus; LEDGF, Lens Epithelium-Derived Growth Factor; DAPI, 4’, 6-DiAmidino-2-PhenylIndole.
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3.3.3 LEDGF-peptide fusions rescue lentiviral vector transduction
Next, we assessed whether the δN93-LEDGF-hybrids supported lentiviral vector transduction by com-
plementing LEDGF-depleted cells (LEDGFKD) and employing wild-type LEDGF/p75 complemented
cells (LEDGFBC) as control. The respective HeLaP4 cell lines were challenged with a dilution series of
a lentiviral vector (multiplicity of infection (MOI)= 1, 0.2 or 0.04 (indicated in lighter colors)) encod-
ing enhanced Green Fluorescent Protein (eGFP) and firefly Luciferase (fLuc) reporters [Ibrahimi et al.,
2009]. Transduction efficiencies were determined by flow cytometry monitoring eGFP fluorescence (Fig-
ure 3.3a and b on page 49, showing transduction efficiency (eGFP positive cells; % Gated) and Mean
Fluorescence Intensity (MFI) respectively). Complementation of LEDGF-depleted cells with LEDGFBC
restored transduction efficiency (Figure 3.3a)(***, p<0.005; two-tailed t-test relative to LEDGFKD),
in line with earlier reports [Vandekerckhove et al., 2006; Gijsbers et al., 2009]. Complementation of
LEDGFKD cells with δN93-LEDGF, lacking the chromatin interacting PWWP-domain, partially res-
cued lentiviral transduction (78% compared to LEDGFBC) (Figure 3.3a, ***, p<0.005 compared to KD,
two-tailed t-test). Addition of chromatin binding peptides to replace the PWWP domain displayed a
significantly improved transduction relative to δN93-LEDGF (***, p<0.005; two-tailed t-test), reaching
efficiencies comparable to LEDGFBC (Figure 3.3a). Similar results were obtained for different vector
dilutions (Figure 3.3 a) or when assessing complemented LEDGF/p75 knock-out cells (Nalm-/-, data not
shown) [Schrijvers et al., 2012a] or evaluating fLuc as a reporter (data not shown). Looking at Mean
Fluorescence Intensities (MFI), all LEDGF-peptide fusions were about 20 % lower than LEDGFBC
(Figure 3.3b). In addition to transduction efficiencies, we also determined the number of integrated
copies (Figure 3.3c). Reintroduction of LEDGF/p75 (LEDGFBC) significantly improved vector inte-
gration (±3.5-fold compared to LEDGFKD, ***, p<0.005, two-tailed t-test). Likewise, δN93-LEDGF
and all LEDGF-peptide fusions restored vector integration (2.5-fold more compared to LEDGFKD,
***, p<0.005, two-tailed t-test), albeit still to a lesser extent (reaching 68-74% of LEDGFBC, Figure
3.3c). The increased transduction efficiencies (%Gated) closely correlate with an increase in integrated
viral vector copies (Figure 3.3c). Complementation with δN93-LEDGF alone, lacking any additional
chromatin-tether, resulted in lower integrated copy numbers than δN93-LEDGF fused to chromatin
engaging peptides (p-values < 0.005, two-tailed t-test relative to δN93-LEDGF; 66.7% of LEDGFBC),
supporting the notion that the chromatin-reading PWWP domain of LEDGF/p75 is not an absolute
requirement for efficient integration.
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Figure 3.3: Rescue of lentiviral vector transduction by artificial LEDGF-hybrids. LEDGF-fusions
were evaluated for their ability to support lentiviral vector transduction. LEDGF-depleted HelaP4-based cell
lines stably complemented with LEDGF-hybrids were challenged with a VSV-G pseudo-typed lentiviral reporter
vector encoding enhanced Green Fluorescent Protein (eGFP). Fluorescence was measured by fluorescence
activated cell sorting and the different variables plotted: (a) Percentage eGFP positive cells (transduction
efficiency) and (b) Mean Fluorescence Intensity (MFI). Data are compiled for a representative experiment and
depict averages of 3 replicates for 3 different vector dilutions (mean ± SD). (c) Lentiviral integrated proviral
copies were determined by Q-PCR analysis on genomic DNA extracts of cells transduced with an MOI=1.
Data are representeded as the mean of 3 replicates ± SD. Statistical significance is calculated using a two-
tailed t-test relative to LEDGFKD or δN93-LEDGF. PFV, Prototype Foamy Virus; LANA, Latency Associated
Nuclear Antigen; HPV, Human Papilloma Virus; LEDGF, Lens Epithelium-Derived Growth Factor.
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3.3.4 LEDGF-peptide fusions efficiently redistribute lentiviral integration
After showing that complementation of LEDGF/p75-depleted cells with δN93-LEDGF or any of the
LEDGF-hybrids rescued vector integration, we determined the integration profiles in the respective
cell lines. HIV-based viral vector integration sites were amplified and sequenced as described earlier
[Marshall et al., 2007; Gijsbers et al., 2009], yielding a total of 62670 unique integration sites and their
computationally generated Matched Random Control (MRC) sites. Note that SIV-based viral vectors
were used to complement LEDGF/p75-depleted cells, in order to avoid interference with the HIV-based
viral vector integration site amplification and analysis. First, we analysed integration relative to a set
of defined genomic features (Table 3.2 and Figure 3.4 on page 52 and 53 respectively). Lentiviral vector
integration in wild-type HeLaP4 cells (endogenous LEDGF/p75, Figure 3.4) is traditionally enriched
in the body of transcription units (75.0% in RefSeq genes; Table 3.2) but disfavoured Transcription
Start Sites (TSS) and promoter regions (2.0% within 2kb of the 5’ of a RefSeq gene and 3.1% within
2kb of a CpG island) [Schroder et al., 2002; Mitchell et al., 2004]. LEDGF-depletion results in a
more random integration site distribution, characterized by reduced integration into genes (51.0% in
RefSeq genes) and increased integration close to TSS (5.4%) and CpG islands (7.0%), in line with
previous work [Shun et al., 2007; Marshall et al., 2007; Gijsbers et al., 2009]. This phenotype was
fully reverted upon LEDGF/p75 complementation (LEDGFBC; 75.6% in RefSeq genes). Comparable
data were obtained for larger window sizes (only 2kb and 4kb are shown in Table 3.2). Integration site
distributions in cells expressing the respective LEDGFD366N mutants were not different from LEDGFKD
cells (n=16473; data not shown). Interestingly, the mere ablation of the PWWP domain (δN93-LEDGF)
resulted in an overall more random distribution compared to LEDGFKD cells, with decreased integration
near retrovirus-specific features like gene bodies, TSS and promoter regions (*** p<0.001; χ2 test
compared to LEDGFKD; Table 3.2). Complementation of LEDGF-depleted cells with LEDGF-peptide
fusions resulted in a comparable more randomized distribution (*** p<0.001; χ2 test compared to
LEDGFKD; Table 3.2). In a more elaborate analysis, we analysed global integration preferences and
included a wide selection of genomic features, depicted as a genomic heatmap (Figure 3.4), comparing
integration site data sets obtained from HeLaP4 LEDGFKD cells to those of cells complemented with
the respective LEDGF-hybrids. Tile color depicts the correlation for an integration dataset with the
respective genomic feature (left) relative to matched random controls, as indicated by the colored
Receiver Operating Characteristic (ROC) curve area scale at the bottom of the panel. LEDGF/p75
depletion shifts integration out of transcriptionally active regions wich is reverted upon complementation
with LEDGF/p75 (compare LEDGFKD and LEDGFBC; shown in Figure 3.4 and Supplementary Figure
S3.2 on page 64 (compared to LEDGFBC and δN93-LEDGF respectively), in line with previous data
[Shun et al., 2007; Marshall et al., 2007; Gijsbers et al., 2009]. Cells complemented with δN93-LEDGF
displayed an more randomly distributed integration profile, with tiles overall coloring less red or blue
compared to LEDGFKD, integrating less near DNase sensitive regions, CpG-islands and GC-rich regions
compared to LEDGFKD (*** p<0.001, Wald statistics). Introduction of the heterologous HPV E2 and
LANA1-31-peptide fragments to replace the PWWP-domain resulted in a δN93-LEDGF-like integration
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profile when compared to LEDGFKD (p<0.001), whereas integration for PFV Gag534-546-δN93-LEDGF
was less random. When displaying statistics relative to δN93-LEDGF (Supplementary Figure S3.2a)
it is clear that integration frequencies relative to these genomic features is not significantly different
between δN93-LEDGF and the respective δN93-LEDGF peptide-fusions, except for PFV Gag534-546-δN93-
LEDGF, which shifts to more random relative to LEDGFKD. The reproducibility of the data observed
for HPV5 E2242-257-δN93-LEDGF and HPV8 E2240-255-δN93-LEDGF complemented cell lines and the
pronounced redistribution towards more random relative to LEDGFBC (Supplementary Figure S3.2b)
underscores the effectiveness of LEDGF-based artificial tethers for retargeting of LV integration. Next
to integration relative to genomic features, we also analyzed integration site densities near epigenetic
features (Figure 3.4b on page 54). The epigenetic heat map displays yellow and blue tiles, with blue
tiles indicating that integration frequency is enriched near these marks relative to MRC, whereas yellow
tiles indicate that integration is disfavored compared to MRC. A near random distribution would
result in a black tile. As reported previously, lentiviral integration correlates with histone marks
associated with open and transcriptionally active chromatin (H3K4 mono-, di- and tri methylation,
H3K14 and H4 acetylation, as well as acetylation and monomethylation of H3K9/K27/K79, H4K20
and H2BK5,...)[De Ravin et al., 2014] while disfavoring integration in transcriptionally silent regions
or heterochromatin (H3K27me3, H3K9me3 or H4K20me3 and H3K79, respectively) [De Ravin et al.,
2014] (WT; Figure 3.4b). Depletion of LEDGF/p75 (LEDGFKD) resulted in a more random distribution
(with tiles displaying a less pronounced blue or yellow color, and shifting towards black). This tendency
was more outspoken for δN93-LEDGF and the HPV E2 and LANA1-31-peptide fusions compared to
LEDGFKD (Figure 3.4, δN93-LEDGF (Supplementary Figure S3.3a) or LEDGFBC (Supplementary
Figure S3.3b on page 65), potentially because integration in LEDGF-depleted cells, at least in part, is
tethered by HRP-2 [Schrijvers et al., 2012a].
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Figure 3.4: LEDGF-hybrids retarget lentiviral integration towards a more randomized pattern.
(a) Genomic heat map comparing integration site data sets obtained from HeLaP4 LEDGF/p75 KD cells
overexpressing different artificial LEDGF-hybrids to genomic features. Tile color depicts the correlation for
an integration dataset with the respective genomic feature (left) relative to matched random controls, as
indicated by the colored Receiver Operating Characteristic (ROC) curve area scale at the bottom of the panel.
Statistical significance (asterisks, ***p<0.001 ranked Wald tests) is shown relative to LEDGFKD population
(double dash). Columns indicate different data sets, while rows indicate different genomic features analyzed
(described in [Ocwieja et al., 2011]). LANA, Latency Associated Nuclear antigen; HPV, Human Papilloma
Virus; PFV, Prototype Foamy Virus; LEDGF, Lens Epithelium-Derived Growth Factor;
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Figure 3.4: LEDGF-hybrids retarget lentiviral integration towards a more randomized pattern.
(b) Epigenetic heat map comparing integration site data sets obtained from HeLaP4 LEDGF/p75 KD cells
overexpressing different artificial LEDGF-hybrids to epigenetic features. Tile color depicting a positive or
negative correlation to the respective epigenetic feature (10kb windows), relative to MRC, as indicated by the
Receiver Operating Characteristic (ROC) curve area scale at the bottom of the panel. Statistical significance
(asterisks, ***p<0.001, ranked Wald tests) is shown relative to LEDGFKD population (dashed). Columns
indicate different data sets while rows indicate different epigenetic features analyzed. Included features were
limited to those identified in high-throughput studies HeLaP4 and primary CD4+ T-cells. Detailed information
on epigenetic marks and their roles can be found in [Barski et al., 2007; Taverna et al., 2007]. LANA, Latency
Associated Nuclear Antigen; HPV, Human Papilloma Virus; PFV, Prototype Foamy Virus; LEDGF, Lens
Epithelium-Derived Growth Factor
3.3.5 Artificial LEDGF/p75-peptide hybrids result in a safer integration
profile
Together, the presented data above indicate that lentiviral vector integration preferences are defined by
LEDGF/p75 as a cellular tether, and are mostly dictated by the N-terminal PWWP-domain. The mere
deletion of this domain, or replacement with alternative chromatin-interacting modules redistributes
vector integration sites in a more random fashion. The question remains whether redistribution of
proviral integration sites obtained for our LEDGF-hybrids also translated in a safer therapy, with a
lower chance on insertional mutagenesis. In an effort to get a better view on the safety profile, we cal-
culated integration frequencies near a specific set of previously defined criteria [Papapetrou et al., 2011;
Sadelain et al., 2011b], such as transcription start sites (<50kb), oncogenes (<300kb) or miRNA coding
regions (<300kb), transcription units and ultraconserved elements to define potentially unsafe integra-
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tion events. The large window sizes impose a very stringent selection for lentiviral integration events
away from these features, which in turn can thus be considered as more safe [Papapetrou et al., 2011].
For each data set we evaluated the percentage of unsafe integrations (Table 3.3 and Supplementary Ta-
ble S3.2 on page 56 and 67 respectively) and in addition determined the percentage of safe sites (events
not captured in any of the other criteria; Table 3.3, % safe). When calculating the percentage in the
parental cell line only 5.4% of all LV integration sites may be considered safe. LEDGF/p75-depletion
results in a shift to 16.3% safe sites (p-value <0.005, Pearsons Chi-square compared to the LEDGFWT
control condition), a phenotype that was fully reverted upon LEDGF/p75BC complementation (5.4%,
no significant difference compare to LEDGFWT). Ablation of the N-terminal PWWP-domain again
boosted the percentage safe integration events to 19.7% (p-value <0.005, Pearsons Chi-square compared
to the LEDGFWT control condition). Addition of heterologous peptide fragments KSHV LANA1-31 and
HPV8 E2240-255 to the N-terminal end of LEDGF93-530 slightly increased the % safe integrations rela-
tive to δN93-LEDGF complementation up to 20.2% for HPV5 E2242-257-δN93-LEDGF, 21.2% for HPV8
E2240-255-δN93-LEDGF and 21.6% for KSHV LANA1-31-δN93-LEDGF when considering these criteria
(p-value <0.005, Pearsons Chi-square compared to the δN93-LEDGF control condition). Relative to
the LEDGFBC condition our LEDGF-chimera increased the percentage of safe sites more than 3 fold
(p-value <0.005, Pearsons Chi-square, Supplementary Table S3.2b). Of note, for the MRC conditions,
we obtained a maximum of 30% integrations in safe harbors. Gene ontology (GO) analyses evaluat-
ing whether our different peptide fusions targeted genes belonging to different GO classes (subdivided
based on (a) Biological processes and (b) Molecular function) did no show substantial shifts in inte-
gration frequencies for specific gene classes compared to those normally targeted by wild-type LEDGF
(Supplementary Table S3.3 on page 68).
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3.4. DISCUSSION
3.4 Discussion
Integration of retroviral vectors into the host cell genome makes them invaluable tools for gene ther-
apeutic applications where life-long correction is key. Different clinical trials showed effective gene
transfer enabling long-term gene correction (For a review see [Naldini, 2015]). However, stable inte-
gration also implies the intrinsic risk of vector-induced genomic perturbation and the possibility of
insertional mutagenesis leading to loss of function or transcriptional deregulation of neighbouring genes
[Hacein-Bey-Abina et al., 2008; Howe et al., 2008; Cavazzana-Calvo et al., 2010]. These concerns became
reality upon the emergence of leukemia in 25% of patients enrolled in a clinical trial for X-SCID and
the development of acute lymphoblastic and myeloid leukemia in 70% of the patients in the Wiskott-
Aldrich Syndrome (WAS) trial, both applying early generation gammaretroviral vectors [Boztug et al.,
2010; Braun et al., 2014]. The yRV preference for integration into enhancer regions and concomitant
activation of proto-oncogenes led to malignant transformation of cells and clonal expansion [Mitchell
et al., 2004; Derse et al., 2007; Deichmann et al., 2007]. For therapeutic gene delivery attention has
since turned to LVs due to their higher efficiency, safer integration profile and lower genotoxicity in pre-
clinical models. In addition, improved vector design led to the development of self-inactivating vectors
resulting in diminished enhancer activity of the U3 region and decreased genotoxicity of RV vectors [Zy-
chlinski et al., 2008; Montini et al., 2009a; Modlich et al., 2009a; Newrzela et al., 2008]. Other attempts
to limit the adverse events involved the use of insulator sequences as enhancer and silencer blockers
[Emery, 2011], retargeting of viral integration [Ferris et al., 2010; Gijsbers et al., 2009; Silvers et al.,
2010] and cell specific promoters to support cell specific expression [Antoniou et al., 2013]. However,
RVs will always carry the intrinsic risk of open reading frame-disruption, as indicated by the report on
SIN-LV affected splicing [Trono, 2012]. In addition, also LV integration may lead to clonal dominance
as reported in the β-thalassemia trial [Cavazzana-Calvo et al., 2010]. Therefore it is important to gain
additional mechanistic insights into the molecular mechanism of integration and integration site selec-
tion for LVs to be accepted for general therapeutic use. We and others substantially contributed to the
elucidation of the role of LEDGF/p75 as a molecular tether of lentiviral vector integration. As a cellular
cofactor of lentiviral integration, LEDGF/p75 orchestrates lentiviral integration preference by binding
H3K36me3 in the body of active transcription units via its N-terminal PWWP domain, but it is the
vector-encoded integrase that catalyzes the integration reaction. Depletion of LEDGF/p75 by knock-
down or knockout strategies shifts lentiviral vector integration out of active genes, yet integration is not
completely random [Ciuffi et al., 2005; Schrijvers et al., 2012a], which at least in part can be explained
by residual targeting via HRP-2 [Schrijvers et al., 2012a]. Here we set out to study whether different
LEDGF-hybrids could be generated to distribute lentiviral integration sites more randomly. This line
of vector development is based on the further increasing interest in new vector platforms displaying
a close-to-random insertional profile potentially reducing the probability of proto-oncogene activation
lowering the genotoxic potential [Staunstrup et al., 2009; Moldt et al., 2011; Suerth et al., 2012]. In an
effort to achieve a more random integration site distribution, we deleted the specific chromatin-binding
PWWP module of LEDGF/p75 (aa 1-93), or we replaced it with alternative pan-chromatin binding
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modules. In case of LEDGF/p75, it is demonstrated that the PWWP domain recognizes H3K36me3,
a chromatin mark that is particularly enriched in the body of active transcription units [De Rijck
et al., 2010; Pradeepa et al., 2012; Eidahl et al., 2013; Gijsbers et al., 2011a; van Nuland et al., 2013].
Complementation of LEDGF-depleted cells with a LEDGF/p75-protein that had its PWWP domain
deleted (δN93-LEDGF) or replaced with alternative chromatin binding modules showed unique subnu-
clear distributions for each of the constructs, indicating that these deletion of the PWWP domain, or
the replacements with any of the other peptides, resulted in a specific redistribution within the nuclear
compartment of the artificial LEDGF chimera (Figure 3.2 on page 47). The latter phenotype can be
attributed to the AT-hook motifs and charged regions present in the N-terminal end of δN93-LEDGF,
together with the specific peptides that replaced the PWWP domain. After working up integration
sites, analysis showed that lentiviral integration preferences for most of the constructs resulted in a
more random distribution than under LEDGF depleted conditions (genomic and the epigenetic heat
map representations; Figure 3.4a and b on page 53), except PFV Gag534-546-δN93-LEDGF. For example,
in the latter cells LV integration was still enriched near epigenetic markers for transcriptionally active
chromatin, albeit less outspoken than observed with LEDGFWT and LEDGFBC cells. Interestingly,
peptide addition was not required to obtain a more random distribution. Lentiviral integrations in
δN93-LEDGF expressing cells were redistributed in a fairly random manner, with tile colors shifting to
grey and black (for the genomic and the epigenetic heat map representations, respectively) indicating
that integration frequencies for these features are not enriched nor depleted compared to the matched
random integration site distribution. Comparison with LEDGFKD shows that integration is more ran-
domly distributed than under LEDGF depletion (*** p<0.001, Wald statistics; Figures 3.4a, b and
Supplementary Figure S3.2 and S3.3 on pages 64 and 65). Fusion of short pan-chromatin binding pep-
tides to the truncated δN93-LEDGF resulted in similar shifts towards a more randomized integration
profile. The fact that all peptide fusions display a unique subnuclear location, suggest that their inter-
action with chromatin is different. Even though the overall integration frequencies are highly similar
(considering the genomic and the epigenetic features analyzed), larger integration site datasets (>10e5
sites) would be required to allow more detailed analysis on the specific subsets. In an effort to estimate
the effect of the more randomized distribution on safety, we calculated the frequency of integration
relative to a set of safe harbor criteria for the individual integration site datasets [Papapetrou et al.,
2011]. This analysis showed that the more random distributions resulted in a lower genotoxic profile
with 18-22% of integrations meeting safe harbor criteria for our LEDGF-chimera compared to only 5.4%
for cells carrying wild-type LEDGF/p75, all LEDGF-chimera resulted in a safer distributions over the
genome. Fully targeted integration towards safe harbor regions like the AAVS1 or CCR5 locus would be
the ultimate solution to circumvent insertional mutagenesis [Lombardo et al., 2011; Papapetrou et al.,
2011; Sadelain et al., 2011b]. Several methods for site-directed gene correction have been developed
using genetic scissors based on Zinc-finger nucleases, transcription activator like effector nucleases or
more recently RNA-guided nucleases (CRISPR/Cas9) (for a review [Mussolino and Cathomen, 2013]
). However, site directed integration would no doubt impair transduction efficiencies. Our approach
improves the therapeutic potential of lentiviral vectors by decreasing the risk/benefit ratio, still sup-
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porting high transduction efficiencies. The fact that integration can be directed to genomic regions that
are not targeted under wild-type conditions nor LEDGF-depleted conditions, indicates that integration
in these areas is disfavored due to the absence of a tether, rather than the presence of specific obstacles
such as steric hindrance resulting from the condensed chromatin structure. As an alternative to the
generation of stable cell lines as employed here, we demonstrated earlier that mRNA-electroporation
ensures timely, high-level recombinant protein expression that is sufficient to retarget lentiviral vector
integration [Vets et al., 2013]. When combined with IN mutant lentiviral vectors that selectively bind
complementary LEDGF/p75 variants [Wang et al., 2014], this approach should be broadly applicable to
introduce therapeutic or suicide genes for cell therapy, such as genetic modification of patient-specific
iPS cells and improve safety of lentiviral vectors. With the occurrence of potential adverse effects being
of multi-factorial nature [Kustikova et al., 2009] and assays lacking to predictively assess the cytotoxic-
ity observed in vivo [Rothe et al., 2014b], a continuous effort aiming at abolishing the risk of insertional
mutagenesis will be required for gene therapy to become a broadly accepted treatment alternative.
3.5 Experimental procedures
3.5.1 Generation of stable cell lines.
SIV-based vector transfer plasmids (pGAE) were a kind gift of D. Nègre (Laboratoire de Vectorologie
Rétrovirale et Thérapie Génique, INSERM U412, IFR 74, Ecole Normale Supérieure de Lyon, Lyon,
France). A lentiviral vector carrying CMV promoter driving a Zeocin resistance gene and a LEDGF
specific miRNA-based shRNA was described earlier [Osório et al., 2014] and used to generate stable
LEDGFKD cells. All LEDGF/p75 hybrid expression constructs were cloned into the pGAE backbone
and cloning steps sequence verified.
Cloning of δN93-LEDGF and δN93-LEDGFD366N controls for the LEDGF δN93-LEDGF fusions.
pGAE_SFFV_ZnF4_δN93_BC_I_BsdR_WPRE cl.9 and pGAE_SFFV_ZnF4_δN93BC_D366N_I
_BsdR_WPRE cl.3 were digested using BglII & XhoI. Ligation of the synthetic adaptor Ad_BglIIKO
_AgeI_kozak generated pGAE_SFFV_ δN93_BC_I_BsdR_WPRE cl. E and pGAE_SFFV_δN93
_BC_D366N_I_BsdR_WPRE cl. 5. We further refer to the controls as δN93-LEDGF and δN93-
LEDGFD366N respectively.
Cloning of LEDGF δN93-LEDGF and δN93-LEDGFD366N hybrids. pGAE_SFFV_ZnF4_ δN93_BC
_I_BsdR_WPRE cl.9 and pGAE_SFFV_ZnF4_ δN93BC_D366N_I_BsdR_WPRE cl.3 were di-
gested using BglII & XhoI. Ligation of the synthetic adaptors (for adaptor sequences see Supplementary
Table S3.1 on page 66) LANA31, PFVCBS13, HPV5E2_16 and HPV8E_216 generated:
pGAE_SFFV_LANA1-31_ δN93_BC_I_BsdR_WPRE cl.A9
pGAE_SFFV_LANA1-31_ δN93_BC_I_BsdR_WPRE cl.H
pGAE_SFFV_ PFVCBS13_ δN93_BC_I_BsdR_WPRE cl.13
pGAE_SFFV_ PFVCBS13_ δN93_BC_I_BsdR_WPRE cl.4
pGAE_SFFV_ HPV5E2_16 _ δN93_BC_I_BsdR_WPRE cl.19
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pGAE_SFFV_ HPV5E2_16 _ δN93_BC_I_BsdR_WPRE cl.8
pGAE_SFFV_ HPV8E2_16 _ δN93_BC_I_BsdR_WPRE cl.23
pGAE_SFFV_ HPV8E2_16 _ δN93_BC_I_BsdR_WPRE cl.11
All cloning steps were confirmed by restriction digest and sequencing.
3.5.2 Cell culture.
All cells were grown in a humidified atmosphere containing 5 % CO2 at 37 °C. HeLaP4 310 LEDGF/p75
depleted cells ([Gijsbers et al., 2009], further referred to as LEDGFKD cells) were grown in Dulbecco’s
Modified Eagle’s Medium (DMEM; GIBCO-BRL, Merelbeke, Belgium) supplemented with 5% v/v
heat inactivated Fetal Calf Serum (FCS; Sigma-Aldrich, Bornem, Belgium), 0.005% w/v gentamicin
(GIBCO), 0.05% w/v geneticin (GIBCO) and 0.01% w/v zeocin (Life Technologies, Ghent, Belgium).
These cells are monoclonal LEDGFKD cells, derived from HeLaP4 cells (gift from P. Charneau, Institut
Pasteur, Paris, France). HelaP4 cells were grown on DMEM (GIBCO) supplemented with 5% v/v
heat inactivated fetal calf serum (FCS; Sigma-Aldrich), 0.005% w/v gentamicin (GIBCO) & 0.05%
w/v geneticin (GIBCO). HEK 293T cells (gift from O. Danos, Evry, France) were cultured in DMEM
medium (GIBCO) with 8% v/v heat inactivated FCS (Sigma-Aldrich) and 0.005% w/v gentamicin
(GIBCO). SupT1 cells were cultured in Roswell Park Memorial Institutes medium (RPMI, GIBCO-
BRL, Merelbeke, Belgium) supplemented with 10% v/v heat inactivated fetal calf serum FCS (Sigma-
Aldrich, Bornem,Belgium) and 0.005% w/v gentamicin (GIBCO). Nalm pre-B cells were cultured in
RPMI (GIBCO) with 10% v/v heat inactivated FCS (Sigma-Aldrich) and 0.005% w/v gentamicin
(GIBCO).
3.5.3 Retroviral vector production (SIV-based) and transduction.
Lentiviral vector production was performed as described earlier [Ibrahimi et al., 2009]. Briefly, for
the generation of vesicular stomatitis virus glycoprotein (VSV-G) pseudo-typed SIV-based lentiviral
vectors, HEK 293T cells were transfected with the packaging plasmid specific for SIV (pAd_SIV3+;
gift from D. Nègre, Lyon, France), the envelope plasmid encoding VSV-G (pLP-VSVG #646 B, from
Invitrogen) and respective transfer plasmids, using polyethylenimine (PEI; Polysciences, Amsterdam,
The Netherlands). After collecting the supernatant, the medium was filtered using a 0.45 µm filter
(Corning Inc., Seneffe, Belgium) and concentrated using a Vivaspin 15 50,000 MW column (Vivascience,
Bornem, Belgium). The vector containing concentrate was then aliquoted per 50 µl and stored at -80 °C.
Stable cell lines expressing a LEDGF-hybrid were generated by transduction of polyclonal LEDGF/p75
KD cells with SIV-based vectors and subsequent selection with 0,0003 % w/v blasticidin (Invitrogen).
For lentiviral transduction experiments (LV eGFP T2A fLuc) cells were transduced over night (ON).
72 hours post-transduction cells were harvested when 90% confluent and used for eGFP FACS-analysis
or measuring luciferase activity. The remainder of the transduced cells was further cultivated for at
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least 10 days to eliminate non-integrated DNA and submitted for integration site sequencing.
3.5.4 Immunocytochemistry and Laser scanning microscopy.
Cells were transfected using Lipofectamine 2000 (Life Technologies, Merelbeke, Belgium) as described
earlier [De Rijck et al., 2006]. LEDGF-hybrids were detected with the primary polyclonal rabbit anti
LEDGF480-530 antibody (A300-848a; 1/500; Bethyl Laboratories-Imtec Diagnostics N.V., Antwerpen,
Belgium) and secondary polyclonal goat anti-rabbit antibody (1/500 in PBS, goat- αRb488; Bethyl
Laboratories-Imtec Diagnostics N.V., Antwerpen, Belgium). Confocal images were acquired using an
LSM 510 META imaging unit (Carl Zeiss, Zaventem, Belgium). Alexa-488 was excited at 488 nm (AI
laser), mRFP at 543 (HeNe laser) and DAPI at 790 nm (Spectra-physics Mai Tai laser; Spectra Physics,
Mountain View CA). After the main beam splitter (HFT KP 700/543 for mRFP, HFT UV/488/543/633
for eGFP, and HFT KP650 for DAPI) a secondary dichroic beam splitter was used to divide the
fluorescence signal (NFT 490 for eGFP, NFT 545 for mRFP). Distinct signals were directed to different
detectors and data analysis was performed with the LSM image browser. Overlay images were obtained
using ImageJ freeware.
3.5.5 Western Blot.
Protein concentration of 1 % SDS (AppliChem, Leuven, Belgium) protein extracts sheared with a 27
G needle (Terumo, Leuven, Belgium) was determined using a bicinchoninic acid (BCA) protein as-
say (Pierce, Aalst, Belgium). Proteins were separated on a 12.5% w/v SDS-polyacrylamide gel and
transferred to a polyvinylidene difluoride membrane (PVDF; BioRad) using an XCell SureLock elec-
trophoresis system (Invitrogen). LEDGF-hybrids were detected using 1/2.000 polyclonal rabbit anti-
LEDGF480-530 antibody (A300-848a; Bethyl Laboratories-Imtec Diagnostics N.V., Antwerpen, Belgium)
and 1/5 000 secondary antibody (polyclonal goat anti-rabbit antibody coupled with horse radish per-
oxidase (HRP); Dako). Chemiluminescence was measured using a ECL plus western blotting detection
kit (Amersham Biosciences, Roosendaal, The Netherlands). Equal loading was verified with a primary
monoclonal antibody directed to α-tubulin (mouse, 1/10 000, 1 h at room temperature; T5168, Sigma-
Aldrich) and secondary antibody in blocking buffer (1/10 000, polyclonal goat-anti mouse labelled with
HRP; Dako). Visualization was done by chemiluminescence (Pierce ECL Western Blotting Substrate,
Thermo scientific).
3.5.6 Luciferase assay.
Cells were transduced with LV eGFP T2A fLuc and lysed with 70 µl of lysis buffer (50 mmol/l Tris pH
7.5, 200 mmol/l NaCl, 0.2% NP40, 10% glycerol). FLuc activity was determined using the ONE-glo
luciferase assay system according to the manufacturers protocol (Promega, Leiden, The Netherlands)
and normalized to the total protein concentration in order to correct for differences in metabolic state.
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The total protein concentration was measured in parallel using a bicinchoninic acid (BCA) protein
assay (Pierce, Aalst, Belgium).
3.5.7 Flow cytometric analysis.
Cells were transduced with LV eGFP T2A fLuc and harvested when 95% confluent. eGFP/YFP
fluorescence was monitored by Flow cytometric analysis (FACS, Fluorescence activated cell sorting)
using a FACSCalibur flow cytometer (BD Biosciences, Erembodegem, Belgium). Data analysis was
performed with the CellQuest Pro software (BD Biosciences, Erembodegem-Aalst, Belgium). The
percentage of eGFP positive cells (% of gated cells) multiplied by the mean fluorescence intensity
(MFI) is further referred to as overall transduction efficiency.
3.5.8 Integration site amplification and sequencing.
Transduced cells were further cultivated for at least 10 days to eliminate non-integrated DNA. Cells were
harvested when ca. 90% confluent. Genomic DNA was extracted using the GenElute Mammalian Ge-
nomic DNA miniprep kit (Sigma-Aldrich). Integration sites were amplified by linker-mediated PCR as
described previously [Marshall et al., 2007] (see Supplementary Figure A.1 on page 163). Genomic DNA
was digested using MseI and linkers were ligated (Supplementary Table S3.1 on page 66). Proviral-host
junctions were amplified by nested PCR using Barcoded primers, generating 454 libraries. This en-
abled pooling of PCR products into one sequencing reaction. Products were gel-purified and sequenced
using 454/Roche pyrosequencing (Titanium technology, Roche) on the 454 GS-FLX-instrument at the
University of Pennsylvania. Reads were filtered based on perfect match to the LTR linker, Barcode and
flanking LTR. All sites were mapped to the human genome requiring a perfect match within 3bp of the
LTR end. Three Random Control sites were computationally generated and matched to experimental
sites with respect to the distance to the nearest MseI Cleavage site (Matched Random Control, MRC).
A more detailed explanation can be found in the supplementary guidelines of [Ocwieja et al., 2011].
Normalization of experimental HIV-derived lentiviral vector sites to those of the MRC sites functions as
a control for recovery bias due to cleavage by restriction enzymes. Analysis was performed as described
previously and genomic heat maps generated using the INSIPID software (Bushman Lab, University of
Pennsylvania) [Marshall et al., 2007]. A detailed guide to interpret the data presented can be found in
[Ocwieja et al., 2011]. The computation of DNase I site density was based on a table of DNase I sites
obtained from [Lewinski et al., 2006]. Datasets used in the safe harbor analysis were retrieved from
ENSEMBLE and/or UCSC (TxDB knownGenes, miRNA biotype, UCR; hg19) using BioMART [Kin-
sella et al., 2011]. The Allonco-list was used for oncogenes as published in [Sadelain et al., 2011b]. GO
Slim classification analysis was done using the Web-based Gene set analysis toolkit (WebGeSTALT).
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Supplementary Figure S3.1: Western analysis of LEDGF-fusions. LEDGF depleted cell lines were
complemented with the respective LEDGF-hybrids. Total cell lysates were prepared and separated on a 12,5
% SDS gel. An antibody recognizing LEDGF325-530 was used for detection. β-tubuline detection was used as
an equal loading control. WT, Wild type; KD, KnockDown; PFV, Prototype Foamy Virus; LANA, Latency
Associated Nuclear Antigen; HPV, Human Papilloma Virus; LEDGF, Lens Epithelium-Derived Growth Factor.
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Supplementary Figure S3.2: LEDGF-hybrids retarget lentiviral integration towards a more
randomized pattern. Genomic heat maps comparing integration site data sets obtained from HeLaP4
LEDGF/p75 KD cells overexpressing different artificial LEDGF-hybrids to genomic features. Tile color de-
picting the nature of the correlation for an integration dataset with the respective genomic feature (left)
relative to matched random controls, as indicated by the colored Receiver Operating Characteristic (ROC)
curve area scale at the bottom of the panel. Statistical significance (asterisks, ***p<0.001, ranked Wald tests)
is shown relative to (a) δN93-LEDGF or (b) LEDGFBC, respectively (double dash). Columns show different
data sets while rows indicate different genomic features analyzed (described in [Ocwieja et al., 2011]). LANA,
Latency associated nuclear antigen; HPV, Human Papilloma Virus; PFV, Prototype Foamy Virus; LEDGF,
Lens Epithelium-Derived Growth Factor.
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Supplementary Figure S3.3: LEDGF-hybrids retarget lentiviral integration towards a more
randomized pattern. Epigenetic heat maps comparing integration site data sets obtained from HeLaP4
LEDGF/p75 depleted cells overexpressing different artificial LEDGF-hybrids to epigenetic features, generated
using the INSIPID software (Bushman Lab, University of Pennsylvania). Tile color depicting a positive or
negative correlation to the respective epigenetic feature (10 kb windows), relative to matched random controls,
as indicated by the Receiver Operating Characteristic (ROC) curve area scale at the bottom of the panel.
Statistical significance (asterisks, ***p<0.001; ranked Wald tests) is shown relative to (a) δN93-LEDGF or (b)
LEDGFBC, respectively (double dash). Significance is reached when p<0.001, compared to MRC. Columns
indicate different data sets while rows indicate different epigenetic features analyzed. Included features were
limited to those identified in high-throughput studies performed in HeLa and primary CD4+ T-cells. Detailed
information on epigenetic marks and their roles can be found in [Barski et al., 2007; Taverna et al., 2007].
LANA, Latency Associated Nuclear Antigen; HPV, Human Papilloma Virus; PFV, Prototype Foamy Virus;
LEDGF, Lens Epithelium-Derived Growth Factor; MRC, Matched Random Control.65
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Name synthetic oligo Sequence Description
Ad_BglIIKO_AgeI_kozak_s GATCACCGGTACCATGC /
Ad_BglIIKO_AgeI_kozak_as TGGCCATGGTACGAGCT /
LANA31_s GATCATGGCCCCTCCTGGCATGCGCCTGCGCAGCGGCCGCAGCACCGGCGCCCCTCTGACCCGCGGCAGCTGCCGCAAGCGCAACCGCAGCCCCGAGC /
LANA31_as TCGAGCTCGGGGCTGCGGTTGCGCTTGCGGCAGCTGCCGCGGGTCAGAGGGGCGCCGGTGCTGCGGCCGCTGCGCAGGCGCATGCCAGGAGGGGCCAT /
PFVCBS13_s GATCATGCAGGGCGGCTACAACCTGCGCCCCCGCACCTACCAGCCCC /
PFVCBS13_as TCGAGGGGCTGGTAGGTGCGGGGGCGCAGGTTGTAGCCGCCCTGCAT /
HPV5E2_16_s GATCATGCAGACCGAGACCCGCGGCCGCCGCTACGGCCGCCGCCCCAGCAGCAAGC /
HPV5E2_16as TCGAGCTTGCTGCTGGGGCGGCGGCCGTAGCGGCGGCCGCGGGTCTCGGTCTGCAT /
HPV8E2_16_s GATCATGCAGACCGAGACCAAGGGCCGCCGCTACGGCCGCCGCCCCAGCAGCCGCC /
HPV8E2_16as TCGAGGCGGCTGCTGGGGCGGCGGCCGTAGCGGCGGCCCTTGGTCTCGGTCTGCAT /
Mse linker+ GTAATACGACTCACTATAGGGCTCCGCTTAAGGGAC linker
Mse linker- [Phosp]TAGTCCCTTAAGCGGAG-[AmC7-Q] linker
MseL1 GTAATACGACTCACTATAGGGC linker primer, PCR1
GW-3 gcctccctcgcgccatcagAGGGCTCCGCTTAAGGGAC linker primer, PCR2, MseL2 fused to 454 primer A
MKL-3 CTTAAGCCTCAATAAAGCTTGCCTTGAG HIV primer, PCR1
B-HIV3p-743 gccttgccagcccgctcagTCGTGATGagacccttttagtcagtgtggaaaatc UPPERCASE IS BARCODE
Supplementary Table S3.1: Primer oligos used in this study. Table depicting the different oligos used
in this study together with their nucleotide sequence.
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Type Controls Total Sites % TSS within 50kb % Onco within 300kb % miRNA within 300kb % in transcript. Units % in UCR % Safe
WT insertion FALSE 3520 36.0 43.2 28.0 79.4 7.0 5.4
LEDGFKD insertion FALSE 5560 33.8 33.8 21.4 57.0 6.2 16.3
LEDGFBC insertion FALSE 1107 32.4 36.4 23.5 80.1 7.0 6.8
N93-LEDGF insertion TRUE 2990 29.7 31.1 20.4 56.5 6.5 19.1
PFV CBS Gag534-546- N93 LEDGF insertion FALSE 8267 33.5 35.4 22.4 57.0 5.9 17.4
HPV5 E2242-257- N93-LEDGF insertion FALSE 9572 30.3 31.4 19.7 54.2 6.1 20.5
HPV8 E2240-255- N93-LEDGF insertion FALSE 6616 30.0 31.8 20.4 54.0 6.0 21.2
KSHV LANA1-31- N93-LEDGF insertion FALSE 8565 30.6 32.9 21.6 54.2 5.5 21.6
WT match
TRUE
10560 24.1 21.4 14.3 46.1 5.2 29.5
LEDGFKD match FALSE 16680 24.1 22.0 15.0 46.1 5.2 29.3
LEDGFBC match FALSE 3321 24.6 20.1 15.0 46.1 4.5 29.9
N93-LEDGF match 8970 23.8 21.1 15.2 45.8 5.4 29.9
PFV Gag 534-546- N93-LEDGF match FALSE 24801 24.3 21.1 14.4 45.7 5.1 29.9
HPV5 E2242-257- N93-LEDGF match FALSE 28716 24.1 21.1 14.6 46.4 5.3 29.7
HPV8 E2240-255- N93-LEDGF match FALSE 19848 24.2 21.2 14.7 46.2 4.8 29.5
KSHV LANA1-31- N93-LEDGF match FALSE 25695 24.3 21.1 14.8 46.1 5.4 29.3
***
***
***
***
***
***
***
***
***
***
***
***
***
***
*
**
**
**
*
*
*
*
**
**
**
**
**
* *
***
*
*
FALSE
Type Controls Total Sites % TSS within 50kb % Onco within 300kb % miRNA within 300kb % in transcript. Units % in UCR % Safe
WT insertion FALSE 3520 36.0 43.2 28.0 79.4 7.0 5.4
LEDGFKD insertion FALSE 5560 33.8 33.8 21.4 57.0 6.2 16.3
LEDGFBC insertion
FALSE
1107 32.4 36.4 23.5 80.1 7.0 6.8
N93-LEDGF insertion
TRUE
2990 29.7 31.1 20.4 56.5 6.5 19.1
PFV CBS Gag534-546- N93 LEDGF insertion FALSE 8267 33.5 35.4 22.4 57.0 5.9 17.4
HPV5 E2242-257- N93-LEDGF insertion FALSE 9572 30.3 31.4 19.7 54.2 6.1 20.5
HPV8 E2240-255- N93-LEDGF insertion FALSE 6616 30.0 31.8 20.4 54.0 6.0 21.2
KSHV LANA1-31- N93-LEDGF insertion FALSE 8565 30.6 32.9 21.6 54.2 5.5 21.6
WT match 10560 24.1 21.4 14.3 46.1 5.2 29.5
LEDGFKD match FALSE 16680 24.1 22.0 15.0 46.1 5.2 29.3
LEDGFBC match TRUE 3321 24.6 20.1 15.0 46.1 4.5 29.9
N93-LEDGF match 8970 23.8 21.1 15.2 45.8 5.4 29.9
PFV Gag 534-546- N93-LEDGF match FALSE 24801 24.3 21.1 14.4 45.7 5.1 29.9
HPV5 E2242-257- N93-LEDGF match FALSE 28716 24.1 21.1 14.6 46.4 5.3 29.7
HPV8 E2240-255- N93-LEDGF match FALSE 19848 24.2 21.2 14.7 46.2 4.8 29.5
KSHV LANA1-31- N93-LEDGF match FALSE 25695 24.3 21.1 14.8 46.1 5.4 29.3
*****
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*** *** *** *
*
***
**
***
***
***
***
***
***
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***
***
***
***
***
***
***
***
***
***
***
*
**
**
**
***
***
***
***
***
***
- - - - - -
- - - - - -
(a)
(b)
FALSE
Supplementary Table S3.2: Integration frequency near safe harbor criteria. Table showing the per-
centage HIV-derived lentiviral vector integration frequencies near features (TSS, Oncogenes [Sadelain et al.,
2011b], miRNA encoding regions, Transcription units and ultra conserved regions) that, when hit, are consid-
ered to be unsafe as defined in [Papapetrou et al., 2011] (Dataset details are described in the MM section).
As such these features are used to define safe harbors as regions that fall outside these criteria. Percentages
depict the fraction of integrations falling within the corresponding range relative to the criteria. The % in-
tegrations negatively associated with these 5 features is used to calculate a safety profile. (*, p-value <0.5;
**, p-value <0.05;***, p-value <0.005, Pearsons Chi-square compared to (a) δN93-LEDGF or (b) LEDGFBC
control condition). TSS, Transcription Start Sites; UCR, Ultra Conserved regions; PFV, Prototype Foamy
Virus; HPV, Human Papilloma Virus; KSHV, Kaposi’s Sarcoma Herpes Virus; LANA, Latency Associated
Nuclear Antigen; match, matched random control.
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Metabolic process 16.57 15.40 16.91 15.17 15.51 15.27 14.54 15.39
Biological regulation 15.00 14.64 15.05 14.83 14.40 14.49 14.54 14.99
Response to stimulus 10.79 11.10 10.83 11.42 10.62 10.90 10.93 10.64
Multicellular organismal process 8.77 9.47 8.74 7.88 9.51 9.31 9.57 9.57
Cellular component organization 8.57 7.81 8.47 8.44 7.54 8.21 7.80 7.77
Cell communication 8.17 8.41 7.87 8.82 8.39 8.50 8.56 8.41
Developmental pocess 7.63 8.06 7.82 7.57 7.92 7.96 8.05 7.87
Localization 7.51 6.81 6.94 7.47 7.39 7.19 7.43 7.46
Death 2.84 2.91 2.97 3.09 2.85 2.77 2.81 2.65
Reproduction 2.66 2.38 2.65 2.40 2.46 2.45 2.67 2.40
Cell proliferation 2.61 2.75 2.55 2.81 2.41 2.25 2.33 2.27
Multi-organism process 1.97 1.83 1.97 1.74 1.99 1.74 1.82 1.70
Growth 1.31 1.23 1.26 1.49 1.43 1.34 1.26 1.01
Unclassified 5.60 7.20 5.96 6.88 7.58 7.65 7.71 7.89
WT LEDGFKD LEDGFBC
PFV Gag534-546
-ΔN93-LEDGF
HPV5 E2242-257
-ΔN93-LEDGF
HPV8 E2240-255
-ΔN93-LEDGF
KSHV LANA1-31
-ΔN93-LEDGF
ΔN93-LEDGF
Protein binding 14.25 13.47 14.60 13.44 13.12 13.00 12.75 13.33
ion binding 10.89 10.32 10.83 10.94 11.27 11.12 10.88 11.02
Nucleic acid binding 6.16 5.00 6.00 4.69 5.33 5.19 4.90 5.76
Nucleotide binding 5.66 4.64 5.39 5.17 5.02 5.03 4.72 5.00
Hydrolase activity 4.05 3.96 4.45 4.17 4.44 4.29 4.18 4.31
Transferase activity 3.82 3.22 3.80 3.33 3.50 3.61 3.56 3.19
Enzym regulator activity 2.09 2.13 2.00 2.60 1.99 1.90 1.99 1.88
Transporter activity 1.58 1.72 1.37 1.63 2.13 1.84 2.10 2.04
Molecular transducer activity 1.39 1.93 1.43 2.26 1.99 1.91 2.14 2.12
Lipid binding 1.27 1.74 1.35 1.70 1.65 1.63 1.60 1.61
Chromatin binding 0.93 0.78 0.89 0.90 0.68 0.77 0.74 0.66
Structural molecule activity 0.83 0.72 0.85 0.90 0.83 0.67 0.82 0.87
Molecular adaptor activity 0.29 0.37 0.32 0.31 0.25 0.29 0.32 0.40
Carbohydrate binding 0.23 0.20 0.27 0.31 0.30 0.37 0.40 0.36
Electron carrier activity 0.21 0.21 0.15 0.17 0.18 0.14 0.12 0.10
Translation regulator activity 0.10 0.08 0.05 0.07 0.01 0.02 0.03 0.03
Antioxidant activity 0.06 0.08 0.03 0.00 0.01 0.01 0.02 0.01
Unclassified 5.52 6.62 5.47 6.77 7.10 7.08 7.43 7.34
WT LEDGFKD LEDGFBC
PFV Gag534-546
-ΔN93-LEDGF
HPV5 E2242-257
-ΔN93-LEDGF
HPV8 E2240-255
-ΔN93-LEDGF
KSHV LANA1-31
-ΔN93-LEDGF
ΔN93-LEDGF
a) Biological processes
b) Molecular function
Supplementary Table S3.3: Gene ontology analysis. Table depicting the gene ontology results using the
a) Biological process or b) Molecular Function classification system. Row names depict the different Biological
processes or Molecular Functions respectively. Numbers depict the percentage of integrations in genes included
in the respective classes for each individual dataset. Color scale is based on the highest and lowest value in the
table. Low percentages are represented in red while high percentages are represented in blue. Table showing the
percentage HIV-based lentiviral vector integration frequencies near features. GO Slim classification analysis
was done using the Web-based Gene set analysis toolkit (WebGeSTALT).
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LEDGIN-Mediated Inhibition of
Integrase-LEDGF/p75 Interaction Reduces
Reactivation of Residual Latent HIV
This chapter has been previously published as an article manuscript in EBioMedicine (2016):
Vranckx, L.S., Demeulemeester, J., Saleh, S., Boll, A., Vansant, G., Schrijvers, R., Weydert, C.,
Battivelli, E., Verdin, E., Cereseto, A., Christ, F., Gijsbers, R., Debyser, Z. (2016). LEDGIN-
Mediated Inhibition of Integrase-LEDGF/p75 Interaction Reduces Reactivation of Residual Latent
HIV. EBioMedicine, Volume 8 , 248 - 264.
A patent application entitled "Functional Cure of Retroviral Infection" was filed to the UK Patent
Office with myself (Lenard Sebastiaan Vranckx), Rik Gijsbers, Frauke Christ and Zeger Debyser
listed as the inventors.
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CHAPTER 4. LEDGIN-MEDIATED INHIBITION OF INTEGRASE-LEDGF/P75 INTERACTION
REDUCES REACTIVATION OF RESIDUAL LATENT HIV
4.1 Abstract
Persistence of latent, replication-competent Human Immunodeficiency Virus type 1 (HIV-1) provirus is
the main impediment towards a cure for HIV/AIDS (Acquired Immune Deficiency Syndrome). There-
fore, different therapeutic strategies to eliminate this latent reservoir are currently being explored. We
here propose a novel strategy to reduce the functional HIV reservoir during primary HIV infection by
means of drug-induced retargeting of HIV integration. A novel class of integration inhibitors, referred
to as LEDGINs, inhibit the interaction between HIV integrase and the LEDGF/p75 host cofactor, the
main determinant of lentiviral integration site selection. We show for the first time that LEDGF/p75
depletion hampers HIV-1 reactivation in cell culture. Next, we demonstrate that LEDGINs relocate
and retarget HIV integration resulting in an HIV reservoir that is refractory to reactivation by different
latency-reversing agents. Taken together, these results support the potential of drugs that modulate
integration site targeting to reduce the likeliness of viral rebound.
4.2 Research in context (Layman’s terms)
Different strategies to cure HIV infection are being explored. Although complete eradication of the
HIV provirus is the ultimate goal, disease remission allowing treatment interruption without viral
rebound would constitute a significant leap forward. HIV integration site selection is orchestrated by
LEDGF/p75. The advent of LEDGINs, that block the interaction between integrase and LEDGF/p75,
allowed us to examine the hypothesis that interference with HIV integration site selection would yield
integration sites that are less optimal for productive infection. Here we provide evidence in cell culture
that LEDGIN treatment during acute HIV infection yields an HIV reservoir refractory to reactivation.
4.3 Introduction
Combination AntiRetroviral Therapy (cART) has revolutionized the treatment of HIV/AIDS, turning
a life-threatening disease into a chronic illness. Yet, current therapies fail to cure infection due to the
existence of a reservoir of latently infected cells [Archin et al., 2014b; Bruner et al., 2015; Siliciano
and Siliciano, 2015]. While the Human Immunodeficiency Virus type 1 (HIV-1) actively replicates in
activated CD4+ T lymphocytes, it is able to reside in a long-lived quiescent state, mainly in resting
memory CD4+ T cells [Chun et al., 1997a,b; Finzi et al., 1997]. This latently infected cell population
is established early on during infection and consists of a small fraction of the resting CD4+ T cells
in patients (about 1 in 10e6 cells) [Chun et al., 1997a,b; Finzi et al., 1997]. The reservoir enables
HIV persistence during cART and is responsible for the rebound of viraemia upon therapy cessation
[Richman et al., 2009]. Lentiviruses, such as HIV-1, preferentially integrate into transcriptionally
active units [Schroder et al., 2002]. The latter integration preference is retained in latently HIV-1
infected primary CD4+ T cells from patients [Han et al., 2004; Liu et al., 2006; Shan et al., 2011] and
determined by Lens Epithelium-Derived Growth Factor (LEDGF/p75), a host-cell cofactor binding
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HIV-1 IN via its C-terminal protein binding domain (Integrase Binding Domain (IBD)) [Cherepanov
et al., 2003, 2005] and reading chromatin through its PWWP domain [Pradeepa et al., 2012; Eidahl
et al., 2013]. LEDGF/p75 depletion shifts lentiviral integration out of transcription units [Ciuffi et al.,
2005], a phenotype even more pronounced in human LEDGF/p75 KnockOut (KO) cells [Schrijvers
et al., 2012a; Shun et al., 2007; Fadel et al., 2014]. In the absence of LEDGF/p75, its paralogue HRP-2
can at least in part take over this targeting role for HIV integration [Schrijvers et al., 2012b,a; Wang
et al., 2012]. Structure-based drug design targeting the well-defined interface [Cherepanov et al., 2005]
between the IBD and the HIV-1 IN catalytic core resulted in the development of 2-(quinolin-3-yl)acetic
acid derivatives that inhibit HIV-1 replication [Christ et al., 2010]. This novel class of antivirals is
referred to as LEDGINs [Christ and Debyser, 2013; Christ et al., 2010, 2012; Debyser et al., 2015;
Demeulemeester et al., 2014a]. Novel congeners with nanomolar activity act as allosteric inhibitors,
preventing the binding of both LEDGF/p75 and HRP-2 and interfering with the catalytic activity
of IN [Christ et al., 2012; Kessl et al., 2012; Tsiang et al., 2012]. Recently, LEDGINs were found to
inhibit late stage HIV replication as well [Jurado et al., 2013; Desimmie et al., 2013; Balakrishnan et al.,
2013; Le Rouzic et al., 2013]. The phenotype requires the binding of LEDGINs to the LEDGF/p75
binding pocket in IN [Desimmie et al., 2013; Le Rouzic et al., 2013] and is mediated by enhanced
multimerisation of IN in the viral particles [Jurado et al., 2013; Desimmie et al., 2013; Balakrishnan
et al., 2013; Borrenberghs et al., 2014]. Inconclusive results have been obtained as to whether LEDGINs
affect the integration site distribution [Sharma et al., 2014; Gupta et al., 2014]. In any case LEDGIN
treatment results in a steep dose-dependent inhibition of viral replication in cell culture, supporting
their clinical development [Fader et al., 2014; Fenwick et al., 2014]. Here we investigated the early
effect of LEDGINs and evaluated their effect on HIV integration site distribution. In addition, we
monitored the effect of LEDGINs on the establishment of the latent reservoir and investigated whether
retargeting of integration could lead to a silent HIV reservoir resistant to reactivation. In a stepwise
approach we first demonstrate that LEDGF/p75 depletion results in reduced integration but a relatively
expanded silent HIV reservoir. Next, we demonstrate that upon treatment with LEDGINs, blocking
the LEDGF/p75-IN interaction, the residual proviral integration shifts away from transcription units.
LEDGIN treatment also shifts the 3D localization of the integrated provirus towards the inner nucleus.
LEDGIN-induced retargeting relatively expands the silent HIV reservoir in cell lines and primary CD4+
cells. This silent reservoir is refractory to reactivation by latency reversing agents (LRAs). Pushing
sufficient proviruses into latency is theoretically predicted to drive the basic reproduction number of
HIV below 1, resulting in an unsustainable infection [Rouzine et al., 2015]. Hence, addition of LEDGINs
to cART regimens during acute HIV infection may represent a new strategy to achieve a remission of
HIV infection in patients.
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4.4 Results
4.4.1 LEDGF/p75 depletion results in a quiescent reservoir.
We and others reported on retargeted proviral integration in LEDGF/p75-depleted cells [Ciuffi et al.,
2005; Schrijvers et al., 2012a; Shun et al., 2007; Fadel et al., 2014]. To study the role of LEDGF/p75 in
establishing the latent reservoir, we used a variant of the recently developed double reporter virus that
simultaneously measures a constitutive and a LTR-driven reporter (see methods, Figure 4.1a on page 73,
[Calvanese et al., 2013; Chavez et al., 2015]). This Orange-Green HIV-1 (OGH) single-round reporter
virus carries an LTR-driven enhanced Green Fluorescent Protein (eGFP) together with a constitutively
active EF1α promoter driving monomeric Kusabira-Orange2 (mKO2) expression (Figure 4.1a). The
double-fluorescent reporter virus allows quantification of distinct populations in the infected cell pool
via FACS analysis (Figure 4.1b). Through the constitutively active EF1α promoter all infected cells
express the mKO2 reporter. Provirus with an active LTR also expresses the eGFP reporter and is
referred to as double positive, active virus, whereas provirus with a quiescent LTR does not express
eGFP and is called here upon the quiescent provirus. Wild type and LEDGF/p75-depleted SupT1
cells (Supplementary Figure S4.1a, bottom panel, on page 102) were infected with a dilution series of
single-round OGH virus. The percentage of infected cells was evaluated at three days post infection,
discriminating productively infected cells (active provirus; eGFP+, mKO2+) from the latently infected
population (quiescent provirus; eGFP-, mKO2+). Single reporter constructs were used for validation
(Figure 4.1b). As expected, LEDGF/p75-depletion reduced HIV-1 infection 2- to 3-fold as judged by the
percentage mKO2 positive cells (Supplementary Figure S4.1a), in line with earlier data [Vandekerckhove
et al., 2006; Gijsbers et al., 2009; Schrijvers et al., 2012a]. Evaluation of the percentage of eGFP-,
mKO2+ cells relative to the total number of infected cells (mKO2+) provides an estimate of the fraction
of quiescently infected cells in the infected pool (% eGFP-, mKO2+ cells) / (% mKO2+ cells) *100. At
all virus dilutions tested, LEDGF/p75 depleted cells contained more quiescent proviruses than WT cells
(Figure 4.1c). When this experiment was repeated in the Nalm+/c control and Nalm-/- LEDGF/p75KO
cell lines [Schrijvers et al., 2012a], similar effects were observed (Supplementary Figure S4.1a, b). Since
LEDGF/p75 depletion results in redistribution of HIV integration [Ciuffi et al., 2005; Schrijvers et al.,
2012a; Shun et al., 2007; Fadel et al., 2014], these results suggest that the altered integration site
distribution after LEDGF/p75 depletion increases the transcriptionally quiescent fraction.
4.4.2 LEDGF/p75 depletion decreases the reactivation potential of the
quiescent reservoir.
To further characterize the latently infected cell pool that is generated in LEDGF/p75-depleted cells, we
set out to reactivate the latent provirus using different Latency Reversing Agents (LRAs). Here, we used
the LEDGF/p75KO cell line (Nalm-/-) to study whether latent provirus in LEDGF/p75-depleted cells
has an altered reactivation potential. We made use of a NL4.3-based single reporter virus containing
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Figure 4.1: LEDGF/p75 depletion increases the silent reservoir.
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Figure 4.1: LEDGF/p75 depletion increases the silent reservoir. (a) Schematic representation of
the two-colored reporter virus carrying an eGFP driven by the viral LTR promoter in the nef position and
an entire constitutive transcriptional unit (EF1α-mKO2) inserted downstream. (b) Dot plots representing
FACS analysis of SupT1 cells infected with the single reporter viral controls (OGH-δmKO2, OGH-δeGFP) or
the double reporter virus OGH. The different cell populations are highlighted in the representative color. (c)
LEDGFKD affects the fraction of silently infected cells (% eGFP-, mKO2+ cells) / (% mKO2+ cells) *100.
Data represent averages of triplicates from a representative experiment and error bars indicate the standard
deviation. All viruses are VSV-G pseudotyped. eGFP, Enhanced Green Fluorescent Protein; mKO2, Mutant
Kusubira Orange 2.
an LTR-driven truncated CD34 (tCD34) as a reporter protein (NL4-3.tCD34.R-.E-/VSV-G, Figure
4.2a on page 75). Control (Nalm+/c) and LEDGF/p75KO (Nalm-/-) cells were infected with a dilution
series of HIV-tCD34. Virus dilutions were selected to result in equal integrated copy numbers, both the
LEDGF/p75 control (Nalm+/c) (1.45E-01± 1.40E-02 copies) and LEDGF/p75KO (Nalm-/-) cells (1.45E-
01 ± 2.41E-02 copies) to compare the fold reactivation between both. Cells were reactivated 11 days
post infection with different LRAs (Figure 4.2b), and the fold reactivation (% tCD34) relative to DMSO
between LEDGF/p75WT and LEDGF/p75KO conditions was measured 24 hrs later. The percentage
living cells amounted at least 78% of the total cell population in all conditions and was independent
of LEDGF/p75 depletion (data not shown). Modest tCD34 reactivation was observed after addition
of Phorbol Myristate Acetate (PMA) or Prostratin. An increase in the percentage tCD34 positive
cells of 1.5-2 fold was observed for the Nalm+/c control while LEDGF/p75KO (Nalm-/-) conditions only
experienced an increase of 1.3-1.5 fold when adding PMA (0.3-3 µM) or Prostratin (5 µM) (t-test
with Sidak-Bonferroni correction; * p<0.05, control compared to LEDGF/p75KO). A similar effect was
observed when stimulating with 1 µM SuberoylAnilide Hydroxamic Acid (SAHA). Yet, addition of 3
µM of SAHA resulted in a 3.2-fold reactivation of tCD34 in the presence of LEDGF/p75 but only a
2.2-fold reactivation in its absence (t-test with Sidak-Bonferroni correction; ** p<0.005, WT compared
to LEDGF/p75KO) (Figure 4.2b). Together, these data indicate that integration in the absence of
LEDGF/p75 results in a larger quiescent cell pool upon infection (Figure 4.1c) with a relatively larger
proportion of cells refractory to reactivation (Figure 4.2b).
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Figure 4.2: LEDGF/p75 depletion reduces HIV reactivation from latency. (a) Schematic represen-
tation of the single round HIV reporter virus encoding a tCD34 driven by the viral LTR promoter in the nef
position. (b) Bar diagram depicting the fold reactivation (as fold increase in % tCD34 positive cells). Nalm
control (+/c) and Nalm LEDGF/p75KO (-/-) cells were infected with a dilution series of single round reporter
virus and the % tCD34 positive cells was monitored. 11 days post infection cells were reactivated using different
LRAs at the concentrations indicated. Data represent averages of 9 replicates from 3 independent experiments
and error bars indicate the standard error of the mean (SEM). A statistical analysis was performed using
multiple t tests and corrected using Sidak-Bonferroni (* p < 0.05, ** p < 0.005 vs. LEDGF/p75KO) (SAHA;
SuberoylAnilide Hydroxamic Acid, PMA; Phorbol 12- Myristate 13-Acetate, Prostratin, DMSO; DiMethyl Sul-
fOxide.). Normalization was based on equal integrated copy (IC) numbers. All viruses are VSV-G pseudotyped.
tCD34; truncated Cluster of Differentiation 34.
4.4.3 LEDGIN treatment shifts HIV integration out of transcription units.
Next, we evaluated the effect of recently developed LEDGINs, small molecules that inhibit LEDGF/p75-
IN interaction and HIV integration [Christ et al., 2010; Demeulemeester et al., 2014a], on the HIV
reservoir in cell culture. SupT1 cells were transduced with a single-round HIV-based lentiviral vector
expressing eGFP in the presence of a dilution series of LEDGIN CX014442 [Christ et al., 2012]. Flow
cytometry and Q-PCR revealed a dose-dependent decrease in lentiviral transduction as represented
by the % eGFP-positive cells and the number of integrated copies (Supplementary Figure S4.2a and
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b on page 104). In a first step, we determined the distribution of HIV-based viral vector integration
sites [Marshall et al., 2007; Gijsbers et al., 2009]. The number of integration sites is indicated for
each data set (Table 4.1 and Figure 4.3 on page 78 and 79 respectively). We analysed lentiviral
integration frequencies relative to a set of genomic features (Table 4.1). In line with previous results,
HIV integration in WT SupT1 cells was enriched in the body of genes (69.54% in RefSeq genes (Table
4.1)) disfavoring transcription start sites (TSS) and promoter regions (1.78% with in 2kb of the 5’ of
a RefSeq gene and 2.02% within 2kb of a CpG island) [Schroder et al., 2002; Mitchell et al., 2004].
The integration sites shifted out of transcription units under LEDGIN-treatment (54.55% in RefSeq
genes (50 µM); *** p<0.0001, Chi-square test compared to DMSO) while integration close to TSS
(6.94% (50 µM); *** p<0.0001, Chi-square test compared to DMSO) and CpG islands (5.50% (50
µM); ** p<0.01, Chi-square test compared to DMSO) increased in a dose-dependent manner. This
shift in integration site distribution surpasses the one observed in LEDGF/p75-depleted cells [Ciuffi
et al., 2005; Shun et al., 2007; Schrijvers et al., 2012a; Fadel et al., 2014]. The fact that LEDGINs
also inhibit the interaction between HRP-2 and HIV-1 IN [Schrijvers et al., 2012a], can explain this
observation. Comparable data were observed for larger window sizes (2kb and 4kb are shown). Our
results were corroborated in MT4 cells using multiple round (WT) HIV NL4-3 and using the less potent
LEDGIN CX05045 (Supplementary Table S4.1 on page 113) [Christ et al., 2010]. A genomic heatmap
comparing integration site data sets obtained in SupT1 LEDGF/p75KD cells with WT SupT1 cells in the
presence of various concentrations of LEDGIN is shown in Figure 4.3a. Analysis of global integration
preferences clearly indicates a shifts out of transcriptionally active regions upon LEDGF/p75KD (Figure
4.3a, compared to DMSO), in line with previously reported data [Shun et al., 2007; Marshall et al., 2007;
Gijsbers et al., 2009]. A similar shift was also observed under LEDGIN treatment at concentrations
above 6 µM. In a more elaborate analysis we analyzed integration site frequencies relative to epigenetic
features described in T cells (Supplementary Figure S4.3b & c on page 106).
Under WT conditions, HIV integration preferentially occurred near epigenetic markers associated
with transcriptionally active regions (H3K4 mono-, di- and tri methylation, H3K14 and H4 acetylation,
as well as acetylation or mono-methylation of H3K9/K27/K79, H4K20 and H2BK5,...) [De Ravin et al.,
2014], while integration in transcriptionally silent regions or heterochromatin is disfavored (H3K27me3,
H3K9me3 or H4K20me3 and H3K79me3, respectively). The overall integration profile is closer to
random upon addition of LEDGIN CX014442 (as shown by the decrease in color intensity towards
black, cfr. Color key Supplementary Figure S4.3b and c). Supplementary Figure S4.3c displays a more
condensed heat map where epigenetic marks are grouped according to the respective chromatin states
they associate with.
Since LEDGINs may potentially affect the inherent integration mechanism, resulting in aberrant in-
tegration or an altered local integration site preference, we evaluated sequence conservation and relative
base frequency in the 18 bp genomic DNA sequence surrounding the integration sites (corresponding to
the intasome footprint) using sequence logos (Supplementary Figure S4.5 on page 110). The WT local
palindromic sequence logo surrounding the integration site [Holman and Coffin, 2005; Demeulemeester
et al., 2014b]) was maintained in all conditions. In addition we calculated the percentage unique inte-
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gration sites with an imperfect LTR-chromosome junction relative to the total integration sites after
LEDGIN treatment (Supplementary Figure S4.6 on page 111 and Supplementary Table S4.2 on page
113, Supplementary experimental procedures). Only a minor fraction (<2%) of the total integration
sites was identified as containing imperfect LTR-chromosome junctions. We conclude that although
LEDGINs retarget integration towards more random, with the residual integration events representing
authentic integration without gross LTR deletions.
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Figure 4.3: LEDGIN inhibition of the LEDGF/p75-IN interaction retargets lentiviral integra-
tion.
4.4.4 Abrogation of LEDGF/p75-IN interaction shifts 3D localization of
the integrated provirus towards the inner nuclear compartment.
HIV-1 PICs and integrated HIV provirus preferentially localize in the nuclear periphery [Albanese et al.,
2008; Di Primio et al., 2013; Francis et al., 2014]. Recent reports associate preferential integration with
nuclear import and distance to nuclear pore complexes [Marini et al., 2015; Lelek et al., 2015]. Here
we analyzed the 3D distribution of HIV-1 integrated provirus upon interruption of the LEDGF/p75-
IN interaction. We first compared the distribution of HIV proviruses 48 h post infection in the Single
Cell Imaging of Proviral HIV-1 assay (SCIP-assay) [Di Primio et al., 2013] between LEDGF/p75WT and
LEDGF/p75 depleted U2OS cells (Figure 4.4a on page 81). The distribution of integrated HIV provirus
79
CHAPTER 4. LEDGIN-MEDIATED INHIBITION OF INTEGRASE-LEDGF/P75 INTERACTION
REDUCES REACTIVATION OF RESIDUAL LATENT HIV
Figure 4.3: LEDGIN inhibition of the LEDGF/p75-IN interaction retargets lentiviral integra-
tion. Integration site data sets obtained from SupT1 cells infected with LVP2A and treated with different
concentrations of CX014442 (IC50 CX014442 ’early effect’: 3.83 µM) were compared to different genomic fea-
tures. A heat map was generated using the INSIPID software (Bushman Lab, University of Pennsylvania).
Tile color is depicting the nature of the correlation for an integration data set with the respective genomic
feature (rows, left) relative to matched random controls, as indicated by the colored Receiver Operating Char-
acteristic (ROC) curve area scale at the bottom of the panel. Columns indicate different data sets. Statistical
significance (asterisks, ranked Wald tests) is shown relative to the DMSO population (dashes). Significance
is reached when p<0.001, compared to the DMSO (**p<0.01; *** p<0.001). CX014442 treatment during
infection shows a dose dependent shift out of transcriptionally active regions. Lower significance is observed
at the highest LEDGIN concentrations due to a lower copy number of integration sites. (a more detailed guide
to the data presented can be found in [Ocwieja et al., 2011]).
was analyzed by detection of γH2AX foci after I-Sce1 digestion (Figure 4.4a). Two-fold less integrants
were detected after LEDGF/p75 depletion (Figure 4.4a). Whereas in WT cells the viral genomes
localized near the nuclear rim (Figure 4.4b), the location of integrated provirus shifted towards the inner
nuclear compartment after LEDGF/p75 depletion as indicated by the cumulative frequency plotted
relative to the distance to the nuclear rim (Figure 4.4b) confirming recent observations [Di Primio
et al., 2013; Marini et al., 2015; Lelek et al., 2015]. Since LEDGIN treatment shifts integration sites
out of transcriptionally active regions comparable to LEDGF/p75KD conditions (Figure 4.3 on page
79), we verified whether LEDGIN treatment might potentially affect the 3D location of integrated
provirus as well. Indeed, addition of 3 µM of LEDGIN CX05045 redistributed the integrated provirus
towards the inner nuclear compartment. An HIV-1 mutant (HIV-INA128T/E170G), resistant to LEDGINs
[Christ et al., 2010], was not redistributed (Figure 4.4d). Therefore, these data demonstrate that
LEDGF/p75 controls the nuclear topology of HIV-1 provirus and that LEDGINs may induce its spatial
randomization.
4.4.5 The residual reservoir upon LEDGIN treatment is more quiescent.
In a next step, we investigated whether LEDGIN-mediated retargeting also affected the quiescent reser-
voir, which would be in line with the effects demonstrated earlier in LEDGF/p75 depleted (KD/KO)
cells. SupT1 cells were infected with the single-round OGH reporter virus in the presence of increas-
ing concentrations of LEDGIN (CX014442). HIV OGH infection was measured 3 days post infection
using flow cytometry resulting in the detection of cell populations carrying both productive (eGFP+,
mKO2+ cells) and quiescent (eGFP-, mKO2+ cells) provirus (see also Figure 4.1 on page 73). LED-
GIN treatment induced a dose-dependent decrease in the % of eGFP+, mKO2+ cells (Figure 4.5a on
page 83) as well as the overall mKO2+ cells (Figure 4.5b). However, similar to LEDGF/p75 deple-
tion (see Figure 4.1c), LEDGIN treatment resulted in a relative increase of the quiescent fraction (%
eGFP-, mKO2+ cells) / (% mKO2+ cells) *100 (Figure 4.5c). No increase in the quiescent fraction was
observed when adding increasing concentrations of the reverse transcriptase inhibitor AZT (data not
shown) suggesting the phenotype was not merely due to inhibition of infection. Interestingly, nearly all
infected cells were quiescent at 25 µM LEDGIN (CX014442). Several studies reported on the effect of
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Figure 4.4: LEDGIN treatment shifts HIV-1 proviral localization towards the inner nuclear
compartment.
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Figure 4.4: LEDGIN treatment shifts HIV-1 proviral localization towards the inner nuclear
compartment. U2OS WT or LEDGF/p75 depleted cells were infected with a HIV derived vector pHR-
CMV-EGFP with or without an I-SceI restriction site (mock) and γH2AX foci quantified per nucleus 48h post
infection after endonuclease digestion. (a) SCIP analysis of proviral DNA corresponding to γH2AX foci (red) in
U2OS cells. Bar diagram in the right panel depicts the number of proviruses (γH2AX foci) detected under each
condition. Error bars represent standard deviations from at least three experiments. (b) 3D nuclear localization
of HIV-1 provirus relative to the nuclear rim in LEDGF/p75KD (empty bars) or WT U2OS cells (grey bars)
(P<0.001, Kolmogorov-Smirnov test) (n=1000). The right panel depicts the cumulative frequency for the
distance relative to the nuclear rim. (c) Cumulative frequency of the 3D nuclear localization of HIV-1 provirus
relative to the nuclear rim in U2OS cells treated (grey) with or without (black) 3 µM of LEDGIN CX05045.
(P<0.001, Kolmogorov-Smirnov test) (n=650). (d) Cumulative frequency of the 3D nuclear localization of
HIV-1 provirus relative to the nuclear rim in U2OS cells infected with the HIV-1 INA128T/E170G and treated
with (grey) or without LEDGINs (black, CX05045, 3 µM, 4 x IC50). (P>0.05, Kolmogorov-Smirnov test)
(n=650). Number of experiments is indicated in each plot (> 100 cells counted/experiment).
integration orientation relative to endogenous genes on the HIV transcriptional state, with a possible
enhancement of transcription when integrated in the same orientation or transcriptional interference
when integrated in the opposite orientation. We therefore evaluated relative orientation frequencies
of those integrations occurring within genes for the different integration site data sets (Supplementary
Table S4.3 on page 113). LEDGIN treatment resulted in a significant, dose-dependent increase in the
fraction of integrations having an opposite orientation from 46.2 % to 56.7% (p-value < 0.005, Pearsons
Chi-square compared to the DMSO control condition) with respect to the targeted gene.
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Figure 4.5: LEDGIN mediated retargeting of integration increases the quiescent reservoir. SupT1
cells were infected with three different dilutions of HIV OGH (a) Dose-response curve showing a decrease in %
eGFP+, mKO2+ positive cells with increasing LEDGIN concentration. Three different virus concentrations are
depicted in green. (b) Dose-response curve showing a decrease in the overall % mKO2+ cells with increasing
LEDGIN concentration. Three different virus concentrations are depicted in red. (c) The fraction of quiescent
cells (% eGFP-, mKO2+ cells) / (% mKO2+ cells) *100 increases upon addition of LEDGINs. Three different
vector dilutions are depicted in red. All viruses are VSV-G pseudotyped. (d) Respresentative dot plots
depicting the different cell populations under two different conditions, numbers in the quadrant indicate the
percentage of cells. All vectors are VSV-G pseudotyped. eGFP, Enhanced Green Fluorescent Protein; mKO2,
Mutant Kusubira Orange 2
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4.4.6 LEDGIN treatment results in a quiescent reservoir resistant to HIV
reactivation.
Next we studied whether LEDGIN treatment also reduces the reactivation potential after reporter
gene silencing, as observed under LEDGF/p75 depletion (Figure 4.2 on page 75). The LEDGIN-
induced increase in the silent reservoir, together with the reduced HIV reactivation potential could
hold promise to reduce the functional reservoir. SupT1 cells were infected with single round HIV-OGH
double reporter virus (Figure 4.6 on page 86) or HIV-tCD34 (Supplementary Figure S4.4 on page
108) under varying LEDGIN (CX014442) concentrations and reactivated with LRAs. To demonstrate
that LEDGIN-retargeted provirus remains refractory to general cell activation TNFα was used as a
reactivation agent. Data depict a representative virus dilution. In Figure 4.6a the percentage of
eGFP+, mKO2+ cells and overall % mKO2+ positive cells is plotted after stimulation with DMSO or
TNFα for 24 h (open squares and open triangles, for TNFα and DMSO, respectively). Stimulation with
TNFα did not affect the percentage living cells (>85% in all conditions 24h post stimulation) neither
in the absence or presence of LEDGIN (data not shown). The % eGFP+, mKO2+ cells are significantly
higher after stimulation with TNFα compared to DMSO at the different LEDGIN concentrations,
while the overall percentages of mKO2+ cells remain constant (compare red and green lines). LEDGIN
treatment resulted in reduced reactivation as measured by the fold increase of productively infected
cells (% eGFP+, mKO2+) in a concentration-dependent manner, with 25 µM CX014442 reducing the
reactivation by TNFα 2-fold (Figure 4.6b). A slope of -0.034 ± 0.009 fold/µM was calculated using a
linear regression model (significant deviation from zero; p<0.0018, Figure 4.6b). On the other hand,
increasing concentrations of LEDGIN CX014442 antagonized the reactivation potential of the latently
infected pool as represented by the decrease in the fraction of quiescent cells (% eGFP-, mKO2+
cells) / (% mKO2+ cells )*100 (Figure 4.6c). A slope of -0.93 ± 0.08 %/µM was calculated using a
linear regression model (significant deviation from zero; p<0.0001, Figure 4.6c). Similar results were
observed for HIV-tCD34 where LEDGIN (CX014442) treatment resulted in a dose-dependent inhibition
of reactivation from latency (reactivation IC50 ≈ 7.24 µM) as evidenced by the reduced increase in the
% tCD34 positive cells (Supplementary Figure S4.4a & b on page 108). This inhibition of reactivation
was seen with various LRAs (Supplementary Figure S4.4c). Raltegravir treatment did not result in this
phenotype (Supplementary figure S4.4 d & e), excluding integration inhibition as such or an increase
in non-integrated 2-LTR circles as the cause of this effect. In conclusion, LEDGIN treatment reduces
the reactivation potential of the quiescent HIV pool.
4.4.7 LEDGIN treatment retargets HIV integration into safer locations
The strategy to push HIV into latency by retargeting provirus integration away from active transcription
units due to uncoupling of the LEDGF/p75-IN interaction may be associated with an altered risk of
insertional mutagenesis. Insertional mutagenesis due to dysregulation of neighboring gene expression is
a concern in gene therapy applications with lentiviral vectors [Cavazzana-Calvo et al., 2010]. In addition,
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two studies revealed the existence of clonally expanded CD4+ cell populations carrying integrated HIV
provirus in HIV-1 patients on prolonged antiretroviral therapy [Maldarelli et al., 2014; Wagner et al.,
2014]. Therefore we evaluated whether the residual integration profile under LEDGIN treatment has a
different "safety" profile using stringent criteria used in gene therapeutic applications [Papapetrou et al.,
2011]. We investigated following criteria defining potentially unsafe integration events: integration
near transcription start sites (<50 kb), oncogenes (<300 kb) or miRNA coding regions (<300 kb) and
integration into transcription units and ultraconserved elements (UCR). Integration events occurring
outside these features are considered to be safe (Table 4.2 on page 88) [Papapetrou et al., 2011].
For each data set, we calculated the percentage of potentially unsafe integration sites according to a
given criterion (Table 4.2) and determined the final percentage of safe sites (positioning outside these
regions). The most pronounced and dose dependent decrease was observed for integrations falling
within transcription units. For the calculation of the final % safe-sites all 5 criteria were taken into
account and the risk analysis is therefore affected by the different parameters. In the parental SupT1
cell line only 10.7 % of all vector integration sites can be considered safe in comparison to 28.5% for the
matched random control datasets (MRC). LEDGF/p75 depletion increased the percentage safe sites to
14.7% (p-value <0.005, Pearsons Chi-square compared to the DMSO control condition), a phenotype
that is reverted upon LEDGF/p75 back complementation (data not shown). The shift in integration
site distribution under LEDGIN treatment (Figure 4.3 on page 79 and Supplementary Figure S4.3a-c
on page 105), coincides with a dose-dependent increase in percentage of safe integrations (16.51 % at
50 µM, p-value < 0.005, Pearsons Chi-square compared to the DMSO control condition), consistent
with the data obtained under LEDGF/p75 depletion.
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Figure 4.6: LEDGIN treatment reduces reactivation from latency.
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Figure 4.6: LEDGIN treatment reduces reactivation from latency. SupT1 cells were infected with
single round double reporter virus (OGH) and treated with different concentrations of CX014442 (as indicated).
% eGFP - % mKO2 positive cells were monitored, respectively. 11 days post infection cells were reactivated
using TNFα (10 ng/mL). (a) Dose-response curve showing the % eGFP+, mKO2+ cells and the overall %
mKO2+ cells after reactivation with DMSO or TNFα. (b) Average fold increase in percentage eGFP+, mKO2+
or productively infected cells upon stimulation with TNFα relative to the DMSO treated condition. (c) Average
decrease in the fraction quiescent cells (% eGFP-, mKO2+ cells) / (% mKO2+ cells) *100 or silent reservoir
fraction upon stimulation with TNFα relative to the DMSO treated condition. Data in (b) and (c) represent
averages of 3 different vector dilutions and error bars indicate the standard deviation. The straight lines
represent the linear regression calculations together with the 95% confidence band plotted in grey and the
residual error relative to the linear regression plot is depicted in the right panel. TNFα; Tumor Necrosis Factor
alpha, DMSO; DiMethyl SulfOxide, eGFP; Enhanced Green Fluorescent Protein, mKO2; Mutant Kusubira
Orange 2, All viruses are VSV-G pseudotyped.
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4.4.8 LEDGIN treatment inhibits integration, relatively increases the qui-
escent viral reservoir and reduces reactivation in primary CD4+ T
cells.
Since recent studies reported the existence of a latently infected cell population after infection of
activated primary CD4+ T cells [Calvanese et al., 2013; Dahabieh et al., 2013; Chavez et al., 2015], we
tried to corroborate the effect of LEDGIN treatment on proviral latency in this model. Human PBMCs
were purified, selectively enriched for CD4+ T cells using Bi-specific MAb CD3.8 and infected with the
OGH reporter virus, in the presence or absence of LEDGINs (Figure 4.7 a and b on page 90). Similar to
the results observed in SupT1 cells, LEDGIN (CX014442) treatment induced a dose-dependent decrease
in the % infected cells (decrease in %eGFP+/mKO2+ cells or overall % mKO2+ cells, Figure 4.7a) and
an increase in the fraction quiescent cells (% eGFP-, mKO2+ cells) / (% mKO2+ cells) *100 (Figure
4.7b) reaching 46.3 % quiescence at a CX014442 concentration of 25 µM (representative data from one
donor are shown for 2 different donors tested). Next we evaluated the multimodal effect of LEDGIN
treatment on integration, assembly and reactivation in a multiple round reactivation model using WT
HIV in resting CD4+ T-cells in order to model the in vivo situation. PHA/IL-2 activated primary
(resting) CD4+ T cells were infected with NL4.3 virus in the presence of submicromolar concentrations
of LEDGINs. At day four post infection (p.i.) LEDGINs were removed and cells were reseeded in
the presence of PMA and PHA. Virus production upon reactivation was measured at day 7 p.i. by
p24 ELISA. LEDGIN treatment reduced the number of proviral DNA copies in CD4+ T-cells in a
dose-dependent manner (Figure 4.7c). These residual integrants were less susceptible to reactivation as
displayed by the reduced p24 production (Figure 4.7d, data show the average for two different donors
tested). Apart from reducing overall integration, these data suggested that LEDGIN treatment during
HIV infection leads to quiescence of the residual integrants both in SupT1 and primary CD4+ T-cells.
This quiescent reservoir appears less susceptible to reactivation.
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Figure 4.7: LEDGIN treatment inhibits integration, induces quiescence of the residual viral
reservoir and reduces reactivation in primary CD4+ T cells. (a) Activated CD4+ T- cells were infected
with single round double reporter virus (OGH) and the % eGFP - % mKO2 positive cells were monitored.
Dose-response curve shows a decrease both in the % eGFP+, mKO2+ cells and overall % mKO2+ cells with
increasing LEDGIN (CX014442) concentration. (b) The fraction of silently infected cell population (% eGFP-,
mKO2+ cells) / (% mKO2+ cells) *100 increases upon addition of LEDGINs. Data are representative for two
different donors. All vectors are VSV-G pseudotyped. eGFP, Enhanced Green Fluorescent Protein; mKO2,
monomeric Kusubira Orange 2. (c) Activated CD4+ T- cells were infected with NL4.3 virus under different
LEDGIN concentrations. 4 days p.i. integrated copy numbers were determined using a quantitative Alu-LTR
PCR. (d) 4 days p.i. CD4+ T-cells were reactivated using PMA/PHA and p24 production in the supernatant
was monitored 7 days p.i. by ELISA. Data show the average for two different donors tested ± SEM. PHA,
PhytoHaemAgglutinin; PMA, Phorbol 12-Myristate 13-Acetate.
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4.4.9 Discussion
The moral duty to respond to the call for an HIV cure calls for exploration of experimental and innova-
tive HIV cure strategies. As a complement to current shock-and-kill approaches aimed at forcing HIV
out of its hiding places to obtain a sterilizing cure, we here provide experimental evidence for a strat-
egy to push the virus towards transcriptional quiescence by interference with LEDGF/p75, the main
determinant of integration site selection. General belief states that latency is an accident rather than a
default pathway of an actively replicating cytopathic virus. The fact that LEDGF/p75, the tethering
determinant of HIV integration, directs integration preferentially towards actively transcribed regions,
ensuring productive infection, is consistent with this notion. Recently, it was proposed that HIV la-
tency is a hardwired, evolutionarily conserved switch increasing the likelihood of successful mucosal
transmission during primary infection [Rouzine et al., 2015; Razooky et al., 2015]. Whereas HIV Tat is
known to be the main viral determinant in controlling the HIV transcriptional state, the contribution
of other viral and host determinants to the transcriptional state of the HIV provirus awaits further
clarification. Here we investigated the role of LEDGF/p75 in the establishment of HIV latency. We
demonstrate that LEDGF/p75 depletion, known to result in retargeting of integration away from the
body of actively transcribed genes [Schrijvers et al., 2012a; Shun et al., 2007; Fadel et al., 2014], in-
creases the fraction of quiescently infected cells and simultaneously decreases the reactivation potential
of the proviruses. In light of the recently proposed role of LEDGF/p75 (and the Iws1/Spt6 complex)
in post-integration HIV transcriptional repression [Gérard et al., 2015], this observed decrease may
even be an underestimation of the contribution of the integration environment to the latent phenotype.
Taken together, these observations suggest that disruption of the LEDGF/p75-IN interaction not only
inhibits integration but could as well affect the establishment of the latent pool and the reactivation
from latency. Recently developed LEDGINs, bona fide small molecule inhibitors of LEDGF/p75-IN in-
teraction, allowed us to test this hypothesis. Indeed here we demonstrate: (i) a LEDGIN-mediated shift
in lentiviral integration site distribution resembling LEDGF/p75 depletion (out of the body of actively
transcribed genes, with increased integration in the vicinity of CpG islands); ii) a strongly reduced but
authentic residual integration, (iii) a LEDGIN-mediated shift in 3D nuclear location of HIV provirus
away from the nuclear rim; (iv) a relative increase in the fraction of quiescent proviruses and (v) a
dose-dependent block in HIV reactivation from latency both in cell lines and primary CD4+ T-cells.
It was recently proposed that pushing enough proviruses into quiescence could drive the basic repro-
duction number of HIV below 1, resulting in unsustainable infection [Rouzine et al., 2015]. LEDGIN
treatment apparently succeeds in rendering (almost) 100 % of the virus into a quiescent state refractory
to reactivation (Figure 4.5c on page 83 and Figure 4.6 on page 86). Although final proof will only be
obtained in clinical trials, our cell culture data in relevant cell lines and primary cells provide evidence
for the feasibility of this strategy. The importance of the site of integration in the human genome
for basal transcriptional activity of HIV was evidenced more than a decade ago [Jordan et al., 2001].
Now it is known that genomic target site selection during lentiviral integration is a multi-step process
where biases are introduced at different levels, which each in part affect the stochastic proviral gene
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expression levels. At least three levels can be recognized. First, nuclear topology and proximity to the
nucleopore affect integration site selection [Di Primio et al., 2013; Marini et al., 2015]. Next, chromatin
readers such as LEDGF/p75 or HRP-2 that recognize epigenetic marks associated with transcriptional
activity tether the preintegration complex to active gene regions. No data exist suggesting a protein
gradient. Therefore, as proposed by Marini et al. [Marini et al., 2015], preferential lentiviral integration
within the proximity of the nuclear periphery probably reflects the encounter by the HIV PIC of the
first LEDGF/p75 bound chromatin close to nucleopores. Finally, bias for target DNA base recognition
by integrases also influences local and global integration patterns [Demeulemeester et al., 2014b; Ser-
rao et al., 2015; Demeulemeester et al., 2015]. In theory, interference with any of those mechanisms
could shift the resulting proviral reservoir from transcriptionally active to quiescent. Both LEDGF/p75
depletion and LEDGIN treatment affect integration, integration site selection (Figure 4.3 on page 79
and Supplementary Figure S4.3a-c on page 105) and nuclear location (Figure 4.4 on page 81). Proba-
bly the reduced reactivation due to altered chromatin context is not entirely reflected by the features
measured in the integration site analysis. As shown, aberrant integrations or LTR deletions are most
likely not contributing, or only to a minor extent (Supplementary Figure S4.5 on page 110 and Table
S4.2 on page 113). In the absence of LEDGF/p75, HRP-2 determines HIV integration site selection.
The fact that LEDGINs also inhibit the interaction between HRP-2 and HIV-1 IN [Schrijvers et al.,
2012a], can explain the more pronounced effect of LEDGINs on reactivation from quiescence compared
to LEDGF/p75-depletion. Identification of the exact nature of the altered chromatin context responsi-
ble for the observed phenotype awaits further experimentation. HIV latency is of multifactorial nature
and the transcriptional state of integrated provirus is not only influenced by molecular determinants
but also depends on the infected host cell and its activation state [Dahabieh et al., 2015]. Therefore
the respective quiescent fraction and responsiveness to different LRAs might alter depending on the
cell model used since promoter activity may differ between cell types. In order to study the effect of
integration site distribution on HIV latency we used NL4.3-based (HIV-tCD34) and LAI-based (OGH)
single round reporter viruses in a concise reactivation setup in T-cell lines and activated CD4+ T-cells.
LEDGINs block HIV replication during integration (referred to as ’the early effect’) as well as during
assembly (i.e. ’the late effect’), with inhibition during the late step having a 10- to 100 fold higher
potency than the early step [Debyser et al., 2015]. In the experiments with single round virus, we
used micromolar concentrations of LEDGIN, required to inhibit the early step. Interestingly, recent
experimental results suggest that addition of submicromolar concentrations of LEDGINs during virus
production results in viruses that after integration are again refractory to LTR-driven gene expres-
sion (Supplementary Figure S4.7 on page 112), suggesting that during multiple round replication also
low concentrations of LEDGINs induce quiescent proviral pools. Our data were corroborated with wt
NL4.3 virus in IL-2/PHA activated primary CD4+ T-cells (Figure 4.7 on page 90). These multiple
round experiments allowed the use of submicromolar LEDGIN (CX014442) concentrations. It will be
of interest to extend these observations in the future to other latency models. Preliminary data in
a more sophisticated model for HIV latency based on infection of CCL19-activated resting CD4+cells
[Spina et al., 2013] corroborates a LEDGIN-mediated shift of the HIV reservoir into a quiescent state
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refractory to reactivation (unpublished data). Evidence is growing that initiation of cART early after
infection is effective in reducing the size of the viral reservoir [Ananworanich et al., 2012; Hoen et al.,
2007; Hocqueloux et al., 2013; Ananworanich et al., 2015; Malatinkova et al., 2015]. Early treatment
initiation with ART will likely become standard clinical practice in HIV care. This is supported by
the recent outcome of the first large-scale international "Strategic Timing of AntiRetroviral Treatment"
(START) study, showing a considerably lower risk of developing AIDS and other serious conditions
when compared to later treatment initiation (INSIGHT START Study Group, 2015). We here propose
that LEDGINs, currently in (pre-)clinical development as antivirals, could eventually and in synergy
with existing antiretrovirals contribute to an HIV remission by acting as potent antivirals with the
additional capacity to affect the transcriptional state of the residual HIV reservoir. In an ideal format
LEDGINs should be be evaluated in combination with cART regimens initiated during acute infection
before reservoirs are established. In light of recent findings on ongoing HIV replication, penetration
of drugs in lymph nodes will be required. For HIV pre-exposure prophylaxis (PrEP) LEDGINs have
the added benefit that any residual provirus may turn out to be refractory to reactivation. It is clear
that this final outcome utterly depends on well-designed clinical trials and surpasses any claims made
in this work. Still, we provide initial evidence in cell culture and primary cells for an important role
of LEDGF/p75 in the establishment of the replicating reservoir. LEDGINs will allow us to investigate
in clinical trials a novel strategy based on a retargeted, more quiescent proviral reservoir. LEDGIN
treatment during acute HIV infection may result in a proviruses that are refractory to reactivation after
treatment interruption leading to an HIV remission.
4.5 Experimental procedures
4.5.1 Cell culture, virus production and transduction.
All cells were tested to be mycoplasma free. Cells were cultured in a humidified atmosphere containing
5% CO2 at 37°C. SupT1 (provided by the National Institutes of Health (NIH) Reagent Program, NIH,
Bethesda, MD). Nalm cells obtained from ATCC [Schrijvers et al., 2012a] were cultured in RPMI
medium (GIBCO-BRL) supplemented with 10% v/v heat inactivated fetal calf serum (FCS, Sigma-
Aldrich) and 0.01% v/v gentamicin (GIBCO). HEK293T-cells (gift from O. Danos, Evry, France) were
cultured in Dulbecco Modified Eagle Medium (DMEM, GIBCO) with 5% v/v FCS (Sigma-Aldrich)
and 0.01% v/v gentamicin (GIBCO). U2OS cells (ATTC) were cultured in DMEM (GIBCO) with
10% v/v FCS. Vesicular stomatitis virus G (VSV-G)-pseudotyped viruses were generated by double
transfection of HEK293T-cells with a plasmid encoding a single round HIV clone (pNL4-3.tCD34.R-.E-
, pOGH, pOGH-csGFP-only or pOGH-mKO2-only) together with a VSV-G protein encoding plasmid
(pVSVG). In other experiments triple transfection was done with the transfer plasmid pHR-CMV-
GFP-I-Sce1 together with the δ8.91 packaging plasmid and pVSVG. Linear polyethylenimine (PEI;
Polysciences) was used for plasmid transfections. Medium was replaced 6 h post transfection and
supernatant collected after 72 h by filtration through a 0.22 µm pore membrane (Corning Inc.). The
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virus was concentrated using a Vivaspin 15-50 kDa cut-off column (Vivascience), DNase (Roche) treated
and stored at -80°C. The HR vectors were concentrated by 2 h of ultracentrifugation in a 20% sucrose
cushion. Cells were seeded and infected for 3 days in 48-well plates (10% FCS, 0.01% gentamicin RPMI)
yielding an infection rate < 40% positive cells, as monitored by FACS analysis using a MACS Quant
VYB FACS analyzer (Miltenyi Biotech GmbH), ensuring single-copy integration. Cells were washed
twice in Phosphate Buffered Saline (PBS) 72 h post infection to remove residual virus and reseeded.
FACS samples were taken every 2 days to monitor reporter gene expression. A SIV-based lentiviral
vector carrying a spleen focus forming viral (SFFV) promoter driving a zeocin resistance gene and
a LEDGF/p75 specific miRNA-based shRNA [Schrijvers et al., 2012a; Osório et al., 2014] was used
to generate a SupT1 LEDGF/p75 knock down (KD) cell line. LEDGF/p75 depletion was monitored
using Western blot and Q-PCR (>85% in SupT1 LEDGF/p75KD cells, Supplementary Fig. 1a bottom
panel). Nalm LEDGF/p75 control (+/c) and LEDGF/p75KO cells (-/-) were generated previously and
are described in [Schrijvers et al., 2012a].
4.5.2 Reporter viruses.
Multi-colored reporter virus (OGH). A variant of the recently described LAI-based double reporter virus
was used [Chavez et al., 2015], where a constitutive and an LTR-driven reporter are simultaneously
measured to study the latent reservoir [Calvanese et al., 2013; Dahabieh et al., 2013]. This orange-
green HIV-1 (OGH) reporter virus variant encodes an LTR-driven enhanced Green Fluorescent Protein
(eGFP) in the nef gene position together with a constitutively active EF1α promoter driving mutant
Kusabira-Orange2 (mKO2) expression instead of mCherry as described previously [Calvanese et al.,
2013; Chavez et al., 2015] (Figure 4.1a). An internal constitutive promoter driving mKO2 expression
allows direct visualization of the LTR-silent latent proviral pool via the FACS measurement of mKO2-
based red fluorescence. HIV NL4-3.tCD34.R-.E-. HIV tCD34 is a NL4.3-based single round reporter
virus containing the LTR-driven truncated CD34 (tCD34) as a reporter protein in the nef gene position
(Figure 4.2a). We replaced the firefly luciferase gene in pNL4-3.Luc.R-.E- (NIH aids reagent program)
via NotI-XhoI digestion with a tCD34 cassette using standard PCR amplification methods. CD34
(cluster of differentiation 34) is a cell surface glycoprotein functioning as a cell-cell adhesion factor in
HSCs but is not present on primary CD4+ T lymphocytes [Fehse et al., 2000]. A truncated version was
used to block signal transduction and expression was visualized using antibody-staining allowing for
non-fluorescent based cell sorting. Human CD34-PE antibody (Miltenyi Biotec, Cat.N°130-081-002)
was used to detect tCD34 expression.
4.5.3 Flow cytometry analysis.
Prior to flow cytometry, cells were fixed for 15 min in 4% paraformaldehyde at room temperature. Ex-
pression of eGFP/mKO2 or tCD34 was monitored using a MACS Quant VYB FACS analyzer (Miltenyi
Biotech GmbH) using a 488 nm, 50 mW DPSS (diode-pumped solid-state) and a 561 nm, 100mW diode
laser respectively and 525/50 nm - 586/15 nm band pass filters. A total of at least 30,000 live cells were
94
4.5. EXPERIMENTAL PROCEDURES
counted, as determined on the basis of forward scatter channel/side scatter channel (FSC-H/SSC-H)
and doublets were excluded based on the FSC-A/FSC-H or SSC-A/SSC-H plot. Single reporter controls
where used for compensation purposes. Data were analyzed using third party software (FlowJo).
4.5.4 Drug treatment.
The LEDGIN CX014442 [Christ et al., 2012] was added at different concentrations during single round
infection and washed away together with residual virus 72 h post infection. Samples were harvested
for FACS analysis and the remainder of infected cells was reseeded. FACS samples were taken every
2 days to monitor reporter gene expression. The infected cells were reactivated from latency 11 days
post infection using Tumor Necrosis Factor alpha (TNFα , 10 ng/mL, Immunosource), suberoylanilide
hydroxamic acid (SAHA, 0.3 to 3 µM, AIDS reagents), Prostratin (5 µM, AIDS reagents) or phorbol
12-myristate 13-acetate (PMA, 0.3 µM, AIDS reagents) 24 h prior to analysis by flow cytometry. Time
courses and drug concentrations are indicated in the individual experiments. In all conditions the
percentage living cells was higher than 75 procent at 24h post LRA administration (except for 3 ÎĳM
SAHA; 55% living cells) based on FSC/SSC FACS analysis. LEDGINs were synthesized at Cistim/CD3
KU Leuven (courtesy of Dr. A. Marchand).
4.5.5 Genomic DNA isolation and quantification of Integrated copy num-
ber.
Two million cells were pelleted and genomic DNA extracted using a mammalian genomic DNA miniprep
kit (Sigma-Aldrich). Standard spectrophotometric methods were used to determine the genomic DNA
concentration. Samples corresponding to 250 ng genomic DNA were used for analysis. Each reaction
contained 12.5 µl iQ Supermix (Biorad), 40 nmol/L forward and reverse primer (5’ TGCACCCTGT-
GTCTCAACAT 3’ and 5’ GGCTTCAAGGTTGTCTCTGG 3’ respectively) and 40 nmol/L of tCD34
probe (5’ (6FAM)-GGCCACAACAAACATCACAG-(TAM) 3’) in a final volume of 25 µl. In all cases,
RNaseP was used as an endogenous control for normalization (TaqMan RNaseP control reagent, Ap-
plied Biosystems, The Netherlands). Samples were run in triplicate for 3 minutes at 95 °C followed by
50 cycles of 10 seconds at 95 °C and 30 seconds at 55 °C in a LightCycler 480 (Roche-applied-science).
Analysis was performed using the LightCycler 480 software.
4.5.6 Integration site amplification.
Integration sites were determined as described previously [Marshall et al., 2007]. In short, cells were
seeded and transduced with a lentiviral vector for 3 days, then washed twice with PBS. Transduced
cells were further cultivated for at least 10 days to eliminate non-integrated DNA. Cells were harvested
and genomic DNA extracted using the GenElute Mammalian Genomic DNA miniprep kit (Sigma-
Aldrich). Integration sites were amplified by linker-mediated PCR as described previously [Marshall
et al., 2007] (see Supplementary Figure A.1). Genomic DNA was fragmented using MseI restriction
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digestion and linkers ligated. Provirus/host genome junctions were amplified by nested PCR using
indexed primers. Products were gel-purified and sequenced using 454/Roche pyrosequencing (Titanium
technology, Roche) on the 454 GS-FLX-instrument. Reads were filtered based on perfect matching of
the LTR linker, barcode and flanking LTR. All sites were mapped to the human reference genome
requiring a perfect match within 3 bp of the LTR end. Matched Random Control (MRC) sites were
computationally generated and matched to experimental sites with respect to the distance to the nearest
MseI cleavage site. Normalization of experimental HIV sites by the MRC sites corrects for the recovery
bias due to cleavage by MseI. Analysis was performed as described previously [Marshall et al., 2007]. A
more detailed guide to the data presented can be found in [Ocwieja et al., 2011]. Sequence logos were
created using WebLogo 3.3 with compositional adjustment for the human genome base background
distribution.
4.5.7 Single Cell Imaging of Proviral HIV (SCIP) assay.
20,000 U2OS cells/well were seeded in a 4 well chamber slides (Lab-TekTM) and transfected the next
day with 200 ng of pCBASce plasmid encoding the I-Sce1 endonuclease using Effectene (Qiagen). Six
hours post transfection cells were infected with 4 reverse transcriptase units (RTUs; SYBR Green-
based Product Enhanced Reverse Transcriptase assay, SGPERT; [Pizzato et al., 2009] of the lentiviral
vectors HR-CMV-GFP-I-SceI/VSV-G or HR CMV-GFP-I-Sce1-INA128T/E170G/VSV-G in Optimem
medium containing 1% FCS for 2 h and fixed 48 h post infection with 4.0% paraformaldehyde in PBS
for 5 minutes at room temperature (RT). After permeabilization with PBS containing 0.2% Triton-
X100 for 10 minutes, samples were blocked overnight with 3% Bovine Serum Albumin (BSA) at 4°C.
The slides were incubated with the primary antibody directed against phosphorylated γH2AX (1:500,
05-636 Millipore) for 1 h at RT and with secondary fluorophore-conjugated antibodies for 1 h at RT.
Slides were mounted with Vectashield mounting medium (Vector Laboratories). Nuclear fluorescent
signal from γH2AX foci was acquired with the TCS SL laser-scanning confocal microscope (Leica
Microsystems) equipped with galvanometric stage using a 63x/1.4 NA HCX PL APO oil immersion
objective and processed by an image software (ImageJ, NIH.gov) [Di Primio et al., 2013]. Background,
i.e. spontaneous γH2AX repair foci, were subtracted before further analysis as described in [Di Primio
et al., 2013].
4.5.8 CD4+ T-cell enrichment.
Human peripheral blood mononuclear cells (PBMCs), obtained from the Red Cross Blood transfu-
sion Center (Mechelen, Belgium) according to approved bioethical guidelines of our institute (S57175-
IRB00002047) , were purified from fresh buffy coats using lymphoprep density gradient centrifugation
(Stem cell technologies). The CD4+ T-cells were selectively enriched using Bi-specific MAb CD3.8
(0.5 µg/mL, AIDS reagents) for 5 days. Cells were cultured in RPMI 1640, 15% v/v FBS, 0.1% v/v
Gentamicin, 100 U/ml IL-2 (Peprotech) (T-cell medium, TCM). Enriched total CD4+ primary T-cells
were infected with single round reporter virus for 2 h at 37°C, washed twice in TCM and reseeded in
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medium containing different concentrations of LEDGIN CX014442. HIV infection was monitored 48h
post infection using flow cytometry analysis.
4.5.9 Reactivation of latent provirus in primary CD4+ T-cells.
Peripheral blood mononuclear cells (PBMCs) were isolated from fresh buffy coats obtained from the Red
Cross Blood transfusion center (Mechelen, Belgium) according to approved bioethical guidelines of our
institute (S57175-IRB00002047). Resting CD4+ T-cells were purified using a custom-made EasySep
negative selection kit (Stem Cell Technologies; 19052 cocktail, with the addition of CD25, CD69,
and HLA-DR antibodies (catalogue number 19309VK)). The resulting 95% pure resting CD4+ T-cells
consisted of both naive and central memory T-cells [Sallusto et al., 1999]. These freshly isolated resting
CD4+ T-cells were activated with 10 µg/ml PHA (Sigma-Aldrich) and 100 U/mL IL-2 (Peprotech)
for 2 days before infecting with NL4.3 wt virus for 2 hrs (3.5 * 103 ng p24 per 1 * 10E7 cells/mL).
Cells were washed twice with PBS and reseeded in the presence of varying concentrations of LEDGIN
(CX014442) and 1 U/mL of IL-2. Four days post-infection cells were washed twice using PBS and some
cells were harvested for quantification of integrated proviral DNA using real-time PCR (nested Alu-
LTR PCR, [Butler et al., 2001; Lewin et al., 2008] normalized for input DNA by qPCR for the CCR5
gene as previously described [Zhang et al., 1999]. Other cells were reseeded in the presence of 10 nM
PMA (Sigma-Aldrich) together with 10 µg/mL PHA (Sigma-Aldrich) or left untreated. PHA activated
feeder peripheral blood mononuclear cells (PBMCs) were added 24 h after the activating stimulus to
amplify virus replication and enhance detection of the infection [Saleh et al., 2011]. Virus production
was measured in culture supernatant at day 7 post-infection by p24 ELISA (Fujirebio Europe).
4.5.10 Statistical analysis.
Reactivation results are expressed as means ± standard error of the mean. Statistical analysis was
assessed using multiple t-tests and corrected using Sidak-Bonferroni with significance levels indicated.
Ranked Wald statistics were used to calculate the statistical significance (asterisks) for a given genomic
feature between integration site datasets relative to the DMSO treated condition (dashes). Significant
deviation from the DMSO treated control dataset for safe harbor criteria was calculated using a Pearsons
Chi-square test. ImageJ software was used to measure the relative distance of γH2AX foci to the nuclear
rim. Statistical differences were calculated using a Kolmogorov-Smirnov test as described previously
[Di Primio et al., 2013].
4.5.11 VISA-trimming non-genomic portions of sequence reads.
24 bp of the LTR sequence are used to generate the ’LTR substrings’ for substring matching. 3
overlapping LTR substrings are generated, each consisting of 12 bp. LTR substring 1 covers 12 bp
located 3’ of the LTR sequence, LTR substring 2 is shifted 6 bp upstream from the 3’ end of the
LTR sequence, and LTR substring 3 is shifted 12 bp upstream from the 3’ end of the LTR sequence
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(Supplementary Figure S4.6). As our primers are binding 9 bp upstream of the LTR end the 2nd
and 3rd string will overlap with our primer. LTR substring 1 is examined first. If LTR substring 1 is
found, the query sequence begins immediately following its position and the LTR-chromosome junction
is deemed ’normal’. If a mismatch in the LTR portion of the sequence read prevents LTR substring
1 to be found, VISA then searches for LTR substring 2. If LTR substring 2 is found, the query will
begin 6 bp downstream of its position to compensate for the 6 bp shift. If a mismatch in the LTR
portion of the sequence read prevents LTR substring 2 to be found, VISA searches for LTR substring
3. If LTR substring 3 is found, the query will begin 12 bp downstream of its position to compensate
for the 12 bp shift (Supplementary Figure S4.6). When either LTR substring 2 or LTR substring 3 is
found, the LTR-Chromosome junction is deemed ’imperfect’. If a mismatch causes LTR substring 3 not
to be found, the above steps are repeated using the sequence read in its reverse orientation. If none of
the LTR substrings are found in either orientation, the sequence read does not contain a valid query
and will not be aligned to the genome. A similar approach was used to trim linker cassettes. A more
detailed explanation on trimming non-genomic portions of the sequence reads can be found in (Hocum
et al., 2015).
4.5.12 Virus production in the presence of LEDGINs
Vesicular stomatitis virus G (VSV-G)-pseudotyped single-round virus particles were generated by dou-
ble transfection of HEK293T-cells with a plasmid encoding a single-round HIV clone (pOGH) together
with a VSV-G protein encoding plasmid (pVSVG). Linear polyethyleneimine (PEI; Polysciences) was
used for plasmid transfections. Cells were washed 6 hrs post transfection (3x with PBS) and medium was
added supplemented with a dilution series of LEDGIN CX014442 (0.27 µM - 0.00375 µM). Supernatant
was collected after 48 hrs by filtration through a 0.45 µm pore membrane (Corning Inc.). The virus
was concentrated using a Vivaspin 15-50 kDa cut-off column (Vivascience), washed 3 times thoroughly
with PBS in order to remove residual compound, DNase (Roche) treated and stored at -80°C. Virus
productions from at least 10 petri dishes were used for each condition to reduce variation in production
efficiency. Productions were normalized for p24/RT. SupT1 and THP1 cells were seeded and infected
with equal RT units for 2 hours, washed twice and seeded in 48-well plates (10% FCS, 0.01% gentamicin
RPMI). Cells were harvested 48 hours post infection yielding an infection rate < 40% positive cells,
as monitored by FACS analysis using a MACS Quant VYB FACS analyzer (Miltenyi Biotech GmbH),
ensuring single-copy integration.
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4.9 Supporting information
4.9.1 Supplementary results
4.9.1.1 LEDGIN treatment shifts HIV integration out of transcription units.
Integration site data sets obtained from SupT1 cells infected with LVP2A and treated with different
concentrations of CX014442 were compared to different genomic (Supplementary Figure S4.3a on page
105) and epigenetic features (Supplementary Figure S4.3b-c). A heat map was generated using the
INSIPID software (Bushman Lab, University of Pennsylvania). Tile color depicting the nature of
the correlation for an integration data set with the respective genomic/epigenetic feature (rows, left)
relative to matched random controls, as indicated by the colored Receiver Operating Characteristic
(ROC) curve area scale at the bottom of the panel. Columns indicate different data sets. Statistical
significance (asterisks, ranked Wald tests) is shown relative to the DMSO or LEDGF/p75KD population
(dashes) **p<0.01; ***p<0.001. Significance is reached when p<0.001, compared to the DMSO or
LEDGFKD respectively control. WT lentiviral integration correlates with histone marks associated with
transcriptionally active chromatin (H3K4 mono-, di- and trimethylation, H3K14 and H4 acetylation, as
well as acetylation and monomethylation of H3K9/K27/K79, H4K20 and H2BK5, etc.) (Supplementary
Figure S4.3b-c) [De Ravin et al., 2014]. In line, integration in regions associated with marks common to
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transcriptionally silent regions or heterochromatin was disfavored (H3K27me3, H3K9me3 or H4K20me3
and H3K79, respectively) (Supplementary Figure S4.3b-c)[De Ravin et al., 2014] corroborating the
preference for open, transcriptionally active chromatin. CX014442 treatment during infection shows
a dose dependent shift out of transcriptionally active regions as supported by both the genomic and
epigenetic analysis. (Supplementary Figure S4.3a-c, a more detailed guide to the data presented can
be found in [Ocwieja et al., 2011]).
4.9.1.2 LEDGIN treatment induces a silent reservoir resistant to HIV reactivation.
SupT1 cells were infected with single round HIV-tCD34 at a MOI yielding < 30 % positive cells
and treated with 0.3-25 µM LEDGIN CX014442. The infected cells were cultured for two weeks in
order for silencing to occur and stimulated 11 days post infection using TNFα (10 ng/mL) in order to
obtain a maximal T-cell activation response, or DMSO as a control (closed circles and open circles,
respectively; Supplementary Figure S4.4a-b on page 108). LEDGIN (CX014442) treatment resulted in
a dose-dependent inhibition of reactivation from latency (reactivation IC50 ≈ 7.24 µM) as evidenced by
the reduced increase in the % tCD34 positive cells (Supplementary Figure S4.4a & b). The experiment
was repeated with a similar reactivation setup. SupT1 cells were infected with single-round HIV-tCD34
during LEDGIN treatment at concentrations equal to 1 and 3 times the IC50 of CX014442 (3 and 12
µM respectively, as described above) (Supplementary Figure S4.4c). Cells were reactivated at day 11
with the same agents used in the LEDGF/p75-depleted cells. No difference was observed between the
no-stimulation and DMSO control condition. A modest 2-fold tCD34 reactivation was observed after
addition of PMA or Prostratin, and an increase in the percentage tCD34 positive cells of 3.5-fold was
observed after stimulation with 10 ng/mL TNFα or 3 µM SAHA (Supplementary Figure S4.4c). The
percentage living cells amounted at least 75% of the total cell population 24h post stimulation (in the
presence of 3 µM SAHA 55% of cells were alive) and was not substantially different upon LEDGIN
treatment (data not shown). When comparing reactivation for the LEDGIN-treated conditions to
the DMSO control we observed an overall reduction in reactivation potential for the different LRAs
(significance was calculated using multiple t-tests and corrected using Sidak-Bonferroni as depicted in
the figure (* p < 0.05, ** p < 0.005, ***p < 0.0005)).
4.9.1.3 LEDGIN treatment does not affect the local integration site preferences.
Retroviral INs show a weak but discernable target sequence specificity at the site of integration.
LEDGIN-mediated inhibition of the LEDGF/p75-IN interaction by binding to the LEDGF/p75 bind-
ing pocket in the catalytic core domain (CCD) dimer interface could potentially affect the inherent
integration mechanism, which may result in an increase of aberrant integrations or an altered local
integration site preference. We therefore evaluated sequence conservation and relative base frequency
in the 18 bp genomic DNA sequence surrounding the integration sites (corresponding to the intasome
footprint) using sequence logos (Supplementary Figure S4.5 on page 110). Sequence conservation is
indicated as the total height of each stack (measured in bits), while the relative height of bases in a
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stack reflects the base frequencies at that position. The site of strand transfer on the plus target DNA
strand is depicted as position 0. When comparing pannels a-h, the WT local palindromic sequence logo
surrounding the integration site is observed in all conditions. With integration sites being amplified
using primers designed to bind 9 bp upstream of the LTR end, we were able to look into sequence
variations in those 9 bp and evaluated whether LEDGIN treatment increased the number of aberrant
integration events. Virus-host DNA junctions were screened and variations close to the viral-host NA
junction evaluated using the VISA platform (Vector Integration Site Analysis server [Hocum et al.,
2015]. VISA uses a Perl substring matching strategy to detect and remove the non-genomic sequences
from the sequence reads to generate the queries for alignment (Supplementary Figure S4.6 on page 111)
[Hocum et al., 2015]. We calculated the percentage unique integration sites with an imperfect LTR
chromosome junction relative to the total integration sites for the respective data sets and plotted the
different percentages (Supplementary Table S4.2 on page 113). Only a minor fraction (<2 %) of the
total integration sites was identified as containing imperfect LTR-chromosome junctions. At 50 µM
of LEDGIN a modest increase in the percentage of aberrant junctions was detected. In an effort to
characterize this low fraction of aberrant integrations (<2 %) in more detail, we analyzed sequence con-
servation and relative base frequency. Nucleotide substitutions rather than indel formation, represented
by high relative base frequencies, were observed for each of the last 7 bp of the LTR (position -7 to -1)
and resembled the genuine LTR sequence end (TCTAGCA) (data not shown). The result was identical
in WT conditions and in LEDGIN treatment conditions. Even though this is a single measurement,
the observed percentages cannot explain the phenotype observed whereby LEDGINs induce a residual
proviral pool that is refractory to reactivation. This analysis allows us to conclude that even though
LEDGINs retarget lentiviral integration towards more random, the actual residual insertion event is
catalyzed by the viral integrase, which dictates the local integration site preference much alike the WT
intasome.
4.9.2 Supplementary figures
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Supplementary Figure S4.1: LEDGF/p75 depletion relatively increases the silent reservoir. (a)
LEDGF/p75KD reduces transduction efficiency in LEDGF/p75 depleted cells. Left panel depicting the overall
% mKO2 positive cells for SupT1 LEDGF/p75WT and KD cells when infected using different concentra-
tions of OGH (VSV-G). Right panel depicting the overall % mKO2 positive cells for Nalm control (+/c) and
LEDGF/p75KO (-/-) cells when infected using different concentrations of OGH (VSV-G). Bottom panel depict-
ing the LEDGF/p75 mRNA levels relative to β-actin levels for de respective cell lines. All viruses are VSV-G
pseudotyped. eGFP, Enhanced Green Fluorescent Protein; mKO2, Mutant Kusubira Orange 2.
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Supplementary Figure S4.1: LEDGF/p75 depletion relatively increases the silent reservoir. (b)
LEDGF/p75KO increases the fraction of silently infected cells (% eGFP-, mKO2+ cells / % mKO2+ cells *100)
in Nalm LEDGF/p75KO cells (-/-) compared to Nalm LEDGF/p75 control (+/c). All viruses are VSV-G
pseudotyped. eGFP, Enhanced Green Fluorescent Protein; mKO2, Mutant Kusubira Orange 2.
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Supplementary Figure S4.2: LEDGIN-mediated inhibition of lentiviral transduction. SupT1 cells
were infected with three different dilutions of a lentiviral vector expressing both eGFP and the firefly luciferase
(LV eGFP-fluc). (a) The dose-response curve shows a decrease in % eGFP positive cells with increasing
LEDGIN concentration. (b) Panel depicting a decrease in integrated copies as determined by Q-PCR analysis.
(Gag normalized to RNaseP, data represent the average of 3 measurements ± SD). All vectors are VSV-G
pseudotyped. eGFP, Enhanced Green Fluorescent Protein.
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Supplementary Figure S4.3: LEDGIN inhibition of the LEDGF/p75-IN interaction retargets
lentiviral integration. Integration site data sets obtained from SupT1 cells infected with LV eGFP-fluc
(LVP2A) and treated with different concentrations of CX014442 were compared to genomic and epigenetic
features. Heat maps were generated using the INSIPID software (Bushman Lab, University of Pennsylvania).
Tile color depicts the nature of the correlation for an integration dataset with the respective genomic/epigenetic
feature (rows, left) relative to matched random controls, as indicated by the colored receiver operating charac-
teristic (ROC) curve area scale at the bottom of the panel. Columns indicate different data sets analyzed. (a)
Genomic heat map comparing different genomic features (windows are indicated, a more detailed guide to the
data presented can be found in [Ocwieja et al., 2011] ). Statistical significance (asterisks, ranked Wald tests)
is shown relative to the LEDGF/p75KD population (dashes) **p<0.01; ***p<0.001. Significance is reached
when p<0.001, compared to the LEDGF/p75KD control.
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Supplementary Figure S4.3: LEDGIN inhibition of the LEDGF/p75-IN interaction retargets
lentiviral integration. (b) Epigenetic heat map comparing different epigenetic feature (10kb windows).
Statistical significance (asterisks, ranked Wald tests) is shown relative to DMSO population (dashes) **p<0.01;
***p<0.001. Significance is reached when p<0.001, compared to MRC. Detailed information on epigenetic
marks and their roles can be found in [Barski et al., 2007; Taverna et al., 2007]. Included features were limited
to those identified in high-throughput studies in HeLaP4 and primary CD4+ T-cells. CX014442 treatment
during infection induces a dose dependent shift out of transcriptionally active regions. Lower significance is
observed at the highest LEDGIN concentrations due to a lower copy number of integration sites. DMSO,
Dimethyl sulfoxide.
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Supplementary Figure S4.3: LEDGIN inhibition of the LEDGF/p75-IN interaction retargets
lentiviral integration.(c) Less elaborate epigenetic heat map comparing epigenetic features known to asso-
ciated with transcriptionally active or repressive regions (10kb windows). Statistical significance (asterisks,
ranked Wald tests) is shown relative to DMSO population (dashes) **p<0.01; ***p<0.001. Significance is
reached when p<0.001, compared to MRC. Included features were limited to those identified in high-throughput
studies in HeLaP4 and primary CD4+ T-cells. CX014442 treatment during infection induces a dose dependent
shift out of transcriptionally active regions. Lower significance is observed at the highest LEDGIN concentra-
tions due to a lower copy number of integration sites. DMSO, Dimethyl sulfoxide.
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Supplementary Figure S4.4: LEDGIN treatment reduces reactivation from latency.
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Supplementary Figure S4.4: LEDGIN treatment reduces reactivation from latency. SupT1 cells
were infected with single round NL4.3 tCD34 and treated with different concentrations of CX014442 (as
indicated). 11 days post infection cells were reactivated using different LRAs at concentrations indicated. (a)
% tCD34 positive cells after stimulation with TNFα(10 ng/mL) or DMSO. (b) Fold increase in % tCD34 cells
relative to DMSO treatment. All data represent averages of 3 replicates and error bars indicate the standard
error of the mean. (c) Bar diagram depicting the fold reactivation (fold increase in % tCD34 positive cells).
All data represent averages of 3 replicates and display a representative image for 4 independent experiments.
Error bars indicate the standard error of the mean (SEM). A statistical analysis was performed using multiple
t-tests and corrected using Sidak-Bonferroni (* p < 0.05, ** p < 0.005, ***p < 0.0005 compared to the
DMSO control treatment during infection). (d) Relative fold increase in % tCD34 positive cells (after TNFα
stimulation) normalized to untreated control for samples treated with either CX014442 or Raltegravir. (e)
Decrease in fraction of quiescent OGH reporter provirus (% eGFP-, mKO2+ cells / % mKO2+ cells *100)
upon TNFα stimulation normalized to untreated control for cells treated with either CX014442 or Raltegravir
during infection. Actual drug concentrations used were based on either the ’early effect’ IC50 of CX014442
equal to 3.83 µM or an IC50 of Raltegravir equal to 0.0035 µM. SAHA; SuberoylAnilide Hydroxamic Acid,
TNFα; Tumor Necrosis Factor alpha, PMA; Phorbol 12- Myristate 13-Acetate, DMSO; DiMethyl SulfOxide,
tCD34; truncated Cluster of Differentiation 34. All viruses are VSV-G pseudotyped.
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Supplementary Figure S4.5: The integration site sequence logo remains unaffected by LEDGIN-
mediated inhibition of the LEDGF/p75-IN interaction. Sequence conservation and relative base fre-
quency in the 18bp genomic DNA sequence surrounding the integration sites (roughly corresponding to the
intasome footprint) were evaluated using sequence logos. Sequence conservation is indicated as the total height
of each stack (measured in bits), while the relative height of bases in a stack reflects the base frequencies at that
position. The site of strand transfer on the plus target DNA strand is depicted as position 0. (a-h) Integration
site sequence logos retrieved at different concentrations of LEDGIN CX014442.
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AGTCAGTGTGGA AAATCTCTAGCA
LTR substring 3 LTR substring 1
LTR substring 2
5′ AGTCAGTGTGGAAAATCTCTAGCA        GT 3′
TGTGGAAAATCT
LTR - END
Primer binding site
3’ processing 
site
Supplementary Figure S4.6: LTR substrings. This example illustrates the process of generating the
LTR and LC substrings for substring matching. A lentiviral vector LTR is shown.
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Supplementary Figure S4.7: Addition of LEDGINs during production results in transcriptionally
silent provirus after integration. HIV-1 double reporter virus (OGH) was produced in HEK293T cells in
the presence of varying LEDGIN concentrations. Infection of either SupT1 cells (Left) or THP1 cells (Right)
with HIV-1 double reporter virus produced in the presence of increasing concentrations of LEDGIN CX014442
(’late’ IC50 = 0.06 µM). (a) Dose-response curve showing a decrease in % eGFP+, mKO2+ cells with increasing
LEDGIN concentration. Three different virus concentrations are depicted in green. (b) Dose-response curve
showing a decrease in the overall % mKO2+ cells with increasing LEDGIN concentration. Three different
virus concentrations are depicted in red. (c) The fraction of quiescent cells (% eGFP-, mKO2+ cells) / (%
mKO2+ cells) *100 increased proportionally with the concentration of LEDGIN added during production.
Three different virus concentrations used are shown in red. All viruses are VSV-G pseudotyped. eGFP,
Enhanced Green Fluorescent Protein; mKO2, Mutant Kusubira Orange 2.
112
4.9. SUPPORTING INFORMATION
Supplementary Table S4.1: LEDGIN inhibition of the LEDGF/p75-IN interaction retargets
lentiviral integration. Table showing the percentage of HIV integration sites relative to features specific for
integration such as integration into the body of genes (Refseq genes). Integration site data sets are obtained
from MT4 cells infected with WT HIV (NL4.3) and treated with different concentrations of CX05045. Asterisks
depict a significant deviation from the DMSO treated control data set (two-tailed Chi-square test; ***, p-values
<0.001).
DataSet % Imperfect LTR-Chromosome junctions
DMSO 1.25
0.78125 1.32
1.5625 1.51
3.125 1.68
6.25 1.37
12.5 0.65
25 1.86
50 2.58
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Supplementary Table S4.2: Percentage of imperfect LTR - chromosome junctions. Non-genomic
sequences were detected and removed from the sequence reads to generate the queries for alignment using a
Perl substring matching strategy (VISA, Vector Integration Site Analysis server [Hocum et al., 2015]. The
percentage imperfect LTR-Chromosome junction was calculated relative to the total number of integration
sites for all LEDGIN integration site data sets.
46.21
47.52
49.34
49.83
49.43
51.76
49.71
56.70
DataSet % Integrations in Refseq genes
having an opposite orientation
DMSO
0.78125
1.5625
3.125
6.25
12.5
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Supplementary Table S4.3: Integration orientation Table depicting the percentage of integration sites
falling within genes that have a similar or opposite orientation relative to the targeted genes. LEDGIN
treatment induces a dose-dependent increase in the fraction of integrations having an opposite orientation
relative to the target gene. Asterisks depict a significant deviation from the DMSO treated control dataset
(Pearsons Chi-square test; ***, p-values <0.005; **, p-values <0.05; *, p-values <0.5).
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114
5
Concluding Discussion
115
CHAPTER 5. CONCLUDING DISCUSSION
The work presented in this doctoral dissertation encompasses two research manuscripts with the
LEDGF/p75-IN interaction forming the common thread throughout the chapters. This discussion
frames the different chapters and puts them into perspective.
I) Engineering Safer Next Generation Viral Vectors for Gene Therapeutic Applications.
The capacity to integrate transgenes into the host cell genome makes retroviral vectors interesting
tools for gene therapeutic applications where life-long correction is required. Although stable inser-
tion resulted in successful correction of several monogenic disorders, it also accounts for insertional
mutagenesis and implies the risk of vector-induced genomic perturbation, major setbacks in otherwise
successful clinical gene therapy trials resulting in leukemia development in a subset of treated patients.
Despite incremental improvements in vector design, their use is still not risk-free as retroviral vector
genotoxicity is largely influenced by the vector integration pattern. A recent retrospective study, how-
ever, highlighted the potential of a gene therapy treatment alternative for SCID-X1 as it outperformed
an allogenic haploidentical Hematopoietic Stem Cell Transplantation (HSCT) accounting for a faster
immune reconstitution and improved thymus response [Touzot et al., 2015]. More importantly, the
gene therapy field recently achieved a huge leap forward as the first retroviral vector (StrimvelisTM) was
approved in 2016 by the European Commission for the treatment of ADA-SCID [Cicalese et al., 2016].
In order for gene therapy to become a widely applicable first in-line treatment alternative a better
understanding of the complex interplay of the parameters responsible for severe adverse events (SAEs)
and improved vector genotoxicity profiles are required. At present, there is an increasing interest in
new vector platforms displaying a more neutral, close-to-random insertional profile potentially reducing
the probability of proto-oncogene activation and lowering the genotoxic potential.
Lentiviral vector (LV) integration is directed into active transcription units by LEDGF/p75, a host-cell
protein co-opted by the viral integrase. In this work (see Chapter 3 on page 41), we contributed to the
development of safer retroviral vectors and engineered LEDGF/p75-based hybrid tethers in an effort to
obtain a more random integration pattern to increase biosafety, and potentially reduce of proto-oncogene
activation. We therefore truncated LEDGF/p75 by deleting the N-terminal chromatin-reading PWWP-
domain. In parallel we replaced this domain with alternative chromatin binding peptides described in
literature as pan-chromatin recognition peptides since they bind cellular chromatin without sequence
specificity aiding episomal viruses to persist during mitosis; The spumavirus, Prototype Foamy Virus
(PFV), contains a 13-amino acid motif in the group-specific antigen (Gag) binding the H2A/H2B core
nucleosome [Tobaly-Tapiero et al., 2008; Nowrouzi et al., 2006; Trobridge et al., 2006]. Likewise, the
Kaposi Sarcoma-associated Herpes Virus (KSHV) genome is tethered to the nucleosomal core via a
chromatin binding sequence (CBS) at the N-terminal end of the Latency-Associated Nuclear Antigen
protein (LANA) [Barbera et al., 2006]. Finally, in the β-Papillomaviruses (PV) a conserved motif in the
E2 hinge promotes binding to chromatin and mitotic chromosomes of the invaded cell [Sekhar et al.,
2010; Sekhar and McBride, 2012; Võsa et al., 2012]. Each of these hybrid constructs showed unique
subnuclear distributions when complemented in LEDGF/p75 depleted cell lines (see Subsection 3.3.2 on
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page 46) and expression of these LEDGF-hybrids in LEDGF-depleted cells efficiently rescued LV trans-
duction and integration (see Subsection 3.3.3 on page 48). We characterized proviral integration sites
using a nested linker mediated PCR approach and 454 pyrosequencing (see Subsection 3.3.4 on page 50).
Analysis revealed LV integrations that distributed more randomly throughout the host-cell genome for
the PWWP truncated LEDGF/p75, suggesting the PWWP domain is not required for integration sup-
port. The latter phenotype could be attributed to presence of the AT-hook motifs and charged regions
present in the N-terminal end of δN93-LEDGF (Cfr. ’scan-and-lock mechanism’, [Hendrix et al., 2011]).
For most of the peptide constructs (except for PFV Gag534-546-δN93-LEDGF) integration resulted in a
more random distribution than under LEDGF/p75 depleted conditions. Only small differences were
observed compared to the δN93-LEDGF. The extent of integration targeting however will be dependent
on competition with endogenous LEDGF/p75 and will be dependent on the exact levels of endogenous
LEDGF/p75 present in the respective target cell. When considering safe harbor criteria, LV integration
sites for these LEDGF-hybrids distributed more safely (4-fold increase in % ’safe’ sites) compared to
LEDGF/p75-mediated integration in wild-type cells. This approach should be broadly applicable to
introduce therapeutic or suicide genes for cell therapy, such as patient-specific iPS cells.
Future Perspectives.
Our findings open new options for next generation viral vectors to display a safer genotoxicity pro-
file. In a next step, our approach should be combined with mRNA electroporation of wild-type cells
expressing endogenous LEDGF/p75. This method has been previously shown to be very effective in a
series of cell types. Alternatively, Hare and colleagues reported on a set of amino-acid substitutions in
HIV IN that abolish LEDGF/p75 binding but do not compromise IN activity in vitro, together with
mutations in the LEDGF/p75 protein that restore binding [Hare et al., 2009]. Engineered viral vectors
harboring an artificial IN-LEDGF/p75 pair could facilitate retargeting in a context where WT LEDGF
is present. Randomized integration targeting should be directly compared with alpharetroviral vectors
displaying an intrinsic, more neutral integration preferences. Ideally, integration is directed towards a
single "ultimate" integration environment able to accommodate integration of new genetic material in
a manner that enables functionality prediction and does not harm the host cell or organism which is
referred to as a "Genomic Safe Harbor" region (GSH) [Papapetrou et al., 2011; Sadelain et al., 2011a;
Papapetrou and Schambach, 2016]). However, such regions are yet to be defined. Incremental progress
has been made in the tools available to target or edit such unique loci; artificial zinc finger nucleases,
meganucleases and TALENs. Fusion of LEDGF to any of these modules has the potential to retarget
integration towards these loci. The extent by which integration can be retargeted to a single locus will
be limited as integration site selection is additionally affected by more up-stream events such as the
nuclear entry route. Therefore it is most likely that targeted integration will display an enrichment of
integration events near those specific loci but will also result in multiple off-target integration events.
As the gene therapy field moves forward, viral vectors will accumulate additive or synergistic safety fea-
tures (SIN promoter, insulator sequences, ...) and be evaluated in more general (IVIM [Modlich et al.,
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2006, 2009b] or Cdkn2a -/- mouse model [Montini et al., 2006, 2009b]) and disease specific pre-clinical
models. The gene therapy field however still lacks powerful assays able to robustly and accurately
predict the exact clinical outcome and adverse events. Moreover, standardized parameters to compare
different vector platforms should be defined in the future. In addition, it remains unclear whether
treatment of polygenic disorders requires different safety criteria. The gene ontology analysis and safe
harbor analysis used in this manuscript give us a first indication on the cytotoxic profile of new vector
platforms and allow us to check whether the reduced integration frequencies in genes for the respective
conditions might result in different GO classes.
II) The Quest for An HIV Cure.
The HIV pandemic represents one of the most important global health challenges in modern history.
In the past 30 years, tremendous efforts to develop antiretroviral therapy have led to the development
and approval of more than 30 drugs acting on different steps of the HIV replication cycle. cART has
revolutionized the treatment of HIV/AIDS dramatically reducing HIV related mortality and morbid-
ity. Yet, anno 2016, cART administration does not cure the patient due to the existence of a latent
reservoir of replication competent virus. The presence of this latent reservoir allows HIV to rapidly
rebound viremia within weeks after therapy cessation. Moreover, drug related co-morbidities, the eco-
nomic and therapeutic burden reduce therapy compliance and allow a window of opportunity for HIV
to accumulate escape mutations and develop drug resistance. Evidence suggests the development of
drug resistance against RAL and EVG (belonging to the potent INSTI class) in treatment-experienced
patients [Canducci et al., 2011; Wainberg et al., 2012]. These factors highlight the importance of a
continuous effort to identify novel druggable targets and the urge for alternative therapy routes able to
exhaust the latent reservoir and control virus replication in the absence of cART, a key priority to the
International AIDS Society (IAS) [Deeks et al., 2016].
To date, the latent reservoir remains an insurmountable obstacle to an HIV cure. Early administration
of antiretroviral therapy during acute infection limits the size of the latent reservoir but does not com-
pletely prevent its establishment. Moreover, cART intensification with the integrase strand transfer
inhibitor (INSTI) raltegravir, failed to achieve a further diminution of the reservoir. In pursuit of an
HIV cure the main focus aims to purge the latent reservoir in order to elicit a subsequent killing of the
reservoir by viral cytopathic effects or immune system clearance while uninfected cells remain protected
by cART. An alternative approach proposes to enforce the virus into a ’deep latent’ state, an idea that
has been lingering in the field but has not been heavily pursued.
LEDGIN-Mediated Inhibition of Integrase-LEDGF/p75 Interaction Reduces Reactivation
of Residual Latent HIV.
Integration of the viral cDNA into the host cell chromatin catalyzed by IN forms a key step in
the viral replication cycle. Targeting of this step led to the development of a potent class of HIV
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inhibitors (INSTIs) currently in clinical use. Meanwhile LEDGF/p75 has been thoroughly validated as
a key cellular cofactor co-opted by the viral IN for directing HIV integration to the body of actively
transcribed genes. The awareness of HIV hijacking endogenous proteins has led to the development of
additional inhibitor classes. LEDGINs are bona fide small molecules able to abrogate the LEDGF/p75-
IN interaction by binding to the IN dimer interface thereby inhibiting HIV replication [Christ et al.,
2010]. Surprisingly these compounds perturb the IN dynamics via multiple, interwoven mechanisms.
Not only do LEDGINs compete with LEDGF/p75 interaction and thereby block chromatin tethering of
the PIC [Christ et al., 2010]; they also inhibit IN catalysis by inducing untimely and unproductive IN
assembly [Christ et al., 2012; Kessl et al., 2012; Tsiang et al., 2012; Le Rouzic et al., 2013; Shkriabai et al.,
2014; Gupta et al., 2014]. This multimodal mechanism of action results in a steep dose-response curve.
Boehringer-Ingelheim (BI) reported on the development of quinoline BI-224436, the first LEDGIN that
advanced into clinical trials [Fenwick et al., 2014].
At present, we do not fully understand why, how and when lentiviruses co-opted the chromatin reader
LEDGF/p75 during evolution. HIV-1 replication however is severely hampered upon its depletion.
Preferential integration of HIV in active transcription units has important implications for the tran-
scriptional activity of the viral promoter and the establishment/maintenance of HIV latency as the
local chromatin context is generally believed to affect the transcriptional activity. Here I provide ex-
perimental evidence for a strategy to push the virus towards transcriptional quiescence by interference
with the LEDGF/p75-IN interaction. In Chapter 4 on page 69 I showed that LEDGF/p75 depletion,
known to result in retargeting of integration away from the body of actively transcribed genes [Ciuffi
et al., 2005; Shun et al., 2007; Marshall et al., 2007; Schrijvers et al., 2012b] resulted in provirus that
was more likely to adopt a transcriptionally quiescent state (Subsection 4.4.1 on page 72). In addition,
we demonstrated for the first time that these integrants are less susceptible to reactivation with a panel
of latency reversing agents (Subsection 4.4.2 on page 72). Results that provide crucial information for
a better understanding of why HIV evolved to use LEDGF/p75 as a cellular cofactor. In addition, I
evidenced that LEDGINs (CX014442), acting as potent inhibitors of HIV replication, specifically alter
the HIV-1 genomic integration site distribution of the residual integrants in a manner reminiscent of
LEDGF/p75 depletion (Subsection 4.4.3 on page 75), a phenotype that was previously unclear. Sharma
et al. and Jurado et al. observed a statistically relevant shift out of gene rich regions upon the addition
of the LEDGIN GS-B during infection, a phenotype that could not be reproduced by Gupta or Sharma
et al. using LEDGIN GSK1264 or KF116 [Sharma et al., 2014; Gupta et al., 2014]. The low number
of integration sites or the lower concentrations used (with respect to the IC50 of the so-called ’early
effect’) can possibly explain why statistical significance was not reached in those papers. Co-inhibition
of the HRP-2-IN interaction possibly explains the more pronounced shift observed at high CX014442
contentrations. Unexpectedly, a slightly higher fraction of the residual integrants under LEDGIN treat-
ment was integrated in the opposite orientation with respect to the host gene targeted. This phenotype
remains a mere observation which possibly contributes to the quiescent phenotype. The underlying
mechanism may be related to the induction of aberrant integrase oligomerization which could affect the
exact manner by which the intasome interacts with bend/coiled chromatin. However, no effect on the
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palindromic sequence logo was observed at increasing LEDGIN concentrations. In addition, LEDGINs
also inhibit the integrase-HRP2 interaction possibly responsible for the observed phenotype.
The HIV PIC and provirus are known to locate in proximity to the nuclear rim [Albanese et al., 2008;
Di Primio et al., 2013; Marini et al., 2015]. I demonstrated that following LEDGF/p75 depletion and
under LEDGIN treatment integration events were located more towards the inner nucleus, away from
the nuclear rim or periphery (Subsection 4.4.4 on page 79). Most likely the virus is able to penetrate
the chromatin environment for a longer time period before integrating into the host cell chromatin. As
previously shown by us and others LEDGINs enhance IN multimerization, inducing a untimely and
unproductive IN assembly. My data suggest that addition of CX014442 during the early infection steps
and binding to the IN dimer interface does not affect its intrinsic local palindromic sequence prefer-
ence therefore residual integrations likely represent authentic integration events catalyzed by a WT
intasome. Most notably, CX014442 treatment reduced the integration frequency near genomic regions
classified as being unsafe based on safe harbor criteria, consistent with the notion that HIV integration
does not result in cellular transformation even though some reports linked integration to cellular clonal
expansion without oncogenesis. Using a next-generation double-reporter virus (HIV OGH) I evaluated
whether a LEDGIN induced shift in integration site distribution could possibly affect the establish-
ment and reactivation of latent provirus. Treatment with LEDGIN, in the first place developed as
antivirals, resulted in an overall decrease in the number of infected cells as represented by a decrease
in integrated copy number and number of positive cells on FACS analysis. However, the relative frac-
tion of transcriptionally silent provirus compared to the total number of infected cells increased upon
increasing concentrations of CX014442 implying that the residual integrants are more likely to adopt a
transcriptionally silent state. In line with the phenotype observed for LEDGF/p75 depletion residual
integrations under LEDGIN treatment where less susceptible to reactivation by a panel of LRAs in
cell lines or general T-cell activating agents in primary CD4+ T-cells. The more pronounced effect
observed under LEDGIN treatment could possibily be attributed to the additional inhibition of HRP-2
[Schrijvers et al., 2012a].
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Figure 5.1: Schematic diagram of the effect of LEDGINs on the residual HIV-1 reservoir. LED-
GINs, developed as bona fide antivirals, result in residual integrants that are more likely to adopt a transcrip-
tionally inactive or quiescent state, less susceptible to reactivation.
Will LEDGIN Molecules Be Able To Play a Role in a Cure for HIV Infection?
HIV reservoirs are believed to be established already at the early Fiebig stages I/II , defined by positive
HIV RNA, negative HIV western blot and negative HIV ELISA for stage I plus positive antigenaemia
P24 for stage II [McMichael et al., 2009], as early as 10 days after symptoms onset [Ananworanich et al.,
2012]. cART provided early during acute infection, drastically reduces the size of the latent reservoir
yet is not able to completely prevent reservoir formation, meaning the latent reservoir is, at least in
part, is still formed during cART administration. Early treatment initiation with cART therefore will
become standard clinical practice in HIV care (INSIGHT START Study Group, 2015) when possi-
ble and will notably enhance the recovery of CD4+ T-cell numbers and functions [Hocqueloux et al.,
2013]. In addition, early cART impacts the rebound of HIV RNA levels during treatment interruption,
allowing greater time off therapy [Wyl et al., 2011]. An approach representing a marked departure
from the "shock and kill" paradigm is to enforce viral latency. It was recently proposed that pushing
enough proviruses into quiescence could drive the basic reproduction number of HIV below 1, resulting
in unsustainable infection [Rouzine et al., 2015]. Suppressing virus production and permanently silence
HIV into a so-called "deep latent" state might therefore allow discontinuation of cART administration.
Several cases of sustained HIV remission or delayed viral rebound have been previously observed (see
Figure 5.2 on page 123) in the setting of HSCT (Berlin and Boston patients, [Henrich et al., 2014]) or
early ART administration (Mississippi baby, [Persaud et al., 2013]). In some cases, long-term control
of HIV viral loads was observed post-treatment (VISCONTI study in France [Sáez-Cirión et al., 2013],
see Figure 5.2). A cART regimen, optimized to significantly and rapidly reduce the latent reservoir size
when added early during acute infection and enforcement of a latent phenotype of the residual reser-
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voir could potentially hold promise for achieving a long-term HIV remission and lead to less frequent
dosing regimens or sustained post-treatment control. Rendering an increased fraction of the ongoing
replicating virus inactive upon integration will reduce the possibility of resistance development and
postpone the time to relapse. Deep latency could allow the immune system to recover and permanently
control the HIV infection as it is promoted to adopt an endogenous retrovirus (ERV)-like state. A
combination of LEDGINs together with transcriptional modulators abrogating the recruitment of P-
TEFb by the viral Tat protein and impeding HIV production might constitute an attractive treatment
option (e.g. Didehydro-Cortistatin A or dCA, [Mousseau et al., 2015]. Tat acts by binding to the TAR
element of all viral RNA transcripts and recruits p-TEFb. Inhibition of this interaction will therefore
hamper transcription elongation which could render integrated provirus inactive. In comparison to a
waddington-epigenetic landscape residual integrants under LEDGIN treatment might display a reduced
stochastic transcriptional noise [Dar et al., 2014]. In other words, the threshold levels of Tat required
for reactivation might turn out to be higher in comparison to those for genuine integrants. Therefore,
residual integrants under a LEDGIN regimen could be more suitable to be locked in a deep latent
state by hampering the Tat positive feedback loop. It is clear that this final outcome utterly depends
on well-designed clinical trials and surpasses any claims made in this work. Moreover, the outcome
of such clinical trials will provide vital information on the time and dynamics of the latent reservoir
formation. Well-controlled treatment interruption will contribute to our understanding of the stability
of the latent reservoir constituents, and the fraction of individual proviruses responsible for viral re-
bound. For HIV pre-exposure prophylaxis (PrEP) LEDGINs have the added benefit that upon PrEP
failure or inappropriate PrEP adherence any residual virus that would escape the PrEP treatment is
more likely to be detargeted and thus may turn out to be non-productive and refractory to reactivation.
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Figure 5.2: Cases of transient or sustained HIV remission off ART. A rapid viral rebound emerges
within weeks after therapy cessation. In several cases, viral rebound has been substantially delayed. (Figure
derived from [Deeks et al., 2016])
Future perspectives.
To better understand the underlying mechanism by which LEDGIN treatment results in transcrip-
tional silencing of the residual integrants and inhibit reactivation from latency it will be of interest to
compare the epigenetic landscape and chromatin environment surrounding the viral LTR promoter after
infection under LEDGIN treatment. One could look at the occupancy of Nuc-0 and Nuc-1 histones in
the LTR promoter, study CpG methylation profiles or compare histone acetylation/methylation marks
using chromatin immune precipitation (ChIP)-based methods and compare these before and after reac-
tivation. For example, acetylation marks and monomethylation marks such as H3K27/K9/K79, H4K20,
H2BK5, etc. are known to correlate with active transcription while transcriptionally repressed regions
are commonly associated with H3K27me3, H3K9me3 and heterochromatin regions with H4K20me3 and
H3K79me3. In addition, a reduced recruitment of RNAP II or host factors supporting HIV transcrip-
tion, such as NFκB, pTEFβ,... to the LTR promoter might explain the more quiescent phenotype. In
parallel, LEDGIN treatment should be compared with alternative antivirals such as raltegravir, elvite-
gravir and dolutegravir (INSTIs), AZT (RT inhibitor) or ritonavir (protease inhibitor). Treatment
with suboptimal doses of the INSTI raltegravir has been reported to lead to aberrant HIV-1 integra-
tions [Varadarajan et al., 2013]. At present, little is known about the exact consequence of aberrant
integration events on the transcriptional activity. Current integration site sequencing methods do not
allow a large scale study of large LTR deletions/insertions or possible translocations. The SMRTbell
circle-sequencing approach of Pacific Biosciences might qualify as an attractive sequencing platform
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to study complete LTR signatures as it also provides the possibility to simultaneously detect DNA
methylation marks. Preliminary results suggest that LEDGINs added during virus production affect
the integration site choice in the next round of infection. The approach employed in this manuscript
can be applied in a similar manner to study the effect of LEDGINs added during production on the
establishment and maintenance of HIV latency. It will be of paramount importance to extend the
observations made in this manuscript to more advanced and clinically relevant primary cell culture
models and evaluate the effect of LEDGINs on the size and reactivation potential of the latent reservoir
in reservoir constituents other than resting memory CD4+ T-cells. Usage of a WT HIV reporter viruses
expressing a fluorescent protein will enable single cell analysis and discriminate between reactivation
(increase in % positive cells) and transcriptional activity (MFI differences) in contrast to extracellular
p24 measurements (bulk analysis). Studies in animal models such as a humanized mouse model (e.g.
the HIS mouse model developed by the French/Swiss company TransCure) or non-human primates
[Whitney et al., 2014] will allow follow up the latent reservoir dynamics and provide the possibility
to measure the time to-relapse and/or viral set-point upon therapy withdrawal after standard cART,
cART + LEDGIN or LEDGIN monotherapy regimens. In the HIS (Human Immune System) mouse
model, highly immunodeficient mice are engrafted with purified human cord blood-derived CD34+ cells.
15 weeks after engraftment, mice develop a fully functional human immune system (differentiation of
hCD45, and more particularly T-Lymphocytes including CD4+ and CD8+ cells). These mice can be
infected with HIV. Recently a mouse viral outgrowth assay was reported showing potential to serve as a
powerful tool to identify residual HIV [Metcalf Pate et al., 2015]. It will be of interest to assess multiple
anatomical compartments and study the tempo-spatial distribution of replication competent provirus
in multiple cell populations. To better understand the exact origin of viral rebound, it will be necessary
to implement viral barcoding strategies in proviral integration site sequencing methods (similar to the
approach taken in [Akhtar et al., 2013]) combined with a sampling of multiple (not to say all) possible
anatomical residencies of latent provirus. Homeostatic proliferation contributing to the latent reservoir
might occur less frequent under a LEDGIN regimen as retargeted residual integrants are expected to be
less likely to deregulate endogenous gene expression profiles. Compound penetration levels in the lym-
phoid tissues should be monitored. Final proof, however, will only be obtained in well-designed clinical
trials (similar to [Chéret et al., 2015a]). Comparative studies set up to determine the exact levels and
ratios of LEDGF/p75 and HRP-2 or other factors contributing to the overall integration preference
will provide novel insights in the mechanism responsible for the establishment and maintenance of HIV
latency in distinct cell types.
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